Index  

# Index

* * *

Note: Page numbers in **Bold** refer to tables; and page numbers in _italics_ refer to figures

-   abnormalities of
    -   aortic arch development104–106
    -   cardiac innervation  [111](c06.xhtml#Page_111)–113
    -   cardiac looping  [88](c06.xhtml#Page_88)–89
    -   conduction system development  [103](c06.xhtml#Page_103)–104
    -   epicardial development  [101](c06.xhtml#Page_101)–102
    -   heart tube formation  [86](c06.xhtml#Page_86)
    -   outflow tract septation  [99](c06.xhtml#Page_99)–100
    -   pulmonary vein development  [108](c06.xhtml#Page_108)
    -   systemic vein development  [111](c06.xhtml#Page_111)
-   accessory pathways  [104](c06.xhtml#Page_104)
-   Accreditation Council for Graduate Medical Education (ACGME)  [25](c02.xhtml#Page_25)
-   activation of coagulation system
    -   amplification phase  [248](c12.xhtml#Page_248)
    -   cardiopulmonary bypass (CPB)  [250](c12.xhtml#Page_250)
    -   cell‐based model of coagulation  [247](c12.xhtml#Page_247)
    -   coagulation cascade model  [247](c12.xhtml#Page_247), _[248](c12.xhtml#Page_248)_
    -   platelet activation _[249](c12.xhtml#Page_249)_
    -   propagation phase  [248](c12.xhtml#Page_248)
-   activation of inflammation
    -   endothelial injury  [246](c12.xhtml#Page_246)
    -   endotoxemia  [247](c12.xhtml#Page_247)
    -   neutrophil activation andsequestration  [247](c12.xhtml#Page_247), _[247](c12.xhtml#Page_247)_
-   acute neurologic injury  [305](c14.xhtml#Page_305)
-   acute normovolemic hemodilution (ANH)  [386](c16.xhtml#Page_386)
-   adrenergic receptors (ARs)
    -   ß‐adrenergic group  [175](c09.xhtml#Page_175), _[175](c09.xhtml#Page_175)_
    -   in cardiac tissue  [176](c09.xhtml#Page_176)
    -   developmental changes  [177](c09.xhtml#Page_177)
    -   schematic classification  _[176](c09.xhtml#Page_176)_
    -   signaling pathway  [176](c09.xhtml#Page_176)
-   Adult Cardiothoracic Anesthesia Database  [32](c03.xhtml#Page_32)
-   adult congenital heart disease (ACHD)
    
    -   adults with down syndrome  [477](c20.xhtml#Page_477)
    -   cardiac lesions
        -   atrial septal defects (ASDs)  [478](c20.xhtml#Page_478)
        -   coarctation of the aorta  [479](c20.xhtml#Page_479)
        -   created shunts and fenestrations  [478](c20.xhtml#Page_478)
        -   D‐TGA  [484](c20.xhtml#Page_484)–486, _[485](c20.xhtml#Page_485), [486](c20.xhtml#Page_486)_
        -   Ebstein’s anomaly  [486](c20.xhtml#Page_486)–488, _[487](c20.xhtml#Page_487)_
        -   L‐TGA  [483](c20.xhtml#Page_483)–484, _[484](c20.xhtml#Page_484)_
        -   patent ductus arteriosus  [479](c20.xhtml#Page_479)
        -   patent foramen ovale (PFO)  [477](c20.xhtml#Page_477)–478
        -   pulmonary atresia  [483](c20.xhtml#Page_483)
        -   pulmonary valve stenosis (PS)  [479](c20.xhtml#Page_479)–480, **[481](c20.xhtml#Page_481),** _[481](c20.xhtml#Page_481), [482](c20.xhtml#Page_482)_
        -   single‐ventricle anatomy/Fontan physiology  [488](c20.xhtml#Page_488)–492
        -   tetralogy of fallot  [481](c20.xhtml#Page_481)–483
        -   ventricular septal defect (VSD)  [479](c20.xhtml#Page_479)
    
    -   heart failure  [492](c20.xhtml#Page_492)
    -   noncardiac surgery  [492](c20.xhtml#Page_492)–493
    -   perioperative risk of patients  [466](c20.xhtml#Page_466)
    -   psychological issues  [477](c20.xhtml#Page_477)
    -   pulmonary arterial hypertension (PAH)  [467](c20.xhtml#Page_467)–468
    -   treatment options  [467](c20.xhtml#Page_467)
    -   vascular access  [470](c20.xhtml#Page_470)
-   advanced monitors in ICU and operating rooms
    -   cardiopulmonary deterioration  _[80](c05.xhtml#Page_80)_
    -   clinical decision support system  _[79](c05.xhtml#Page_79)_
    -   historical and real‐time physiologic patient data  [78](c05.xhtml#Page_78)
    -   pediatric risk and acuity scores  [79](c05.xhtml#Page_79)
    -   PRISM  [79](c05.xhtml#Page_79)
    -   real‐time analytics  [79](c05.xhtml#Page_79)
-   airway management, thoracic surgery
    
    -   single‐lung ventilation (SLV)
        -   balloon tipped bronchial blockers  [566](c23.xhtml#Page_566)
        -   bending the rules approach  _[570](c23.xhtml#Page_570)_
        -   bronchial diameters in children  [567](c23.xhtml#Page_567)
        -   in children  **[567](c23.xhtml#Page_567)**
        -   double lumen tubes (DLTs)  [567](c23.xhtml#Page_567)
        -   in infants and young children  **[571](c23.xhtml#Page_571)**
        -   intraluminal _versus_ extraluminal approach _[568](c23.xhtml#Page_568)_
        -   intra‐to extraluminal approach  _[570](c23.xhtml#Page_570)_
        -   OLV in infants and young children **[568](c23.xhtml#Page_568)**
        -   single lumen endotracheal tube  [566](c23.xhtml#Page_566)
        -   univent tube  [566](c23.xhtml#Page_566)
    
    -   ventilation‐perfusion abnormalities  [565](c23.xhtml#Page_565)
-   analgesic agents, hemodynamic and cardiac conduction **[204](c10.xhtml#Page_204)**
-   Andersonian nomenclature systems  [117](c07.xhtml#Page_117)–118
-   anesthesia
    
    -   cardiac catheterization laboratory (CCL)  [890](c34.xhtml#Page_890)–932
    -   cardiac transplantation  [832](c32.xhtml#Page_832)–851
    -   errors in surgery  [29](c03.xhtml#Page_29)–30
        -   chest tube bleeding  [30](c03.xhtml#Page_30)
        -   near‐misses  [30](c03.xhtml#Page_30)
        -   non‐functioning infusion pump  [30](c03.xhtml#Page_30)
        -   unplanned transfusion of blood products  [30](c03.xhtml#Page_30)
    
    -   functional residual capacity (FRC)  [496](c21.xhtml#Page_496)
    -   history of
        -   cardiac MRI (cMRI)  [11](c01.xhtml#Page_11)
        -   deep hypothermic circulatory arrest (DHCA)  _[5](c01.xhtml#Page_5),_ [5](c01.xhtml#Page_5)–6
        -   extracorporeal membrane oxygenation (ECMO)  [11](c01.xhtml#Page_11), _[11](c01.xhtml#Page_11)_
        -   first successful operation  [1](c01.xhtml#Page_1)–2
        -   Fontan and catheterization laboratory  [9](c01.xhtml#Page_9)–11
        -   future aspects  [11](c01.xhtml#Page_11)–13
        -   halothane  [3](c01.xhtml#Page_3)
        -   heart–lung machine  [2](c01.xhtml#Page_2)–4
        -   hypoplastic left heart syndrome (HLHS)  [7](c01.xhtml#Page_7)–9
        -   patent ductus arteriosus (PDA)  [6](c01.xhtml#Page_6)–7
        -   transesophageal echocardiography (TEE)  [11](c01.xhtml#Page_11)
    
    -   left‐sided obstructive lesions  [650](c27.xhtml#Page_650)–672
    -   left‐to‐right shunt lesions  [624](c26.xhtml#Page_624)–648
    -   management of patients with CHD  **[14](c01.xhtml#Page_14)**
    -   miscellaneous cardiac lesions [781](c31.xhtml#Page_781)–831
    -   noncardiac surgery  [934](c35.xhtml#Page_934)–956
    -   outcomes  [30](c03.xhtml#Page_30)–31
        -   closed claims analysis  [37](c03.xhtml#Page_37)
        -   outcome transparency  [30](c03.xhtml#Page_30)
        -   predictive outcomes analysis  [37](c03.xhtml#Page_37)
    
    -   patient with a single ventricle  [741](c30.xhtml#Page_741)–779
    -   pediatric lung transplantation  [851](c32.xhtml#Page_851)–867
    -   pulmonary hypertension  [869](c33.xhtml#Page_869)–889
    -   right‐sided obstructive lesions  [674](c28.xhtml#Page_674)–709
    -   transposition of great arteries (TGA)  [710](c29.xhtml#Page_710)–739
-   anesthetic agents
    
    -   antagonists  [205](c10.xhtml#Page_205)–206
    -   benzodiazepines  [194](c10.xhtml#Page_194)–195
    -   dexmedetomidine  [200](c10.xhtml#Page_200)–203, _[201](c10.xhtml#Page_201),_ **[202](c10.xhtml#Page_202)**
    -   etomidate  _[199](c10.xhtml#Page_199),_ [199](c10.xhtml#Page_199)–200, _[200](c10.xhtml#Page_200)_
    -   hemodynamic and cardiac conduction **[204](c10.xhtml#Page_204)**
    -   ketamine  _[197](c10.xhtml#Page_197),_ [197](c10.xhtml#Page_197)–199, _[198](c10.xhtml#Page_198)_
    -   neuromuscular blocking agents  [203](c10.xhtml#Page_203)–205
        
        -   atracurium  [205](c10.xhtml#Page_205)
        -   cisatracurium  [205](c10.xhtml#Page_205)
        -   pancuronium  [205](c10.xhtml#Page_205)
        -   rocuronium  [205](c10.xhtml#Page_205)
        -   succinylcholine  [203](c10.xhtml#Page_203), [205](c10.xhtml#Page_205)
        -   vecuronium  [205](c10.xhtml#Page_205)
        
    
    -   nitrous oxide (N2O)  [193](c10.xhtml#Page_193)–194
    -   opioids  [194](c10.xhtml#Page_194)–195
    -   propofol  [196](c10.xhtml#Page_196), _[196](c10.xhtml#Page_196)_
    -   volatile agents  [190](c10.xhtml#Page_190)–193, **[191](c10.xhtml#Page_191),** _[191](c10.xhtml#Page_191), [192](c10.xhtml#Page_192)_
        -   desflurane  [193](c10.xhtml#Page_193)
        -   effects of  [191](c10.xhtml#Page_191)
        -   force of contraction over time  _[191](c10.xhtml#Page_191), [192](c10.xhtml#Page_192)_
        -   halothane  **[191](c10.xhtml#Page_191),** [193](c10.xhtml#Page_193)
        -   hemodynamic changes  _[194](c10.xhtml#Page_194)_
        -   isoflurane  **[191](c10.xhtml#Page_191),** [193](c10.xhtml#Page_193)
        -   myocardial performance index (MPI)  [192](c10.xhtml#Page_192)
        -   sarcoplasmic reticulum (SR)  [190](c10.xhtml#Page_190)
        -   sevoflurane  [191](c10.xhtml#Page_191), **[191](c10.xhtml#Page_191)**
        -   troponin–actin–myosin complex  [190](c10.xhtml#Page_190)
-   anesthetic and sedative neurotoxicity
    -   Boston circulatory arrest study (BCAS)  [322](c14.xhtml#Page_322)–323
    -   children’s hospital of Philadelphia cohort  [323](c14.xhtml#Page_323)
    -   cohorts **[328](c14.xhtml#Page_328)**
    -   GABA receptors  [321](c14.xhtml#Page_321)
    -   Heart and Minds study  [324](c14.xhtml#Page_324)
    -   ICCON investigators group  [326](c14.xhtml#Page_326), _[326](c14.xhtml#Page_326)_
    -   longer term neurodevelopmental testing  [322](c14.xhtml#Page_322)
    -   Milwaukee cohort  [324](c14.xhtml#Page_324)
    -   modifiable and monmodifiable factors  **[329](c14.xhtml#Page_329)**
    -   NMDA receptors  [321](c14.xhtml#Page_321), [322](c14.xhtml#Page_322)
    -   single ventricle reconstruction (SVR) trial  [325](c14.xhtml#Page_325)–326
    -   Texas Children’s Hospital cohort  [324](c14.xhtml#Page_324)
    -   Western Canadian study  [323](c14.xhtml#Page_323)–324
    -   Zurich cohort  [326](c14.xhtml#Page_326)–327
-   anesthetic management, PH
    
    -   airway management techniques  [887](c33.xhtml#Page_887)
    -   hemodynamic effects, drugs  [885](c33.xhtml#Page_885)–888, **[886](c33.xhtml#Page_886)**
        -   Dexmedetomidine  [886](c33.xhtml#Page_886)
        -   Etomidate  [886](c33.xhtml#Page_886)
        -   ketamine  [886](c33.xhtml#Page_886)
        -   Midazolam  [886](c33.xhtml#Page_886)
        -   Opioids  [886](c33.xhtml#Page_886)
        -   Propofol  [886](c33.xhtml#Page_886)
        -   volatile anesthetics  [886](c33.xhtml#Page_886)
    
    -   monitoring  [888](c33.xhtml#Page_888), _[888](c33.xhtml#Page_888)_
    -   perioperative pulmonary vasodilators  [887](c33.xhtml#Page_887)
    -   postanesthesia disposition  [888](c33.xhtml#Page_888)
    -   ventilation management techniques  [887](c33.xhtml#Page_887)–888, _[888](c33.xhtml#Page_888)_
-   Anomalous Aortic Origin of the Coronary Arteries (AAOCA)  [49](c04.xhtml#Page_49)
-   anterior mediastinal masses
    -   anatomy [826](c31.xhtml#Page_826)
    -   anesthesia [828](c31.xhtml#Page_828)–830
    -   diagnosis of [826](c31.xhtml#Page_826)–827, _[827](c31.xhtml#Page_827)_
    -   incidence [826](c31.xhtml#Page_826)
    -   natural history [826](c31.xhtml#Page_826)
    -   pathophysiology [827](c31.xhtml#Page_827)–828
    -   superior vena cava compression _[829](c31.xhtml#Page_829)_
    -   surgery [828](c31.xhtml#Page_828)
    -   tracheobronchial compression _[829](c31.xhtml#Page_829)_
-   antifibrinolytic therapy. _see also_ aprotinin; epsilon‐aminocaproic acid (EACA); tranexamic acid (TA)
    -   comparison of antifibrinolytics  [229](c11.xhtml#Page_229)
-   aortic aneurysm
    -   after aortic root replacement _[824](c31.xhtml#Page_824)_
    -   anatomy [820](c31.xhtml#Page_820)
    -   anesthesia [825](c31.xhtml#Page_825)–826
    -   and aortic dilation [822](c31.xhtml#Page_822)–823
    -   classification [820](c31.xhtml#Page_820)
    -   definition [820](c31.xhtml#Page_820)
    -   Ehlers–Danlos syndrome [822](c31.xhtml#Page_822)
    -   incidence [820](c31.xhtml#Page_820)
    -   Loeys–Dietz syndrome (LDS) [820](c31.xhtml#Page_820)
    -   Marfan syndrome [820](c31.xhtml#Page_820)–822, _[821](c31.xhtml#Page_821)_, **[821](c31.xhtml#Page_821)**
    -   natural history [820](c31.xhtml#Page_820)
    -   pathophysiology [823](c31.xhtml#Page_823)–824
    -   sinus of Valsalva aneurysms [822](c31.xhtml#Page_822), _[823](c31.xhtml#Page_823)_
    -   surgical approaches [824](c31.xhtml#Page_824)–825
-   aortic arch development  [129](c07.xhtml#Page_129)
    -   abnormalities of  [104](c06.xhtml#Page_104)–106
    -   coarctation of the aorta  [106](c06.xhtml#Page_106)
    -   dorsal aortae fuse  [104](c06.xhtml#Page_104)
    -   double aortic arch  [104](c06.xhtml#Page_104)
    -   Edward’s developmental model  _[106](c06.xhtml#Page_106)_
    -   schematic representation _[105](c06.xhtml#Page_105)_
    -   vascular ring  [106](c06.xhtml#Page_106)
    -   vascular sling  [106](c06.xhtml#Page_106)
-   aortopulmonary window (APW)  [628](c26.xhtml#Page_628)–630
    -   anesthetic considerations  [630](c26.xhtml#Page_630)
    -   classification of  _[629](c26.xhtml#Page_629)_
    -   incidence, anatomy, and natural history  [628](c26.xhtml#Page_628)–629
    -   patch closure of type II  _[630](c26.xhtml#Page_630)_
    -   pathophysiology  [630](c26.xhtml#Page_630)
    -   surgical and transcatheter approaches  [630](c26.xhtml#Page_630)
-   apprenticeship model  [16](c02.xhtml#Page_16)
-   Aristotle Basic Complexity (ABC) score  [33](c03.xhtml#Page_33), [444](c18.xhtml#Page_444)
-   arterial access
    -   arterial cutdown  [283](c13.xhtml#Page_283)
    -   axillary artery  [281](c13.xhtml#Page_281)
    -   brachial artery  [280](c13.xhtml#Page_280)–281
    -   catheter sizes and lengths  **[280](c13.xhtml#Page_280)**
    -   dorsalis pedis/posterior tibial arteries  [282](c13.xhtml#Page_282)
    -   femoral artery  [280](c13.xhtml#Page_280)
    -   radial artery  [280](c13.xhtml#Page_280), _[281](c13.xhtml#Page_281)_
    -   temporal artery  [282](c13.xhtml#Page_282)
    -   ulnar artery  [282](c13.xhtml#Page_282)–283
    -   umbilical artery  [281](c13.xhtml#Page_281)–282
-   arterial switch operation (ASO)
    -   flowchart  _[721](c29.xhtml#Page_721)_
    -   indications  [719](c29.xhtml#Page_719)–720
    -   outcomes  [723](c29.xhtml#Page_723)–726
    -   postoperative management  [731](c29.xhtml#Page_731)
    -   timing  [719](c29.xhtml#Page_719)–720
-   atrial chambers characteristics  [123](c07.xhtml#Page_123)
-   atrial isomerism  [89](c06.xhtml#Page_89)
-   atrial septal defects (ASDs)  [354](c15.xhtml#Page_354), [630](c26.xhtml#Page_630)–633, [674](c28.xhtml#Page_674), [895](c34.xhtml#Page_895)
    
    -   anesthetic considerations  [633](c26.xhtml#Page_633)
    -   clinical manifestations  [354](c15.xhtml#Page_354)
    -   coronary sinus ASD  [632](c26.xhtml#Page_632)
    -   coronary sinus defect  [354](c15.xhtml#Page_354)
    -   device occlusion  _[356](c15.xhtml#Page_356)_
    -   embryologic development  _[631](c26.xhtml#Page_631)_
    -   incidence  [630](c26.xhtml#Page_630)–631
    -   natural history  [632](c26.xhtml#Page_632)
    -   ostium secundum defect  [354](c15.xhtml#Page_354)
    -   patent foramen ovale  [632](c26.xhtml#Page_632)
    -   primum ASD  [631](c26.xhtml#Page_631)–632
    -   secundum ASD  [631](c26.xhtml#Page_631)
    -   sinus venosus ASD  [632](c26.xhtml#Page_632)
    -   surgical and transcatheter approaches  [632](c26.xhtml#Page_632)–633
    -   surgical repair of  _[633](c26.xhtml#Page_633)_
    -   TEE examination  [354](c15.xhtml#Page_354)–356
        -   postdeployment  [354](c15.xhtml#Page_354)
        -   postsurgical  [354](c15.xhtml#Page_354)
        -   preoperative  [354](c15.xhtml#Page_354)
    
    -   types of  _[632](c26.xhtml#Page_632)_
-   atrial septation
    -   AV endocardial cushions  [91](c06.xhtml#Page_91), _[92](c06.xhtml#Page_92)_
    -   common atrium  [93](c06.xhtml#Page_93)
    -   coronary sinus defect  [92](c06.xhtml#Page_92)
    -   defects in  [92](c06.xhtml#Page_92)–93
    -   endothelial‐to‐mesenchymal transformation (EMT)  [91](c06.xhtml#Page_91)
    -   foramen ovale  [91](c06.xhtml#Page_91)
    -   ostium primum defect  [92](c06.xhtml#Page_92)
    -   patent foramen ovale (PFO)  [92](c06.xhtml#Page_92)
    -   primary atrial foramen  [91](c06.xhtml#Page_91)
    -   sinus venosus defect  [92](c06.xhtml#Page_92)
    -   venous pole  [91](c06.xhtml#Page_91), [92](c06.xhtml#Page_92)
-   atrial situs  [120](c07.xhtml#Page_120)–122, _[121](c07.xhtml#Page_121), [122](c07.xhtml#Page_122)_
-   atrioventricular canal (AVC)  [636](c26.xhtml#Page_636)–639
    -   anesthetic considerations  [639](c26.xhtml#Page_639)
    -   complete  [636](c26.xhtml#Page_636)–637, _[637](c26.xhtml#Page_637), [638](c26.xhtml#Page_638)_
    -   defects of  [97](c06.xhtml#Page_97)
    -   development of  _[96](c06.xhtml#Page_96)_
    -   incidence  [636](c26.xhtml#Page_636)
    -   natural history  [637](c26.xhtml#Page_637)
    -   partial  [636](c26.xhtml#Page_636)
    -   pathophysiology  [637](c26.xhtml#Page_637)
    -   surgical approaches  [637](c26.xhtml#Page_637)–639
    -   transitional  [636](c26.xhtml#Page_636)
-   atrioventricular septal defects
    -   complete defect  [357](c15.xhtml#Page_357)
    -   intermediate defect  [358](c15.xhtml#Page_358)
    -   partial defect  [358](c15.xhtml#Page_358)
    -   transitional defect  [358](c15.xhtml#Page_358)
-   AV nodal re‐entry tachycardia (AVNRT)  [104](c06.xhtml#Page_104)
-   AV node (AVN)  [102](c06.xhtml#Page_102)

-   bleeding
    
    -   cell salvage  [393](c16.xhtml#Page_393)–394
    -   global hemostasis cartridge  [394](c16.xhtml#Page_394), _[394](c16.xhtml#Page_394)_
    -   platelet‐poor plasma (PPP)  [394](c16.xhtml#Page_394)
    -   QuantraR QPlus System
        -   QPlus cartridge, and parameters _[396](c16.xhtml#Page_396)_
        -   QuantraR Hemostasis Analyzer  [395](c16.xhtml#Page_395)
    
    -   ROTEM®
        -   assays and clinical indications  **[395](c16.xhtml#Page_395)**
        -   charge‐coupled device  [395](c16.xhtml#Page_395)
        -   clot initiation  [397](c16.xhtml#Page_397), _[397](c16.xhtml#Page_397)_
        -   clot lysis  [397](c16.xhtml#Page_397), _[397](c16.xhtml#Page_397)_
        -   clot strength  [397](c16.xhtml#Page_397), _[397](c16.xhtml#Page_397)_
        -   sigma and cartridges  _[395](c16.xhtml#Page_395)_
        -   trace _[396](c16.xhtml#Page_396)_
    
    -   standard coagulation assays  [394](c16.xhtml#Page_394)
    -   TEG®
        -   clot initiation  [397](c16.xhtml#Page_397), _[397](c16.xhtml#Page_397)_
        -   clot lysis  [397](c16.xhtml#Page_397), _[397](c16.xhtml#Page_397)_
        -   clot strength  [397](c16.xhtml#Page_397), _[397](c16.xhtml#Page_397)_
        -   device and cartridge  _[394](c16.xhtml#Page_394)_
        -   PlateletMapping cartridge  [394](c16.xhtml#Page_394)
        -   resonance‐frequency viscoelasticity  [394](c16.xhtml#Page_394)
        -   trace _[396](c16.xhtml#Page_396)_
    
    -   transfusion algorithms  [394](c16.xhtml#Page_394)–397
    -   viscoelastic hemostatic tests  [395](c16.xhtml#Page_395)
-   Blood Conservation Using Antifibrinolytics in a Randomized Trial (BART)  [404](c16.xhtml#Page_404)
-   blood transfusion
    
    -   fibrinogen supplementation  [398](c16.xhtml#Page_398)–400
        -   cryoprecipitate  [398](c16.xhtml#Page_398)
        -   cryoprecipitate _vs._  **[399](c16.xhtml#Page_399)**
        -   fibrinogen concentrate (FC)  [398](c16.xhtml#Page_398)–399, **[402](c16.xhtml#Page_402)**
        -   fibrinogen levels  _[400](c16.xhtml#Page_400)_
        -   maximal clot firmness (MCF)  [398](c16.xhtml#Page_398)
    
    -   platelet transfusion  [398](c16.xhtml#Page_398)
    -   prothrombin Complex Concentrates (PCCs)  [401](c16.xhtml#Page_401)–402
    -   recombinant factor VIIa  [400](c16.xhtml#Page_400)–401, _[401](c16.xhtml#Page_401)_
    -   red blood cells  [398](c16.xhtml#Page_398), _[399](c16.xhtml#Page_399)_
    -   whole blood  [398](c16.xhtml#Page_398)
    
-   Boston Children’s Hospital
    -   anesthetic outcomes database  [38](c03.xhtml#Page_38)
    -   cardiovascular surgery at  **[10](c01.xhtml#Page_10)**
    -   ERAS at  _[66](c04.xhtml#Page_66)_
    -   Esophageal and Airway Treatment (EAT) center [785](c31.xhtml#Page_785)
    -   hematocrit goals  [309](c14.xhtml#Page_309)
    -   hyperbaric chamber at  _[4](c01.xhtml#Page_4)_
    -   single‐center reports  [600](c25.xhtml#Page_600)
-   Buretrol®  [924](c34.xhtml#Page_924)

-   calcium cycling  _[177](c09.xhtml#Page_177)_
    -   actin‐myosin system  [177](c09.xhtml#Page_177), [179](c09.xhtml#Page_179)
    -   developmental changes  [180](c09.xhtml#Page_180)
    -   neonatal and mature hearts  **[180](c09.xhtml#Page_180)**
    -   sarcolemmal membrane  [178](c09.xhtml#Page_178)
-   cardiac arrhythmias
    
    -   pharmacologic therapy of
        -   adenosine  [551](c22.xhtml#Page_551)
        -   amiodarone  [549](c22.xhtml#Page_549)–550
        -   anti‐arrhythmic agents  **[548](c22.xhtml#Page_548)**
        -   class IA agents  [547](c22.xhtml#Page_547)–552
        -   class IB agents  [549](c22.xhtml#Page_549)
        -   class III agents  [549](c22.xhtml#Page_549)–550
        -   class IV agents  [550](c22.xhtml#Page_550)
        -   dexmedetomidine  [551](c22.xhtml#Page_551)
        -   digoxin  [550](c22.xhtml#Page_550)–551
        -   ibutilide  [550](c22.xhtml#Page_550)
        -   ivabradine  [551](c22.xhtml#Page_551)
        -   lidocaine  [549](c22.xhtml#Page_549)
        -   magnesium sulfate  [551](c22.xhtml#Page_551)
        -   procainamide  [548](c22.xhtml#Page_548)–549
        -   sotalol  [550](c22.xhtml#Page_550)
        -   verapamil  [550](c22.xhtml#Page_550)
    
    -   rhythm disturbances  [527](c22.xhtml#Page_527)–547
        -   conduction disorders (_see_ [conduction disorders, arrhythmias](#ind775))
        -   junctional rhythm  [529](c22.xhtml#Page_529), _[529](c22.xhtml#Page_529)_
        -   low atrial rhythm  [528](c22.xhtml#Page_528), _[528](c22.xhtml#Page_528)_
        -   sinus bradycardia  [527](c22.xhtml#Page_527)–528, **[535](c22.xhtml#Page_535)**
        -   sinus node dysfunction  [528](c22.xhtml#Page_528)
        -   sinus tachycardia  [528](c22.xhtml#Page_528)–529, **[535](c22.xhtml#Page_535)**
        -   supraventricular arrhythmias  [531](c22.xhtml#Page_531)–542
        -   ventricular arrhythmias  [543](c22.xhtml#Page_543)–547
        -   ventricular fibrillation [535](c22.xhtml#Page_535), [547](c22.xhtml#Page_547)
-   cardiac catheterization laboratory (CCL)
    
    -   adverse events  [914](c34.xhtml#Page_914)–916, **[915](c34.xhtml#Page_915)**
        -   mortality  [916](c34.xhtml#Page_916)
        -   serious adverse events (SAEs)  [916](c34.xhtml#Page_916)
        -   termed major adverse events (MAEs)  [916](c34.xhtml#Page_916)
    
    -   anesthetic management
        -   anesthetic drugs  [921](c34.xhtml#Page_921)–922, **[922](c34.xhtml#Page_922)**
        -   anesthetic techniques  [920](c34.xhtml#Page_920)–921
        -   intravascular volume management  [924](c34.xhtml#Page_924)
        -   monitoring  _[923](c34.xhtml#Page_923),_ [923](c34.xhtml#Page_923)–924
        -   operator‐directed sedation  [918](c34.xhtml#Page_918)–919
        -   periprocedural planning  _[919](c34.xhtml#Page_919),_ [919](c34.xhtml#Page_919)–920, **[920](c34.xhtml#Page_920)**
        -   premature PDA closures  **[897](c34.xhtml#Page_897)**
        -   recovery  [924](c34.xhtml#Page_924)
    
    -   diagnostic catheterization
        -   cardiac magnetic resonance imaging‐guided catheterization  [894](c34.xhtml#Page_894)–895, **[895](c34.xhtml#Page_895)**
        -   endomyocardial biopsy  [891](c34.xhtml#Page_891)–892, _[893](c34.xhtml#Page_893)_
        -   indications  [890](c34.xhtml#Page_890)–891
        -   procedure overview  [891](c34.xhtml#Page_891), **[893](c34.xhtml#Page_893)**
        -   pulmonary hypertension  _[891](c34.xhtml#Page_891)_
        -   pulmonary hypertension study  [892](c34.xhtml#Page_892)–894, **[892](c34.xhtml#Page_892)–894**
    
    -   electrophysiology procedures  [924](c34.xhtml#Page_924)–932
    -   hemodynamic calculations  _[893](c34.xhtml#Page_893)_
    -   interventional catheterization  [895](c34.xhtml#Page_895)–914
        -   balloon angioplasty/stent placement  [902](c34.xhtml#Page_902)–907
        -   balloon dilation  [899](c34.xhtml#Page_899)–902
        -   cardiovascular communications  [907](c34.xhtml#Page_907)–908
        -   device closure  [896](c34.xhtml#Page_896)–899
        -   hybrid procedures  [911](c34.xhtml#Page_911), _[911](c34.xhtml#Page_911)_
        -   percutaneous mechanical circulatory support  _[913](c34.xhtml#Page_913),_ [913](c34.xhtml#Page_913)–914, **[914](c34.xhtml#Page_914),** _[915](c34.xhtml#Page_915)_
        -   pericardiocentesis  _[912](c34.xhtml#Page_912),_ [912](c34.xhtml#Page_912)–913
        -   transcatheter valve replacement  [908](c34.xhtml#Page_908)–911
    
    -   risk assessment
        -   adverse events  _[918](c34.xhtml#Page_918)_
        -   complications  [917](c34.xhtml#Page_917)–918
        -   noncardiac comorbidities  [916](c34.xhtml#Page_916)
        -   patient characteristics  [916](c34.xhtml#Page_916), **[918](c34.xhtml#Page_918)**
        -   preprocedural status  [916](c34.xhtml#Page_916)
        -   procedure‐type categories  **[917](c34.xhtml#Page_917)**
-   cardiac development  [83](c06.xhtml#Page_83)–84
-   cardiac intensive care unit (CICU)
    
    -   admissions  [984](c36.xhtml#Page_984)
    -   airway management  [964](c36.xhtml#Page_964)
    -   arrhythmias  [993](c36.xhtml#Page_993)
    -   cardiopulmonary resuscitation (CPR)
        -   arrest phase management  [975](c36.xhtml#Page_975)
        -   monitoring and risk reduction  [974](c36.xhtml#Page_974)–975
        -   post‐resuscitation management  [975](c36.xhtml#Page_975)–976
    
    -   cardiorespiratory interactions  [965](c36.xhtml#Page_965)
    -   complete mixing lesions  [960](c36.xhtml#Page_960)
    -   early extubation  [967](c36.xhtml#Page_967)–968
    -   feeding algorithm  _[991](c36.xhtml#Page_991)_
    -   fluid management  [987](c36.xhtml#Page_987)–990
        -   acute kidney injury (AKI)  [988](c36.xhtml#Page_988), **[989](c36.xhtml#Page_989)**
        -   aquapheresis  [990](c36.xhtml#Page_990)
        -   post‐CPB  [987](c36.xhtml#Page_987)
    
    -   gastrointestinal complications  [990](c36.xhtml#Page_990)–992
    -   hemodynamic monitoring
        -   cardiac output  [970](c36.xhtml#Page_970), **[970](c36.xhtml#Page_970), [971](c36.xhtml#Page_971)**
        -   high afterload  [972](c36.xhtml#Page_972)
        -   low preload  [972](c36.xhtml#Page_972)
    
    -   hemostasis  [983](c36.xhtml#Page_983)
    -   high‐frequency oscillatory ventilation (HFOV)  [966](c36.xhtml#Page_966)–967
    -   infection control  [983](c36.xhtml#Page_983)–984, **[984](c36.xhtml#Page_984)**
    -   influence of intrathoracic pressure
        -   left ventricle  [966](c36.xhtml#Page_966)
        -   positive pressure ventilation  _[966](c36.xhtml#Page_966)_
        -   right ventricle  [965](c36.xhtml#Page_965)–966
        -   transmural aortic pressure  _[967](c36.xhtml#Page_967)_
    
    -   influence of lung volume  [965](c36.xhtml#Page_965), _[965](c36.xhtml#Page_965)_
    -   intercirculatory mixing lesions  [959](c36.xhtml#Page_959)–960, _[960](c36.xhtml#Page_960)_
    -   mechanical circulatory support
        -   extracorporeal membrane oxygenation (ECMO)  _[979](c36.xhtml#Page_979),_ [979](c36.xhtml#Page_979)–981
        -   ventricular assist devices  [981](c36.xhtml#Page_981)–982
    
    -   mechanical ventilation  [964](c36.xhtml#Page_964)–965
        -   airway  [969](c36.xhtml#Page_969)
        -   analgesia and sedation  [969](c36.xhtml#Page_969)
        -   fluid restriction  [968](c36.xhtml#Page_968)–969
        -   restrictive defects  [968](c36.xhtml#Page_968)
        -   sepsis  [969](c36.xhtml#Page_969)
        -   weaning from  **[968](c36.xhtml#Page_968),** [968](c36.xhtml#Page_968)–969
    
    -   multisystem inflammatory syndrome in children (MIS‐C)  [992](c36.xhtml#Page_992)–994
        -   case definition  [992](c36.xhtml#Page_992)
        -   clinical pathway  _[995](c36.xhtml#Page_995)_
        -   evaluation and management [994](c36.xhtml#Page_994)
        -   initial evaluation  [993](c36.xhtml#Page_993)
        -   multidisciplinary approach [994](c36.xhtml#Page_994)
    
    -   myocardial dysfunction
        -   decreased contractility  [972](c36.xhtml#Page_972)–973
        -   delayed sternal closure  [973](c36.xhtml#Page_973)–974
        -   dysrhythmias  [972](c36.xhtml#Page_972)
        -   ischemia  [971](c36.xhtml#Page_971)
        -   surgical factors  [970](c36.xhtml#Page_970)–971
        -   systemic inflammatory response  [971](c36.xhtml#Page_971)–972
    
    -   neurological complications  [984](c36.xhtml#Page_984)–986
    -   neurological monitoring  [984](c36.xhtml#Page_984)–986
    -   noninvasive ventilation (NIV)  [967](c36.xhtml#Page_967)
    -   nutrition complications  [990](c36.xhtml#Page_990)–992
    -   nutrition management  [968](c36.xhtml#Page_968)–969
    -   outflow obstruction  [963](c36.xhtml#Page_963)–964
    -   patient safety issues  [977](c36.xhtml#Page_977)–978
    -   pediatric  [958](c36.xhtml#Page_958), _[959](c36.xhtml#Page_959)_
    -   positive end‐expiratory pressure (PEEP)  [966](c36.xhtml#Page_966)
    -   postoperative complications  [976](c36.xhtml#Page_976)–977
        -   etiologies and interventions  _[977](c36.xhtml#Page_977)_
        -   low cardiac output state (LCOS)  [977](c36.xhtml#Page_977)
        -   residual lesion score figure  _[978](c36.xhtml#Page_978)_
    
    -   quality improvement  [977](c36.xhtml#Page_977)–978
    -   renal dysfunction management  [987](c36.xhtml#Page_987)–990
    -   SARS‐CoV‐2 infection  [992](c36.xhtml#Page_992)–994
        -   clinical presentation  [992](c36.xhtml#Page_992)
        -   management strategies  [993](c36.xhtml#Page_993)
        -   personal protective equipment (PPE)  [993](c36.xhtml#Page_993)
        -   polymerase chain reaction (PCR)  [992](c36.xhtml#Page_992)
    
    -   shunts
        -   clinical consequences  [961](c36.xhtml#Page_961)–962, _[962](c36.xhtml#Page_962)_
        -   complex  [961](c36.xhtml#Page_961)
        -   decreased pulmonary blood flow  [962](c36.xhtml#Page_962)–963
        -   increased pulmonary blood flow  [961](c36.xhtml#Page_961)–962
        -   simple  [961](c36.xhtml#Page_961)
        -   target systemic oxygen saturation level  [963](c36.xhtml#Page_963), **[963](c36.xhtml#Page_963)**
    
    -   streaming  [960](c36.xhtml#Page_960)–961
-   cardiac lesions, AHCD
    -   atrial septal defects (ASDs)  [478](c20.xhtml#Page_478)
    -   coarctation of the aorta  [479](c20.xhtml#Page_479)
    -   created shunts and fenestrations  [478](c20.xhtml#Page_478)
    -   D‐TGA  [484](c20.xhtml#Page_484)–486, _[485](c20.xhtml#Page_485), [486](c20.xhtml#Page_486)_
    -   Ebstein’s anomaly  [486](c20.xhtml#Page_486)–488, _[487](c20.xhtml#Page_487)_
    -   L‐TGA  [483](c20.xhtml#Page_483)–484, _[484](c20.xhtml#Page_484)_
    -   patent ductus arteriosus  [479](c20.xhtml#Page_479)
    -   patent foramen ovale (PFO)  [477](c20.xhtml#Page_477)–478
    -   pulmonary atresia  [483](c20.xhtml#Page_483)
    -   pulmonary valve stenosis (PS)  [479](c20.xhtml#Page_479)–480, **[481](c20.xhtml#Page_481),** _[481](c20.xhtml#Page_481), [482](c20.xhtml#Page_482)_
    -   single‐ventricle anatomy/Fontan physiology  [488](c20.xhtml#Page_488)–492
    -   tetralogy of fallot  [481](c20.xhtml#Page_481)–483
    -   ventricular septal defect (VSD)  [479](c20.xhtml#Page_479)
-   cardiac neural crest  [97](c06.xhtml#Page_97), _[98](c06.xhtml#Page_98)_
-   cardiac POCUS
    -   apical four‐chamber view  [411](c17.xhtml#Page_411), _[414](c17.xhtml#Page_414)_
    -   atria and valves assesment  [417](c17.xhtml#Page_417)–418
    -   cardiac arrest assistance  [418](c17.xhtml#Page_418)
    -   central line placement assistance  [418](c17.xhtml#Page_418)
    -   early tamponade physiology  [416](c17.xhtml#Page_416)–417
    -   hemodynamic instability _[419](c17.xhtml#Page_419)_
    -   hypotension or shock  [418](c17.xhtml#Page_418)
    -   Impella® device  [420](c17.xhtml#Page_420)
    -   inferior vena cava views  [411](c17.xhtml#Page_411)–412, _[416](c17.xhtml#Page_416)_
    -   left ventricle assessment  [412](c17.xhtml#Page_412)–414
    -   parasternal long‐axis (PLAX) view  [411](c17.xhtml#Page_411), _[412](c17.xhtml#Page_412)_
    -   parasternal short‐axis (PSAX) view  [411](c17.xhtml#Page_411), _[413](c17.xhtml#Page_413)_
    -   pediatric  [410](c17.xhtml#Page_410)
    -   pericardial space assessment  _[416](c17.xhtml#Page_416),_ [416](c17.xhtml#Page_416)–417
    -   position of cannulae/device [419](c17.xhtml#Page_419)
    -   right ventricle assessment  [414](c17.xhtml#Page_414)–416
    -   shock assesment  [418](c17.xhtml#Page_418)–419
    -   structure assessment  [412](c17.xhtml#Page_412)–420
    -   subcostal four‐chamber view  [411](c17.xhtml#Page_411)–412, _[415](c17.xhtml#Page_415), [417](c17.xhtml#Page_417), [418](c17.xhtml#Page_418)_
-   cardiac tumors in childhood
    -   anatomy [816](c31.xhtml#Page_816)–820
    -   anesthesia considerations [819](c31.xhtml#Page_819)–820
    -   benign and malignant tumors prevalence _[816](c31.xhtml#Page_816)_
    -   frequency distribution **[816](c31.xhtml#Page_816)**
    -   incidence [816](c31.xhtml#Page_816)–820
    -   natural history [816](c31.xhtml#Page_816)–820
    -   pathophysiology [817](c31.xhtml#Page_817)–818, _[818](c31.xhtml#Page_818)_
    -   surgical approaches and outcomes [818](c31.xhtml#Page_818)–819
    -   Wilm’s tumor extension _[819](c31.xhtml#Page_819)_
-   cardiomyocyte receptor function
    
    -   adrenergic receptors (ARs)
        -   ß‐adrenergic group  [175](c09.xhtml#Page_175), _[175](c09.xhtml#Page_175)_
        -   in cardiac tissue  [176](c09.xhtml#Page_176)
        -   developmental changes  [177](c09.xhtml#Page_177)
        -   schematic classification  _[176](c09.xhtml#Page_176)_
        -   signaling pathway  [176](c09.xhtml#Page_176)
    
    -   calcium cycling  _[177](c09.xhtml#Page_177)_
        -   actin‐myosin system  [177](c09.xhtml#Page_177), [179](c09.xhtml#Page_179)
        -   developmental changes  [180](c09.xhtml#Page_180)
        -   neonatal and mature hearts  **[180](c09.xhtml#Page_180)**
        -   sarcolemmal membrane  [178](c09.xhtml#Page_178)
    
    -   thyroid hormone  [180](c09.xhtml#Page_180)
-   cardiopulmonary bypass (CPB)
    
    -   activation of coagulation system  [250](c12.xhtml#Page_250)
    -   adult _vs._ pediatric  **[213](c11.xhtml#Page_213)**
        -   aortopulmonary collaterals  [217](c11.xhtml#Page_217)–218
        -   blood gas management  [217](c11.xhtml#Page_217)
        -   equipment  [218](c11.xhtml#Page_218)
        -   flow rates  [216](c11.xhtml#Page_216)–217, _[217](c11.xhtml#Page_217)_
        -   glucose management  [218](c11.xhtml#Page_218)
        -   hemodilution  [216](c11.xhtml#Page_216)
        -   perfusion pressures  [216](c11.xhtml#Page_216)
        -   temperature ranges  [218](c11.xhtml#Page_218)
        -   ultrafiltration  [218](c11.xhtml#Page_218)
    
    -   anticoagulation  [389](c16.xhtml#Page_389)–390
        -   monitoring  [240](c11.xhtml#Page_240)–242, _[241](c11.xhtml#Page_241),_ **[242](c11.xhtml#Page_242),** _[242](c11.xhtml#Page_242)_
    
    -   bypass circuit setup  [212](c11.xhtml#Page_212)–218
        -   cannulation and tubing  _[213](c11.xhtml#Page_213),_ [213](c11.xhtml#Page_213)–214, **[214](c11.xhtml#Page_214),** _[214](c11.xhtml#Page_214)_
        -   oxygenator  [214](c11.xhtml#Page_214)–215
        -   priming  **[215](c11.xhtml#Page_215),** [215](c11.xhtml#Page_215)–216
        -   pumps  [214](c11.xhtml#Page_214)
        -   schematic diagram  _[212](c11.xhtml#Page_212)_
    
    -   complications and safety  [242](c11.xhtml#Page_242)–243
    -   deleterious effects
        -   biocompatible circuits  [251](c12.xhtml#Page_251)
        -   corticosteroids  [250](c12.xhtml#Page_250)
        -   modified ultrafiltration  [250](c12.xhtml#Page_250)–251
        -   protease inhibitors  [251](c12.xhtml#Page_251)
    
    -   dilutional anemia  [388](c16.xhtml#Page_388)
    -   dilution of coagulation factors  [388](c16.xhtml#Page_388)
    -   effects on organ systems
        -   endocrine and metabolic response  [232](c11.xhtml#Page_232)
        -   gastrointestinal effects  [232](c11.xhtml#Page_232)
        -   hepatic effects  [231](c11.xhtml#Page_231)–232
        -   neurological injury and protection  [230](c11.xhtml#Page_230), _[231](c11.xhtml#Page_231)_
        -   pulmonary effects  [230](c11.xhtml#Page_230)–231
        -   renal effects  [231](c11.xhtml#Page_231)–232
    
    -   emergency  [243](c11.xhtml#Page_243)
    -   exposure to circuit [387](c16.xhtml#Page_387)–388
    -   future aspects  [243](c11.xhtml#Page_243)
    -   hemodilution and CPB prime  [388](c16.xhtml#Page_388), _[388](c16.xhtml#Page_388)_
    -   heparin‐induced thrombocytopenia  _[390](c16.xhtml#Page_390),_ [390](c16.xhtml#Page_390)–393
        -   antithrombin (AT)  [391](c16.xhtml#Page_391)
        -   argatroban  [391](c16.xhtml#Page_391), _[392](c16.xhtml#Page_392)_
        -   bivalirudin  [391](c16.xhtml#Page_391), _[392](c16.xhtml#Page_392)_
        -   pretest probability  **[391](c16.xhtml#Page_391)**
    
    -   management issues
        -   blood gas management  [236](c11.xhtml#Page_236)–237, _[237](c11.xhtml#Page_237)_
        -   blood products irradiation  [239](c11.xhtml#Page_239)
        -   cold agglutinin disease  [238](c11.xhtml#Page_238)–239, _[240](c11.xhtml#Page_240)_
        -   deep hypothermic circulatory arrest  _[232](c11.xhtml#Page_232)–234,_ [233](c11.xhtml#Page_233)–234
        -   leukoreduction  [239](c11.xhtml#Page_239)
        -   pH‐stat _vs._ alpha‐stat  [236](c11.xhtml#Page_236)–237, _[237](c11.xhtml#Page_237)_
        -   regional cerebral perfusion  [234](c11.xhtml#Page_234)–236, _[235](c11.xhtml#Page_235)_
        -   sickle cell disease  [237](c11.xhtml#Page_237)–238, **[239](c11.xhtml#Page_239)**
        -   warm CPB  _[232](c11.xhtml#Page_232),_ [232](c11.xhtml#Page_232)–233
    
    -   management of pediatric
        -   anticoagulation  _[219](c11.xhtml#Page_219),_ [219](c11.xhtml#Page_219)–220
        -   antifibrinolytic therapy  [227](c11.xhtml#Page_227)–229
        -   aortic cross‐clamping  [221](c11.xhtml#Page_221)–222
        -   cardioplegic cardiac arrest  [222](c11.xhtml#Page_222)–223
        -   conventional ultrafiltration (CUF)  [224](c11.xhtml#Page_224)–226
        -   cooling and temperature management  [221](c11.xhtml#Page_221)
        -   failure to separate  [226](c11.xhtml#Page_226)–227, _[228](c11.xhtml#Page_228)_
        -   hemostatic management  _[219](c11.xhtml#Page_219),_ [219](c11.xhtml#Page_219)–220
        -   heparin reversal  [227](c11.xhtml#Page_227)
        -   initiation of CPB  [220](c11.xhtml#Page_220)–221, _[221](c11.xhtml#Page_221)_
        -   modified ultrafiltration (MUF)  [224](c11.xhtml#Page_224)–226, **[226](c11.xhtml#Page_226)**
        -   myocardial ischemia  [221](c11.xhtml#Page_221)–222
        -   post‐bypass phase  [224](c11.xhtml#Page_224), _[225](c11.xhtml#Page_225)_
        -   pre‐bypass period  [218](c11.xhtml#Page_218)–219
        -   reperfusion  [223](c11.xhtml#Page_223)–224
        -   separation from CPB  [224](c11.xhtml#Page_224), _[225](c11.xhtml#Page_225)_
        -   stages  [218](c11.xhtml#Page_218)
        -   transfusion management  [227](c11.xhtml#Page_227)
    
    -   prime composition  [389](c16.xhtml#Page_389)
    -   systemic inflammatory response  [971](c36.xhtml#Page_971)–972
    -   ultrafiltration  [393](c16.xhtml#Page_393)
-   cardiopulmonary interactions
    -   bidirectional cavopulmonary (Glenn) anastomosis  [517](c21.xhtml#Page_517)
    -   delayed sternal closure  [516](c21.xhtml#Page_516), _[516](c21.xhtml#Page_516)_
    -   diastolic RV dysfunction and Fontan circulation  [517](c21.xhtml#Page_517)
    -   intrathoracic pressure on PVR  [515](c21.xhtml#Page_515)–516, _[516](c21.xhtml#Page_516)_
    -   intrathoracic pressure on right heart  [515](c21.xhtml#Page_515)
    -   postoperative PHT  [518](c21.xhtml#Page_518)–519
    -   systemic‐to‐pulmonary artery anastomosis  [518](c21.xhtml#Page_518)
    -   systolic LV dysfunction  [516](c21.xhtml#Page_516)–517
-   cardiopulmonary resuscitation (CPR)
    
    -   anomalous aortic origin of a coronary artery (AAOCA)  [614](c25.xhtml#Page_614)–616
    -   aortic valve disease  [611](c25.xhtml#Page_611)–612
    -   arrest phase management  [975](c36.xhtml#Page_975)
    -   arrhythmias  [617](c25.xhtml#Page_617)–618
    -   cardiomyopathies  [618](c25.xhtml#Page_618)
    -   coaching  [621](c25.xhtml#Page_621)
    -   complete superior‐inferior cavo‐pulmonary connection  [614](c25.xhtml#Page_614), **[615](c25.xhtml#Page_615), [616](c25.xhtml#Page_616)**
    -   current guidelines
        -   advanced airway interventions  [602](c25.xhtml#Page_602)
        -   drug administration  [602](c25.xhtml#Page_602), **[604](c25.xhtml#Page_604)**– **[606](c25.xhtml#Page_606)**
        -   guidelines recommendations **[601](c25.xhtml#Page_601), [602](c25.xhtml#Page_602)**
        -   pediatric resuscitation  [602](c25.xhtml#Page_602), _[603](c25.xhtml#Page_603)_
        -   techniques  [602](c25.xhtml#Page_602)
        -   VF/pulseless VF management  [602](c25.xhtml#Page_602)
    
    -   epidemiology  [599](c25.xhtml#Page_599)–600
    -   head‐up  [621](c25.xhtml#Page_621)
    -   interposed abdominal compression  [619](c25.xhtml#Page_619)–621
    -   intrathoracic pressure regulation  [621](c25.xhtml#Page_621)
    -   mechanical circulatory support  [616](c25.xhtml#Page_616), **[616](c25.xhtml#Page_616),** _[620](c25.xhtml#Page_620)_
    -   mitral valve disease  [611](c25.xhtml#Page_611)
    -   monitoring and risk reduction  [974](c36.xhtml#Page_974)–975
    -   myocarditis  [618](c25.xhtml#Page_618)
    -   open‐sternum  [619](c25.xhtml#Page_619), **[619](c25.xhtml#Page_619)**
    -   post‐cardiac arrest care
        -   acute kidney injury  [609](c25.xhtml#Page_609)–610
        -   checklist  **[608](c25.xhtml#Page_608)**
        -   neurologic monitoring  [607](c25.xhtml#Page_607)–609
        -   neuroprotective management  [607](c25.xhtml#Page_607)–609
        -   outcomes and follow‐up  [610](c25.xhtml#Page_610)
        -   postarrest myocardial dysfunction  [609](c25.xhtml#Page_609)
    
    -   post‐resuscitation management  [975](c36.xhtml#Page_975)–976
    -   pulmonary hypertension (PH)  [618](c25.xhtml#Page_618)–619
    -   right‐heart lesions  [612](c25.xhtml#Page_612)
    -   simulation/education  [621](c25.xhtml#Page_621)–622
    -   single ventricle lesions  [612](c25.xhtml#Page_612)–613
    -   superior cavo‐pulmonary connection  [613](c25.xhtml#Page_613)
    -   team training  [622](c25.xhtml#Page_622)
    -   total anomalous pulmonary venous connection (TAPVC)  [612](c25.xhtml#Page_612)
    -   Williams‐Beuren syndrome  [617](c25.xhtml#Page_617)
-   cardiovascular development
    
    -   aortic arches  [104](c06.xhtml#Page_104)–106, _[105](c06.xhtml#Page_105)_
    -   atrioventricular canal septation  [95](c06.xhtml#Page_95)–97
    -   AV valve development  [95](c06.xhtml#Page_95)–97
    -   cardiac cell lineage and specification  [84](c06.xhtml#Page_84), _[87](c06.xhtml#Page_87)_
    -   cardiac innervation  [111](c06.xhtml#Page_111), _[112](c06.xhtml#Page_112)_
    -   cardiac looping  [87](c06.xhtml#Page_87)–89, _[89](c06.xhtml#Page_89), [90](c06.xhtml#Page_90)_
    -   cardiac lymphatics  [113](c06.xhtml#Page_113)
    -   cardiac septation  [90](c06.xhtml#Page_90)
        -   atrial septation  [90](c06.xhtml#Page_90)–93
        -   ventricular septation  [93](c06.xhtml#Page_93)–95
    
    -   cardiogenic fields  [84](c06.xhtml#Page_84)
    -   conduction system  [102](c06.xhtml#Page_102)–104
    -   coronary artery development  [100](c06.xhtml#Page_100)–102, _[101](c06.xhtml#Page_101)_
    -   epiblast cells  [84](c06.xhtml#Page_84), _[84](c06.xhtml#Page_84)_
    -   epicardium  [100](c06.xhtml#Page_100)–102
    -   heart tube formation  _[85](c06.xhtml#Page_85),_ [85](c06.xhtml#Page_85)–86
    -   outflow tract septation  [97](c06.xhtml#Page_97)–100
    -   pulmonary veins  [106](c06.xhtml#Page_106)–108, _[107](c06.xhtml#Page_107)_
    -   semilunar valve development  [97](c06.xhtml#Page_97)–98
    -   stages of human development  **[113](c06.xhtml#Page_113)**
    -   systemic veins  _[108](c06.xhtml#Page_108),_ [108](c06.xhtml#Page_108)–111, _[109](c06.xhtml#Page_109)_
-   catheter‐related bloodstream infections (CRBSIs)  [300](c13.xhtml#Page_300)
-   Central Cardiac Audit Database  [31](c03.xhtml#Page_31)
-   cerebrovascular physiology
    -   circulatory arrest  [310](c14.xhtml#Page_310), _[310](c14.xhtml#Page_310)_
    -   cooling and rewarming  [308](c14.xhtml#Page_308), _[308](c14.xhtml#Page_308)_
    -   glucose management  [309](c14.xhtml#Page_309)–310
    -   hemodilution and transfusion practices  [309](c14.xhtml#Page_309)
    -   metabolic autoregulation  _[308](c14.xhtml#Page_308)_
    -   neurovascular coupling  [308](c14.xhtml#Page_308)
    -   pH‐stat _vs._ alpha‐stat blood gas management  [308](c14.xhtml#Page_308)–309
    -   selective cerebral perfusion  _[310](c14.xhtml#Page_310),_ [310](c14.xhtml#Page_310)–312, **[312](c14.xhtml#Page_312),** _[312](c14.xhtml#Page_312)_
    -   temperature management  [309](c14.xhtml#Page_309)
-   child to adult development  [172](c09.xhtml#Page_172)
-   circulatory function
    -   beta‐adrenergic receptor antagonists  [510](c21.xhtml#Page_510)
    -   calcium  [510](c21.xhtml#Page_510)–511
    -   corticosteroids  [510](c21.xhtml#Page_510)
    -   fenoldopam  [511](c21.xhtml#Page_511)
    -   isoproterenol  [511](c21.xhtml#Page_511)
    -   sodium bicarbonate  [511](c21.xhtml#Page_511)
    -   thyroid hormone  [510](c21.xhtml#Page_510)
-   clinical informatics systems  [81](c05.xhtml#Page_81)–82
-   closed‐loop communication  [31](c03.xhtml#Page_31), _[31](c03.xhtml#Page_31)_
-   coagulation
    
    -   coagulation factors  _[381](c16.xhtml#Page_381)_
    -   components  **[379](c16.xhtml#Page_379)**
    -   CPB‐associated changes [387](c16.xhtml#Page_387)–393
        -   anticoagulation  [389](c16.xhtml#Page_389)–390
        -   CPB prime composition  [389](c16.xhtml#Page_389)
        -   dilutional anemia  [388](c16.xhtml#Page_388)
        -   dilution of coagulation factors  [388](c16.xhtml#Page_388)
        -   exposure to CPB circuit [387](c16.xhtml#Page_387)–388
        -   hemodilution and CPB prime  [388](c16.xhtml#Page_388), _[388](c16.xhtml#Page_388)_
        -   heparin‐induced thrombocytopenia  _[390](c16.xhtml#Page_390),_ [390](c16.xhtml#Page_390)–393
        -   ultrafiltration  [393](c16.xhtml#Page_393)
    
    -   developmental hemostasis
        -   at birth  [380](c16.xhtml#Page_380)
        -   clots  [380](c16.xhtml#Page_380), _[382](c16.xhtml#Page_382)_
        -   maternal coagulation factors  [379](c16.xhtml#Page_379)
        -   neonatal plasminogen levels  [380](c16.xhtml#Page_380)
        -   platelet counts  [379](c16.xhtml#Page_379)
    
    -   hemostasis mechanism
        -   hemostatic  _[378](c16.xhtml#Page_378),_ [379](c16.xhtml#Page_379)
        -   primary  [378](c16.xhtml#Page_378), _[378](c16.xhtml#Page_378)_
        -   secondary  _[378](c16.xhtml#Page_378),_ [378](c16.xhtml#Page_378)–379
        -   tertiary  _[378](c16.xhtml#Page_378),_ [379](c16.xhtml#Page_379)
    
    -   influence of CHD  [381](c16.xhtml#Page_381)–383
        -   erythrocytosis and hemostasis  [383](c16.xhtml#Page_383)
        -   hypoplastic left heart syndrome (HLHS)  [383](c16.xhtml#Page_383)
        -   secondary erythrocytosis  [383](c16.xhtml#Page_383)
    
    -   vitamin K‐dependent coagulation factors  _[380](c16.xhtml#Page_380), [381](c16.xhtml#Page_381)_
-   communication  [31](c03.xhtml#Page_31)
    -   closed‐loop communication  [31](c03.xhtml#Page_31), _[31](c03.xhtml#Page_31)_
    -   failure  [31](c03.xhtml#Page_31)
-   communication and team functioning
    
    -   cardiac catheterization laboratory (CCL)  [65](c04.xhtml#Page_65), _[65](c04.xhtml#Page_65)_
    -   COVID‐19 pandemic era _[51](c04.xhtml#Page_51), [53](c04.xhtml#Page_53),_ [67](c04.xhtml#Page_67)–68
    -   during emergencies  [60](c04.xhtml#Page_60)
    -   enhanced recovery after surgery (ERAS)  [65](c04.xhtml#Page_65)–66, _[66](c04.xhtml#Page_66)_
    -   intensive care unit handoffs  [62](c04.xhtml#Page_62)–64, **[64](c04.xhtml#Page_64)**
    -   intraoperative multidisciplinary collaborations  [60](c04.xhtml#Page_60)–62
    -   major and minor events during arterial switch operation  **[54](c04.xhtml#Page_54)–55**
    -   in operating room
        -   anesthesiology‐specific checklists  [56](c04.xhtml#Page_56)–57, **[58](c04.xhtml#Page_58)**
        -   central venous catheter insertion checklist  _[57](c04.xhtml#Page_57)_
        -   surgical safety checklist (SSCL)  [55](c04.xhtml#Page_55)–56, _[56](c04.xhtml#Page_56)_
    
    -   during the operation
        -   call‐back communication  _[58](c04.xhtml#Page_58)_
        -   closed‐loop communication  _[58](c04.xhtml#Page_58)_
        -   critical events and subteams  **[59](c04.xhtml#Page_59)**
        -   not needing to know  [57](c04.xhtml#Page_57)
        -   open‐loop communication  _[58](c04.xhtml#Page_58)_
        -   procedures in medical practice  [57](c04.xhtml#Page_57)
        -   standardized approach  [60](c04.xhtml#Page_60)
        -   sterile cockpit  [57](c04.xhtml#Page_57)
-   competency‐based assessment  [25](c02.xhtml#Page_25)
-   conduction disorders, arrhythmias
    
    -   atrioventricular (AV) block
        -   complete  _[531](c22.xhtml#Page_531)_
        -   first‐degree  [529](c22.xhtml#Page_529)
        -   second‐degree  [529](c22.xhtml#Page_529)–530, _[530](c22.xhtml#Page_530)_
        -   third‐degree  [530](c22.xhtml#Page_530)–531
    
    -   bundle branch block  [529](c22.xhtml#Page_529)
-   congenital cardiac anesthesia
    -   pharmacokinetics and pharmacodynamics  [206](c10.xhtml#Page_206)–209
        -   cardiopulmonary bypass  [206](c10.xhtml#Page_206)–207, _[208](c10.xhtml#Page_208)_
        -   hypothermia  [207](c10.xhtml#Page_207)–208
        -   intracardiac shunts  [206](c10.xhtml#Page_206)
-   Congenital Cardiac Anesthesia Society (CCAS)  [16](c02.xhtml#Page_16), [32](c03.xhtml#Page_32)
    -   international efforts  [42](c03.xhtml#Page_42)
    -   Joint CCAS‐STS Congenital Cardiac Anesthesia Database  [40](c03.xhtml#Page_40)–41, **[40](c03.xhtml#Page_40)**–**[41](c03.xhtml#Page_41)**
-   Congenital Cardiac Catheterization Project on Outcomes (C3PO) registry  [37](c03.xhtml#Page_37)
-   congenital heart disease (CHD)
    
    -   anatomic evaluation  [116](c07.xhtml#Page_116)
    -   Andersonian nomenclature systems  [117](c07.xhtml#Page_117)–118
    -   anesthetic management of patients  **[14](c01.xhtml#Page_14)**
    -   classification of  **[426](c18.xhtml#Page_426)**
    -   common abnormalities associated with  **[429](c18.xhtml#Page_429)**
    -   CT _vs._ MRI  **[441](c18.xhtml#Page_441)**
    -   delivery room emergencies  [464](c19.xhtml#Page_464), **[464](c19.xhtml#Page_464)–465**
    -   ENCI classification system  **[464](c19.xhtml#Page_464)**
    -   epicardial echocardiography (E‐echo)  [371](c15.xhtml#Page_371)–374
    -   ethics in  [163](c08.xhtml#Page_163)–164
        -   considerations  [163](c08.xhtml#Page_163)–164
        -   palliative care  [164](c08.xhtml#Page_164)
    
    -   fetus to the adult patient  [13](c01.xhtml#Page_13)
    -   genetic testing  [161](c08.xhtml#Page_161)–163
        -   chromosomal karyotype  [162](c08.xhtml#Page_162)
        -   chromosomal microarray (CMA)  [162](c08.xhtml#Page_162)
        -   fluorescence in‐situ hybridization (FISH)  [162](c08.xhtml#Page_162)
        -   by lesion  **[162](c08.xhtml#Page_162)**– **[163](c08.xhtml#Page_163)**
        -   single gene sequencing  [162](c08.xhtml#Page_162)
        -   by suspected diagnosis  **[163](c08.xhtml#Page_163)**
        -   whole exome sequencing (WES)  [162](c08.xhtml#Page_162)–163
    
    -   hypoxic gas mixtures and inspired CO2  [575](c23.xhtml#Page_575)
    -   lung function in children
        -   Blalock‐Taussig (BT) shunt placement  [570](c23.xhtml#Page_570)
        -   cardiopulmonary interactions  [571](c23.xhtml#Page_571)–572
        -   CPB  [571](c23.xhtml#Page_571)
    
    -   mechanical ventilation for children
        -   airway pressure release ventilation (APRV)  [575](c23.xhtml#Page_575)
        -   anesthesia ventilators  [574](c23.xhtml#Page_574)–575
        -   high‐frequency oscillatory ventilation (HFOV)  [575](c23.xhtml#Page_575)
        -   lung management during CPB  [573](c23.xhtml#Page_573)
        -   monitoring ventilation  [574](c23.xhtml#Page_574)
        -   operating room to ICU transition  [575](c23.xhtml#Page_575)
        -   positive end‐expiratory pressure (PEEP)  [572](c23.xhtml#Page_572)
        -   volume control _vs._ pressure control ventilation  [574](c23.xhtml#Page_574)
    
    -   multidisciplinary approach  [426](c18.xhtml#Page_426)
    -   neurodevelopmental disability  [305](c14.xhtml#Page_305), _[306](c14.xhtml#Page_306)_
    -   nitric oxide (iNO)  [575](c23.xhtml#Page_575)–576
    -   nomenclature and database project  [117](c07.xhtml#Page_117)
    -   non‐invasive assessment of  [439](c18.xhtml#Page_439)–440
    -   patients demographics  [425](c18.xhtml#Page_425)
    -   risk assessment  [443](c18.xhtml#Page_443)–447
    -   risk stratification score for  **[446](c18.xhtml#Page_446)**
    -   segmental evaluation, _[130](c07.xhtml#Page_130) see also_ [segmental approach, CHD](#ind2439)
    -   sequential segmental approach  [117](c07.xhtml#Page_117), _[118](c07.xhtml#Page_118)_
    -   terminology and classification  [425](c18.xhtml#Page_425)–426
    -   tracheostomy
        -   cardiac surgery  [577](c23.xhtml#Page_577)
        -   incidence of  [576](c23.xhtml#Page_576)
        -   placement of  [576](c23.xhtml#Page_576)–577
        -   primary diagnoses and procedures  **[576](c23.xhtml#Page_576)**
    
    -   transesophageal echocardiography (TEE)  [331](c15.xhtml#Page_331)–371
    -   Van Praagh nomenclature systems  [117](c07.xhtml#Page_117)–118
-   Congenital Heart Disease Adjustment for Risk Method (CHARM)  [37](c03.xhtml#Page_37)
-   congenital heart surgery (CHS)
    
    -   antifibrinolytics  [253](c12.xhtml#Page_253)–254
    -   coagulation system changes  [253](c12.xhtml#Page_253)
    -   critical illness‐related corticosteroid insufficiency (CIRCI)
        -   diagnosis of  [266](c12.xhtml#Page_266)–267
        -   hypothalamic–pituitary–adrenal (HPA) axis  [266](c12.xhtml#Page_266), _[266](c12.xhtml#Page_266)_
        -   management of  [267](c12.xhtml#Page_267)
    
    -   early extubation
        -   anesthesia technique  [584](c24.xhtml#Page_584)–585
        -   enhanced recovery after pediatric cardiac surgery  [579](c24.xhtml#Page_579)
        -   failed extubation and prolonged mechanical ventilation  [585](c24.xhtml#Page_585)–587
        -   fast‐tracking (_see_ fast‐tracking)
        -   patient selection  [580](c24.xhtml#Page_580), [582](c24.xhtml#Page_582), [583](c24.xhtml#Page_583)
        -   surgical and CPB techniques  [585](c24.xhtml#Page_585)
    
    -   hemostasis and thrombosis
        -   cyanosis effects  **[252](c12.xhtml#Page_252)**
        -   hemorrhagic complications  [252](c12.xhtml#Page_252)–253
        -   hemostasis  [252](c12.xhtml#Page_252), _[252](c12.xhtml#Page_252)_
        -   pediatric coagulation  [252](c12.xhtml#Page_252)
    
    -   hemostatic agents  [254](c12.xhtml#Page_254)–255
    -   hypoglycemia risks  [269](c12.xhtml#Page_269)
    -   minimize transfusion  [254](c12.xhtml#Page_254)
    -   modified ultrafiltration  [254](c12.xhtml#Page_254)
    -   neuraxial techniques
        -   anesthesia in children  **[591](c24.xhtml#Page_591)**
        -   benefits of  [592](c24.xhtml#Page_592)–593
        -   catheter‐based neuraxial techniques  [592](c24.xhtml#Page_592)
        -   risks and complications  [593](c24.xhtml#Page_593)–594
        -   single‐shot neuraxial techniques  [590](c24.xhtml#Page_590)–592
    
    -   postoperative considerations  [589](c24.xhtml#Page_589)–560
    -   pulmonary effects
        -   cardiac performance  [257](c12.xhtml#Page_257)
        -   CPB and lung parenchyma  [259](c12.xhtml#Page_259)–260
        -   CPB and pulmonary vascular resistance  [258](c12.xhtml#Page_258)
        -   lung physiology in children  **[258](c12.xhtml#Page_258)**
        -   mechanical compromise  [256](c12.xhtml#Page_256)
        -   metabolic compromise  [256](c12.xhtml#Page_256)
        -   neonatal oxygen delivery  [257](c12.xhtml#Page_257)
        -   post‐CPB pulmonary hypertension  [258](c12.xhtml#Page_258)–259
        -   pulmonary vascular disease (PVD)  [257](c12.xhtml#Page_257)
        -   respiratory function  [260](c12.xhtml#Page_260)–261
        -   respiratory physiology in neonates and small infants  **[256](c12.xhtml#Page_256)**
        -   ventilatory compromise  [256](c12.xhtml#Page_256)
    
    -   regional blocks
        -   erector spinae plane block (ESPB)  [596](c24.xhtml#Page_596), _[596](c24.xhtml#Page_596)_
        -   paravertebral blocks  [595](c24.xhtml#Page_595)
        -   pecto‐intercostal fascial block (PIFB)  [595](c24.xhtml#Page_595), _[595](c24.xhtml#Page_595)_
        -   serratus anterior plane block (SAPB)  [596](c24.xhtml#Page_596), _[596](c24.xhtml#Page_596)_
        -   transverse thoracic muscle plane block (TTPB)  [595](c24.xhtml#Page_595), _[595](c24.xhtml#Page_595)_
    
    -   renal effects
        -   acute kidney injury in children  **[262](c12.xhtml#Page_262)**
        -   clinical outcomes  [262](c12.xhtml#Page_262)–263
        -   continuous veno‐venous hemofiltration  [264](c12.xhtml#Page_264)
        -   cystatin C  [262](c12.xhtml#Page_262), _[263](c12.xhtml#Page_263)_
        -   emerging biomarkers  [261](c12.xhtml#Page_261)–262
        -   glomerular filtration rate (GFR)  [261](c12.xhtml#Page_261)
        -   KDIGO classification systems  [261](c12.xhtml#Page_261)
        -   low cardiac output syndrome (LCOS)  [261](c12.xhtml#Page_261)
        -   neutrophil gelatinase‐associated lipocalin (NGAL)  [262](c12.xhtml#Page_262)
        -   peritoneal dialysis  [263](c12.xhtml#Page_263)–264
        -   PRIMACOR study  [261](c12.xhtml#Page_261)
        -   renal replacement therapy  [263](c12.xhtml#Page_263)–264
        -   RIFLE score  [261](c12.xhtml#Page_261)
    
    -   splanchnic circulation
        -   elevated systemic venous pressure  [265](c12.xhtml#Page_265)
        -   feeding and nutrition  [265](c12.xhtml#Page_265)–266
        -   hepatic dysfunction  [265](c12.xhtml#Page_265)
        -   mesenteric ischemia and NEC  [264](c12.xhtml#Page_264)–265
    
    -   steroid therapy postoperatively in children  **[268](c12.xhtml#Page_268)**
    -   stress hyperglycemia  [268](c12.xhtml#Page_268)–269
    -   systemic response
        -   activation of coagulation system  [247](c12.xhtml#Page_247)–250
        -   activation of inflammation  [246](c12.xhtml#Page_246)–247
        -   activation of kinin system  [246](c12.xhtml#Page_246)
        -   cardiopulmonary bypass (CPB) [244](c12.xhtml#Page_244), _[245](c12.xhtml#Page_245)_
        -   complement pathway activation  [246](c12.xhtml#Page_246)
        -   kinin–kallikrein–bradykinin system [244](c12.xhtml#Page_244), _[245](c12.xhtml#Page_245)_
    
    -   thrombosis  [255](c12.xhtml#Page_255)
    -   thyroid hormone  [269](c12.xhtml#Page_269)–270
    -   transfusion  [253](c12.xhtml#Page_253)
-   congenitally corrected TGA (CCTGA)
    -   anatomy  [733](c29.xhtml#Page_733)–734, _[736](c29.xhtml#Page_736)_
    -   diagnostic testing  [735](c29.xhtml#Page_735)
    -   double switch (DS) procedure  [737](c29.xhtml#Page_737), _[738](c29.xhtml#Page_738)_
    -   Fontan procedure  [738](c29.xhtml#Page_738)
    -   incidence  [733](c29.xhtml#Page_733)
    -   with L‐loop ventricles  [103](c06.xhtml#Page_103)
    -   long‐term outcomes  **[738](c29.xhtml#Page_738)**
    -   natural history  [734](c29.xhtml#Page_734)–735
    -   normal anatomy  _[733](c29.xhtml#Page_733)_
    -   outcomes  [738](c29.xhtml#Page_738)
    -   pathophysiology  [735](c29.xhtml#Page_735)
    -   postoperative complications  [739](c29.xhtml#Page_739)
    -   preoperative assessment  [739](c29.xhtml#Page_739)
    -   section of heart with  _[734](c29.xhtml#Page_734)_
    -   Senning and Rastelli  [737](c29.xhtml#Page_737)–738
    -   surgical options
        -   anatomic repair  [737](c29.xhtml#Page_737)
        -   physiologic repair  [736](c29.xhtml#Page_736)–737
-   consent issue  [426](c18.xhtml#Page_426)
-   continuous positive airway pressure (CPAP) [785](c31.xhtml#Page_785)
-   coronary arteries anomalies
    
    -   aneurysms [801](c31.xhtml#Page_801)
    -   anomalous aortic origins [800](c31.xhtml#Page_800)
    -   anomalous left coronary artery arising from the pulmonary artery (ALCAPA) _[796](c31.xhtml#Page_796)_
        -   anesthetic considerations [798](c31.xhtml#Page_798)–799
        -   pathophysiology [795](c31.xhtml#Page_795)–796
        -   surgery for [796](c31.xhtml#Page_796)–798
        -   Takeuchi procedure [796](c31.xhtml#Page_796), _[797](c31.xhtml#Page_797)_
    
    -   congenital atresia of the left main coronary artery (CALM) [800](c31.xhtml#Page_800)
    -   coronary arteriovenous fistulas (CAVFs) _[800](c31.xhtml#Page_800)_
        -   anesthesia [801](c31.xhtml#Page_801)
        -   pathophysiology [801](c31.xhtml#Page_801)
        -   surgery and catheter treatment [801](c31.xhtml#Page_801)
    
    -   coronary artery bridging [801](c31.xhtml#Page_801)
    -   stenosis [801](c31.xhtml#Page_801)
    -   surpravalvular aortic stenosis [801](c31.xhtml#Page_801)
-   coronary heart disease (CHD)
    -   anesthetic regimen selection  [209](c10.xhtml#Page_209)
    -   cardiopulmonary resuscitation  [599](c25.xhtml#Page_599)–624
    -   classification of  **[935](c35.xhtml#Page_935)**
    -   risk assessment  **[935](c35.xhtml#Page_935),** [935](c35.xhtml#Page_935)–936

-   data processing pipelines
    -   analytical processing and algorithms  [75](c05.xhtml#Page_75)
    -   cleaning  [75](c05.xhtml#Page_75)
    -   data collection  [75](c05.xhtml#Page_75)
    -   data selection  [75](c05.xhtml#Page_75)
    -   feature extraction  [75](c05.xhtml#Page_75)
    -   presentation and knowledge  [75](c05.xhtml#Page_75)
-   data types
    -   character arrays  [73](c05.xhtml#Page_73)
    -   floating‐point numbers  [73](c05.xhtml#Page_73)
    -   within a hospital  [73](c05.xhtml#Page_73)
    -   integers  [72](c05.xhtml#Page_72)
    -   strings  [73](c05.xhtml#Page_73)
    -   text  [73](c05.xhtml#Page_73)
-   deep hypothermic circulatory arrest (DHCA)  [306](c14.xhtml#Page_306)
-   Dexmedetomidine  [886](c33.xhtml#Page_886)
-   dextro‐transposition of the great arteries (D‐TGA)
    -   with arterial switch  [486](c20.xhtml#Page_486)
    -   interventricular septum  _[485](c20.xhtml#Page_485)_
    -   left ventricular outflow obstruction  _[485](c20.xhtml#Page_485)_
    -   Mustard procedure  [485](c20.xhtml#Page_485), _[486](c20.xhtml#Page_486)_
    -   ventricular septal defect  _[485](c20.xhtml#Page_485)_
    -   VSD and PS and Rastelli repair  [486](c20.xhtml#Page_486)
-   diagnostic catheterization  [890](c34.xhtml#Page_890)–895
    -   cardiac magnetic resonance imaging‐guided catheterization  [894](c34.xhtml#Page_894)–895, **[895](c34.xhtml#Page_895)**
    -   endomyocardial biopsy  [891](c34.xhtml#Page_891)–892, _[893](c34.xhtml#Page_893)_
    -   indications  [890](c34.xhtml#Page_890)–891
    -   procedure overview  [891](c34.xhtml#Page_891), **[893](c34.xhtml#Page_893)**
    -   with pulmonary hypertension  _[891](c34.xhtml#Page_891)_
    -   pulmonary hypertension study  [892](c34.xhtml#Page_892)–894, **[892](c34.xhtml#Page_892)–894**
-   difficult airway
    -   congenital and acquired airway abnormalities  **[561](c23.xhtml#Page_561)**
    -   congenital syndromes and laryngoscopy grade  **[560](c23.xhtml#Page_560)**
    -   emergency cricothyrotomy  [564](c23.xhtml#Page_564)
    -   extubation  [564](c23.xhtml#Page_564)–565
    -   fiberoptic‐guided tracheal intubation  [563](c23.xhtml#Page_563)–564
    -   infographic _[562](c23.xhtml#Page_562)_
    -   intubation  [560](c23.xhtml#Page_560), [561](c23.xhtml#Page_561), [563](c23.xhtml#Page_563)
    -   management cart  [563](c23.xhtml#Page_563)
    -   patient demographics  **[561](c23.xhtml#Page_561)**
-   double outlet right ventricle (DORV)  [639](c26.xhtml#Page_639)–642
    -   anatomic sub‐types  _[640](c26.xhtml#Page_640)_
    -   anesthetic considerations  [641](c26.xhtml#Page_641)–642
    -   doubly committed VSD  [639](c26.xhtml#Page_639)
    -   incidence  [639](c26.xhtml#Page_639)
    -   natural history  [640](c26.xhtml#Page_640)–641
    -   noncommitted VSD  [639](c26.xhtml#Page_639)–640
    -   pathophysiology  [640](c26.xhtml#Page_640)–641
    -   subaortic VSD  [639](c26.xhtml#Page_639)
    -   subpulmonary VSD  [639](c26.xhtml#Page_639)
    -   surgical approaches  [641](c26.xhtml#Page_641)
    -   surgical repair  _[641](c26.xhtml#Page_641)_
-   dysautonomias  [111](c06.xhtml#Page_111)

-   Ebstein anomaly (EA)  [97](c06.xhtml#Page_97)
    
    -   anesthetic considerations
        -   intraoperative  [683](c28.xhtml#Page_683)–684
        -   postoperative  [684](c28.xhtml#Page_684)
        -   preoperative  [681](c28.xhtml#Page_681)–683, _[682](c28.xhtml#Page_682)_
    
    -   arrhythmia  [487](c20.xhtml#Page_487)
    -   cardiac magnetic resonance imaging  _[682](c28.xhtml#Page_682)_
    -   cardiac surgery  [487](c20.xhtml#Page_487)–488
    -   Carpentier classifications  _[676](c28.xhtml#Page_676)_
    -   characteristics  **[675](c28.xhtml#Page_675)**
    -   circular shunt  [682](c28.xhtml#Page_682), _[683](c28.xhtml#Page_683)_
    -   cone repair  [679](c28.xhtml#Page_679), _[679](c28.xhtml#Page_679), [680](c28.xhtml#Page_680)_
    -   Cryoablation  _[681](c28.xhtml#Page_681)_
    -   diagnostic procedures  [487](c20.xhtml#Page_487)
    -   electrophysiologic abnormalities  **[677](c28.xhtml#Page_677)**
    -   electrophysiology  [487](c20.xhtml#Page_487)
    -   incidence, anatomy, and natural history  [675](c28.xhtml#Page_675)–676
    -   noncardiac surgery  [488](c20.xhtml#Page_488)
    -   normal heart and  _[677](c28.xhtml#Page_677)_
    -   normal tricuspid valve attachments  _[676](c28.xhtml#Page_676)_
    -   outcomes  [680](c28.xhtml#Page_680)–681
    -   pathophysiology  [676](c28.xhtml#Page_676)–677
    -   pre‐operative TEE  _[487](c20.xhtml#Page_487)_
    -   surgical and transcatheter approaches  [677](c28.xhtml#Page_677)–681
    -   surgical intervention _[678](c28.xhtml#Page_678)_
    -   timing of intervention  [677](c28.xhtml#Page_677)
    -   treatment _[678](c28.xhtml#Page_678),_ **[679](c28.xhtml#Page_679)**
    -   tricuspid valve (TV) leaflet augmentations  _[680](c28.xhtml#Page_680)_
-   education
    
    -   current model  [17](c02.xhtml#Page_17)
    -   curriculum  [17](c02.xhtml#Page_17)–27
        -   content  [21](c02.xhtml#Page_21)
        -   general needs assessment  [17](c02.xhtml#Page_17)–19
        -   goals and objectives  [19](c02.xhtml#Page_19)–21
        -   implementation  [23](c02.xhtml#Page_23)–24
        -   maintenance and enhancement  [27](c02.xhtml#Page_27)
        -   targeted needs assessment  [19](c02.xhtml#Page_19)
    
    -   dissemination  [27](c02.xhtml#Page_27)
    -   evaluation and feedback  [24](c02.xhtml#Page_24)–27
        -   curriculum evaluation and feedback  [24](c02.xhtml#Page_24)
        -   faculty members  [26](c02.xhtml#Page_26)
        -   learner assessment methods  [25](c02.xhtml#Page_25)
        -   milestones  [25](c02.xhtml#Page_25)
        -   overall program effectiveness  [26](c02.xhtml#Page_26)–27
        -   program evaluation methods  [25](c02.xhtml#Page_25)–26
    
    -   methodology  [21](c02.xhtml#Page_21)–23
    -   professional society role  [27](c02.xhtml#Page_27)
    -   strategies  [21](c02.xhtml#Page_21)–23
-   Edward’s developmental model  _[106](c06.xhtml#Page_106)_
-   Ehlers‐Danlos syndrome (EDS) **[140](c08.xhtml#Page_140),** [156](c08.xhtml#Page_156)
-   eisenmenger syndrome  [468](c20.xhtml#Page_468)
-   electrophysiology procedures, CCL
    
    -   anesthetic considerations  [926](c34.xhtml#Page_926)–927
    -   anesthetic drugs and
        -   automatic tachycardias  [928](c34.xhtml#Page_928)–929
        -   cardiac conduction system  [927](c34.xhtml#Page_927)–929
        -   reentry tachycardias  [927](c34.xhtml#Page_927)–928, **[928](c34.xhtml#Page_928)**
    
    -   defibrillators implantation  [929](c34.xhtml#Page_929)–932
    -   elective cardioversion  [929](c34.xhtml#Page_929)–930
    -   pacemakers implantation  [929](c34.xhtml#Page_929)–932
    -   studies and ablations
        -   arrhythmia pathogenesis  [925](c34.xhtml#Page_925)
        -   complications and risk factors  [925](c34.xhtml#Page_925)–926
        -   electroanatomical map  _[926](c34.xhtml#Page_926)_
        -   radiofrequency ablation and cryoablation  [925](c34.xhtml#Page_925)
        -   techniques  [925](c34.xhtml#Page_925), _[926](c34.xhtml#Page_926)_
    
    -   transvenous lead extraction  [930](c34.xhtml#Page_930)–932, _[931](c34.xhtml#Page_931)_
        -   anesthetic preparation  [930](c34.xhtml#Page_930)
        -   complications  **[932](c34.xhtml#Page_932)**
-   Emergent neonatal cardiac intervention (ENCI) classification system  **[464](c19.xhtml#Page_464)**
-   endotracheal tube (ETT)
    -   airway management  [559](c23.xhtml#Page_559)
    -   alveolar ventilation  [559](c23.xhtml#Page_559)
    -   cuffed  [559](c23.xhtml#Page_559)
    -   fiberoptic bronchoscope (FOB)  [563](c23.xhtml#Page_563)
    -   Microcuff® endotracheal tube  [559](c23.xhtml#Page_559)
    -   orotracheal _vs._ nasotracheal intubation  [559](c23.xhtml#Page_559)–560
    -   single‐lung ventilation in children  **[567](c23.xhtml#Page_567)**
    -   sizes in pediatric patients  **[559](c23.xhtml#Page_559)**
    -   supraglottic airway  _[564](c23.xhtml#Page_564)_
    -   uncuffed  [558](c23.xhtml#Page_558), [559](c23.xhtml#Page_559)
-   epicardial echocardiography (E‐echo)
    -   additional views  _[374](c15.xhtml#Page_374)_
    -   drawbacks of  [374](c15.xhtml#Page_374)
    -   intraoperative  [371](c15.xhtml#Page_371)
    -   standard views _[373](c15.xhtml#Page_373)_
-   Epoprostenol (Flolan®)  [881](c33.xhtml#Page_881)
-   epsilon‐aminocaproic acid (EACA)  [229](c11.xhtml#Page_229)
-   Etomidate  [886](c33.xhtml#Page_886)
-   European Association for Cardio‐Thoracic Surgery (EACTS)  [752](c30.xhtml#Page_752)
    -   database  [32](c03.xhtml#Page_32), [33](c03.xhtml#Page_33)
    -   STAT mortality score **[34](c03.xhtml#Page_34)**–**[36](c03.xhtml#Page_36)**
-   evaluation
    -   curriculum  [24](c02.xhtml#Page_24)
    -   educational outcomes  [24](c02.xhtml#Page_24)
-   extracorporeal Life Support Organization (ELSO) registry  [980](c36.xhtml#Page_980)
-   extracorporeal membrane oxygenation (ECMO)  [1002](c37.xhtml#Page_1002)–1004
    -   anticoagulation  [980](c36.xhtml#Page_980)
    -   cardiac support  [1019](c37.xhtml#Page_1019)–1020
    -   cardiac surgical intervention  [979](c36.xhtml#Page_979)
    -   cardiac transplantation  [980](c36.xhtml#Page_980)
    -   draining deoxygenated blood  _[1004](c37.xhtml#Page_1004)_
    -   future of  [1024](c37.xhtml#Page_1024)
    -   Jostra Rotaflow®  [1002](c37.xhtml#Page_1002), _[1002](c37.xhtml#Page_1002)_
    -   mechanical complications  **[1020](c37.xhtml#Page_1020)**
    -   neurological outcome  [1022](c37.xhtml#Page_1022)–1023
    -   Norwood palliation  [980](c36.xhtml#Page_980)
    -   outcomes and complications  [1019](c37.xhtml#Page_1019)–1024
    -   overall long‐term survival  [1022](c37.xhtml#Page_1022)
    -   oxygenator  _[1002](c37.xhtml#Page_1002),_ [1003](c37.xhtml#Page_1003)
    -   parental outcomes  [1024](c37.xhtml#Page_1024)
    -   patient‐related complications  **[1020](c37.xhtml#Page_1020)**
    -   postcardiotomy support  [979](c36.xhtml#Page_979)
    -   pump  _[1002](c37.xhtml#Page_1002),_ [1002](c37.xhtml#Page_1002)–1003
    -   quality of life  [1023](c37.xhtml#Page_1023)
    -   renal function  [1021](c37.xhtml#Page_1021)–1022
    -   renal injury  **[1021](c37.xhtml#Page_1021)**
    -   renal insufficiency  [981](c36.xhtml#Page_981)
    -   respiratory support  [1020](c37.xhtml#Page_1020)–1021
    -   sepsis  [1021](c37.xhtml#Page_1021)
    -   thromboresistant surfaces  [1003](c37.xhtml#Page_1003)–1004
    -   training  [20](c02.xhtml#Page_20)
    -   Transthoracic echocardiography (TTE)  [1009](c37.xhtml#Page_1009)
    -   _vs._ VAD  [1023](c37.xhtml#Page_1023)
    -   volume of cases  [1023](c37.xhtml#Page_1023)–1024
    -   weaning  [1013](c37.xhtml#Page_1013)–1015

-   familial dysautonomia  [112](c06.xhtml#Page_112)
-   fast‐tracking
    -   benefits of  [587](c24.xhtml#Page_587)–588
    -   concerns and safety of  [589](c24.xhtml#Page_589)
    -   feasibility of  [579](c24.xhtml#Page_579)–580, **[580](c24.xhtml#Page_580)–581**
    -   implementation and maintaining  [583](c24.xhtml#Page_583)
-   feedback
    -   curriculum  [24](c02.xhtml#Page_24)
    -   trainee performance  [24](c02.xhtml#Page_24)
-   fetal cardiac intervention (FCI)
    -   catheter‐based FCI  [462](c19.xhtml#Page_462)–463, _[463](c19.xhtml#Page_463)_
    -   congenital heart conditions  **[462](c19.xhtml#Page_462)**
    -   fetal aortic valvuloplasty  [463](c19.xhtml#Page_463)
    -   fetal left chest  _[462](c19.xhtml#Page_462)_
    -   open FCIs  [462](c19.xhtml#Page_462)
    -   transplacental pharmacotherapy  [461](c19.xhtml#Page_461)
    -   in utero development  [461](c19.xhtml#Page_461)
-   fetus to neonate development
    -   circulatory pathways  [166](c09.xhtml#Page_166)–167
    -   myocardial contractility  [167](c09.xhtml#Page_167)–168
-   fiberoptic‐guided tracheal intubation  [563](c23.xhtml#Page_563)–564
-   Fontan completion
    
    -   anesthetic considerations  [769](c30.xhtml#Page_769)–772
    -   complications
        -   arrhythmias  [773](c30.xhtml#Page_773)
        -   atrioventricular valve regurgitation  [773](c30.xhtml#Page_773)
        -   cardiac arrest  [777](c30.xhtml#Page_777)
        -   cavopulmonary assist device  _[777](c30.xhtml#Page_777)_
        -   lymphatic intervention  [775](c30.xhtml#Page_775)–776
        -   mechanical circulatory support  [776](c30.xhtml#Page_776)–777, _[777](c30.xhtml#Page_777)_
        -   morbidity  [773](c30.xhtml#Page_773), _[773](c30.xhtml#Page_773)_
        -   plastic bronchitis  [774](c30.xhtml#Page_774)–775
        -   pregnancy  [776](c30.xhtml#Page_776)
        -   protein‐losing enteropathy  [774](c30.xhtml#Page_774)–775, _[775](c30.xhtml#Page_775), [776](c30.xhtml#Page_776)_
    
    -   extracardiac Fontan Y‐graft  _[770](c30.xhtml#Page_770)_
    -   flow/pressure/saturation diagram  _[774](c30.xhtml#Page_774)_
    -   intra/extracardiac conduit fenestrated Fontan  _[770](c30.xhtml#Page_770)_
    -   intraoperative considerations
        -   epidural opioids  [771](c30.xhtml#Page_771)
        -   instability  [772](c30.xhtml#Page_772)
        -   positive pressure ventilation  [772](c30.xhtml#Page_772)
        -   vascular access  [770](c30.xhtml#Page_770)
    
    -   lateral tunnel Fontan  _[769](c30.xhtml#Page_769)_
    -   physiology  [768](c30.xhtml#Page_768)–769
    -   postoperative considerations  [772](c30.xhtml#Page_772)
    -   pre‐Fontan characteristics  **[771](c30.xhtml#Page_771)**
    -   preoperative considerations  [769](c30.xhtml#Page_769)
    -   surgical procedure  [767](c30.xhtml#Page_767)–768
    -   total cavopulmonary connection  _[768](c30.xhtml#Page_768)_
-   Fontan physiology
    -   arrhythmia  [489](c20.xhtml#Page_489)
    -   check list for cardioversion  **[491](c20.xhtml#Page_491)**
    -   conversion  [490](c20.xhtml#Page_490)
    -   diagnostic procedures  [489](c20.xhtml#Page_489)
    -   electrophysiology intervention  [489](c20.xhtml#Page_489)
    -   extracardiac Fontan conversions (ECFC)  [488](c20.xhtml#Page_488)
    -   Glenn shunt  [491](c20.xhtml#Page_491)
    -   in HLHS  _[491](c20.xhtml#Page_491)_
    -   procedures and outcomes  **[489](c20.xhtml#Page_489)**
    -   techniques  _[488](c20.xhtml#Page_488)_
    -   TEE images  _[490](c20.xhtml#Page_490)_
-   formative assessment  [25](c02.xhtml#Page_25)
-   Friedman’s fundamental theorem  [71](c05.xhtml#Page_71), _[71](c05.xhtml#Page_71)_
-   functional assessment, TEE
    
    -   diastolic function evaluation  [348](c15.xhtml#Page_348)
    -   LV systolic function
        -   Doppler estimation  [347](c15.xhtml#Page_347)
        -   echocardiographic evaluation  _[346](c15.xhtml#Page_346)_
        -   eyeballing  [345](c15.xhtml#Page_345)
        -   pulsed‐wave Doppler interrogation  [347](c15.xhtml#Page_347)
        -   strain and strain rate imaging  [347](c15.xhtml#Page_347)
    
    -   regional wall motion  [347](c15.xhtml#Page_347), _[348](c15.xhtml#Page_348)_
    -   RV systolic function
        -   echocardiographic assessment  [347](c15.xhtml#Page_347)
        -   tricuspid annular plane systolic excursion (TAPSE)  [348](c15.xhtml#Page_348)

-   Gartner Hype Cycle  [81](c05.xhtml#Page_81), _[81](c05.xhtml#Page_81)_
-   genes with obstructive lesions on CHD type  [100](c06.xhtml#Page_100), **[100](c06.xhtml#Page_100)**
-   genetic syndromes
    
    -   alagille syndrome **[138](c08.xhtml#Page_138)**
    -   aortopathy syndromes
        -   Ehlers‐Danlos syndrome (EDS) **[140](c08.xhtml#Page_140),** [156](c08.xhtml#Page_156)
        -   Loeys‐Dietz syndrome (LDS) **[144](c08.xhtml#Page_144),** [156](c08.xhtml#Page_156)
        -   Marfan syndrome **[144](c08.xhtml#Page_144)**–**[145](c08.xhtml#Page_145),** [154](c08.xhtml#Page_154), [156](c08.xhtml#Page_156), **[156](c08.xhtml#Page_156)**
    
    -   CHARGE syndrome **[138](c08.xhtml#Page_138),** [158](c08.xhtml#Page_158)–159, _[159](c08.xhtml#Page_159),_ **[160](c08.xhtml#Page_160)**
    -   chromosome 22q11 deletion syndrome  [132](c08.xhtml#Page_132)
    -   DiGeorge (22q11‐) syndrome  [132](c08.xhtml#Page_132), **[139](c08.xhtml#Page_139)**
    -   down syndrome (DS)  _[133](c08.xhtml#Page_133),_ [133](c08.xhtml#Page_133)–134, **[140](c08.xhtml#Page_140)**
    -   Edwards syndrome  [134](c08.xhtml#Page_134), _[134](c08.xhtml#Page_134)_
    -   elastin arteriopathies  [134](c08.xhtml#Page_134)–135
    -   Goldenhar syndrome  [136](c08.xhtml#Page_136), _[137](c08.xhtml#Page_137),_**[142](c08.xhtml#Page_142)**
    -   heterotaxy syndrome **[142](c08.xhtml#Page_142)**–**[143](c08.xhtml#Page_143),** [159](c08.xhtml#Page_159)–161, **[161](c08.xhtml#Page_161)**
    -   Hunter syndrome  [137](c08.xhtml#Page_137), **[143](c08.xhtml#Page_143)**
    -   Hurler syndrome  [137](c08.xhtml#Page_137), **[143](c08.xhtml#Page_143)–144,** _[154](c08.xhtml#Page_154)_
    -   maroteaux‐lamy syndrome  [137](c08.xhtml#Page_137), **[145](c08.xhtml#Page_145)**–**[146](c08.xhtml#Page_146)**
    -   morquio syndrome  [137](c08.xhtml#Page_137), **[146](c08.xhtml#Page_146)**–**[147](c08.xhtml#Page_147)**
    -   mucopolysaccharidoses (MPSs)  [136](c08.xhtml#Page_136)–137, **[155](c08.xhtml#Page_155)**
    -   noonan syndrome (NS)  _[135](c08.xhtml#Page_135),_ [135](c08.xhtml#Page_135)–136, **[147](c08.xhtml#Page_147)**–**[148](c08.xhtml#Page_148)**
    -   patau syndrome  [134](c08.xhtml#Page_134)
    -   pompe disease  [137](c08.xhtml#Page_137), **[141](c08.xhtml#Page_141),** [154](c08.xhtml#Page_154)
    -   Trisomy 13  [134](c08.xhtml#Page_134), **[148](c08.xhtml#Page_148)**–**[149](c08.xhtml#Page_149)**
    -   Trisomy 18  [134](c08.xhtml#Page_134), **[149](c08.xhtml#Page_149)**–**[150](c08.xhtml#Page_150)**
    -   Trisomy 21  [133](c08.xhtml#Page_133)–134
    -   Turner syndrome (TS)  [136](c08.xhtml#Page_136), _[136](c08.xhtml#Page_136),_**[151](c08.xhtml#Page_151)**
    -   VACTERL association **[152](c08.xhtml#Page_152),** [156](c08.xhtml#Page_156)–158, _[157](c08.xhtml#Page_157)_
    -   velocardiofacial syndrome (VCFS)  [132](c08.xhtml#Page_132), _[132](c08.xhtml#Page_132)_
    -   Williams‐Beuren syndrome  [134](c08.xhtml#Page_134)–135, _[135](c08.xhtml#Page_135),_**[152](c08.xhtml#Page_152)–153**
-   genetic testing  [161](c08.xhtml#Page_161)–163
    -   chromosomal karyotype  [162](c08.xhtml#Page_162)
    -   chromosomal microarray (CMA)  [162](c08.xhtml#Page_162)
    -   fluorescence in‐situ hybridization (FISH)  [162](c08.xhtml#Page_162)
    -   by lesion  **[162](c08.xhtml#Page_162)**– **[163](c08.xhtml#Page_163)**
    -   single gene sequencing  [162](c08.xhtml#Page_162)
    -   by suspected diagnosis  **[163](c08.xhtml#Page_163)**
    -   whole exome sequencing (WES)  [162](c08.xhtml#Page_162)–163

-   heart transplantation  [832](c32.xhtml#Page_832)–835
    
    -   ABO‐incompatible  [835](c32.xhtml#Page_835)
    -   anesthetic management
        -   CPB period  [840](c32.xhtml#Page_840)
        -   induction and monitoring  [840](c32.xhtml#Page_840)
        -   post‐CPB period  [840](c32.xhtml#Page_840), [842](c32.xhtml#Page_842)
        -   pre‐CPB period  [839](c32.xhtml#Page_839)–840
    
    -   coronary allograft vasculopathy  [849](c32.xhtml#Page_849)–850
    -   diagnostic indications  [832](c32.xhtml#Page_832)–833, **[833](c32.xhtml#Page_833),** _[833](c32.xhtml#Page_833)_
        -   congenital heart disease  [833](c32.xhtml#Page_833)–834, _[834](c32.xhtml#Page_834)_
        -   dilated cardiomyopathy  [833](c32.xhtml#Page_833), **[835](c32.xhtml#Page_835)**
        -   hypertrophic cardiomyopathies (HCM)  [834](c32.xhtml#Page_834)
        -   restrictive cardiomyopathies (RCM)  [834](c32.xhtml#Page_834)
        -   retransplantation  [834](c32.xhtml#Page_834)–835, **[835](c32.xhtml#Page_835)**
    
    -   donor management  [838](c32.xhtml#Page_838)–839
    -   donor–recipient size matching  [838](c32.xhtml#Page_838)–839, _[839](c32.xhtml#Page_839)_
    -   early and late mortality  **[848](c32.xhtml#Page_848)**
    -   failing fontan transplants  [842](c32.xhtml#Page_842)–843, _[844](c32.xhtml#Page_844)_
    -   future aspects  [851](c32.xhtml#Page_851)
    -   heart‐liver transplantation  [843](c32.xhtml#Page_843), _[844](c32.xhtml#Page_844)_
    -   heart–lung transplantation  [843](c32.xhtml#Page_843), [845](c32.xhtml#Page_845)
    -   hyperlipidemia  [850](c32.xhtml#Page_850)
    -   immunosuppression  [845](c32.xhtml#Page_845)–847, **[846](c32.xhtml#Page_846)**
        -   antiproliferative agents  [846](c32.xhtml#Page_846)–847
        -   calcineurin inhibitors  [846](c32.xhtml#Page_846), _[847](c32.xhtml#Page_847)_
        -   mTOR inhibitors  [847](c32.xhtml#Page_847)
        -   rejection therapy  [847](c32.xhtml#Page_847)
    
    -   infection  [850](c32.xhtml#Page_850)
    -   Kaplan–Meier survival  _[848](c32.xhtml#Page_848)_
    -   malignancy  [850](c32.xhtml#Page_850)
    -   management of children  [851](c32.xhtml#Page_851)
    -   quality of life  [850](c32.xhtml#Page_850)–851
    -   recipient evaluation  [836](c32.xhtml#Page_836)–837
        -   chronic noncardiac disease  [836](c32.xhtml#Page_836)–837
        -   CVS anatomy  [836](c32.xhtml#Page_836)
        -   end‐organ dysfunction  [836](c32.xhtml#Page_836)–837
        -   hemodynamics  [836](c32.xhtml#Page_836)
        -   HLA sensitization  [837](c32.xhtml#Page_837)
        -   immune function  [837](c32.xhtml#Page_837)
        -   psychosocial evaluation  [837](c32.xhtml#Page_837)
        -   UNOS waitlist status and mortality  [837](c32.xhtml#Page_837)
    
    -   recipient pretransplant management  [837](c32.xhtml#Page_837)–838
    -   rejection
        -   characteristics  _[849](c32.xhtml#Page_849)_
        -   clinical evidence  [849](c32.xhtml#Page_849)
        -   clinical types of  [848](c32.xhtml#Page_848)
        -   methylprednisolone  [849](c32.xhtml#Page_849)
        -   treatment  [849](c32.xhtml#Page_849)
    
    -   renal dysfunction  [850](c32.xhtml#Page_850)
    -   surgical technique  [839](c32.xhtml#Page_839)
    
-   hemodynamic management  [494](c21.xhtml#Page_494)
    
    -   cardiopulmonary interactions
        -   bidirectional cavopulmonary (Glenn) anastomosis  [517](c21.xhtml#Page_517)
        -   delayed sternal closure  [516](c21.xhtml#Page_516), _[516](c21.xhtml#Page_516)_
        -   diastolic RV dysfunction and Fontan circulation  [517](c21.xhtml#Page_517)
        -   intrathoracic pressure on PVR  [515](c21.xhtml#Page_515)–516, _[516](c21.xhtml#Page_516)_
        -   intrathoracic pressure on right heart  [515](c21.xhtml#Page_515)
        -   postoperative PHT  [518](c21.xhtml#Page_518)–519
        -   systemic‐to‐pulmonary artery anastomosis  [518](c21.xhtml#Page_518)
        -   systolic LV dysfunction  [516](c21.xhtml#Page_516)–517
    
    -   inotropic agents
        -   amrinone  [504](c21.xhtml#Page_504)
        -   arginine vasopressin (AVP)  [506](c21.xhtml#Page_506)
        -   β‐adrenergic receptor agonists  [500](c21.xhtml#Page_500)–501
        -   calcium sensitizers  [505](c21.xhtml#Page_505)–506
        -   catecholamines  [503](c21.xhtml#Page_503)–504
        -   circulatory function  [510](c21.xhtml#Page_510)–511
        -   current practices  [511](c21.xhtml#Page_511)–512, **[512](c21.xhtml#Page_512)**
        -   dobutamine  [503](c21.xhtml#Page_503)
        -   dopamine  [502](c21.xhtml#Page_502)–503
        -   epinephrine  [501](c21.xhtml#Page_501)–502, **[502](c21.xhtml#Page_502)**
        -   hemodynamic effects  **[501](c21.xhtml#Page_501)**
        -   inhibitors of phosphodiesterase type [3](c01.xhtml#Page_3)  [504](c21.xhtml#Page_504)
        -   milrinone  [504](c21.xhtml#Page_504)–505
        -   norepinephrine  [503](c21.xhtml#Page_503), [506](c21.xhtml#Page_506)
        -   phenylephrine  [506](c21.xhtml#Page_506)
        -   postoperative hemodynamic management  [513](c21.xhtml#Page_513)–515, **[514](c21.xhtml#Page_514)**
        -   pulmonary vasodilators  [507](c21.xhtml#Page_507)–509, _[508](c21.xhtml#Page_508)_
        -   schematic representation  _[501](c21.xhtml#Page_501)_
        -   systemic vasodilators  [506](c21.xhtml#Page_506)–507
        -   vasoactive scores  [512](c21.xhtml#Page_512)–513
    
    -   monitoring
        -   assessment of cardiac output  [519](c21.xhtml#Page_519)–522
        -   blood lactate  _[524](c21.xhtml#Page_524),_ [524](c21.xhtml#Page_524)–525
        -   clinical hemodynamic variables  [518](c21.xhtml#Page_518)–519
        -   mixed venous saturation (SvO2)  _[523](c21.xhtml#Page_523),_ [523](c21.xhtml#Page_523)–524
        -   near‐infrared spectroscopy (NIRS)  [522](c21.xhtml#Page_522)–523
        -   practices  [525](c21.xhtml#Page_525)–526
        -   standard perioperative monitoring  [518](c21.xhtml#Page_518)–519, _[519](c21.xhtml#Page_519)_
        -   venous to arterial CO2 partial pressure  [525](c21.xhtml#Page_525)
    
    -   postoperative oxygen transport balance  [499](c21.xhtml#Page_499)–500, **[500](c21.xhtml#Page_500),** _[500](c21.xhtml#Page_500)_
    -   VO2/DO2 balance, CHD surgery
        -   low cardiac output syndrome (LCOS  [496](c21.xhtml#Page_496)–498, _[497](c21.xhtml#Page_497)_
        -   mechanisms underlying in DO2  [496](c21.xhtml#Page_496)–499
        -   mechanisms underlying in VO2  [496](c21.xhtml#Page_496)
        -   oxygen extraction rate (OER)  [495](c21.xhtml#Page_495)
        -   pathologic imbalance  [495](c21.xhtml#Page_495)
        -   pathophysiological changes  _[495](c21.xhtml#Page_495)_
        -   systemic and pulmonary circulations  [495](c21.xhtml#Page_495)
-   high‐risk cardiovascular conditions **[795](c31.xhtml#Page_795)**
-   high‐risk patient groups
    -   adult CHD  **[949](c35.xhtml#Page_949),** [949](c35.xhtml#Page_949)–950
    -   ductal dependent unpalliated neonates  [943](c35.xhtml#Page_943)
    -   Eisenmenger syndrome  **[948](c35.xhtml#Page_948),** [948](c35.xhtml#Page_948)–949
    -   hypertrophic cardiomyopathy (HCM)  [946](c35.xhtml#Page_946), [948](c35.xhtml#Page_948), **[948](c35.xhtml#Page_948)**
    -   pulmonary hypertension  _[944](c35.xhtml#Page_944),_ [944](c35.xhtml#Page_944)–945
    -   severe aortic stenosis  [945](c35.xhtml#Page_945)
    -   shunt‐dependent single‐ventricle  [943](c35.xhtml#Page_943)–944
    -   single‐ventricle with AV valve regurgitation  [944](c35.xhtml#Page_944)
    -   transplant coronary artery disease (TCAD)  [948](c35.xhtml#Page_948)
    -   Williams syndrome  [945](c35.xhtml#Page_945)–946, **[946](c35.xhtml#Page_946), [947](c35.xhtml#Page_947)**
-   hypertrophy  [173](c09.xhtml#Page_173)
-   hypoplastic left heart syndrome (HLHS)  [44](c04.xhtml#Page_44), [188](c09.xhtml#Page_188)
    
    -   anatomy  [742](c30.xhtml#Page_742)
    -   anesthetic considerations  [747](c30.xhtml#Page_747)–752
    -   incidence  [742](c30.xhtml#Page_742)
    -   intraoperative considerations
        -   airway and ventilation management  [748](c30.xhtml#Page_748)
        -   airway secretions  [748](c30.xhtml#Page_748)
        -   physiologic goals  [748](c30.xhtml#Page_748)
        -   point‐of‐care viscoelastic tests  [749](c30.xhtml#Page_749)
        -   PRBC transfusion  [750](c30.xhtml#Page_750)
        -   recombinant activated factor VII (rFVIIa)  [749](c30.xhtml#Page_749)
        -   technical result  [748](c30.xhtml#Page_748)
        -   ultrafiltration techniques  [749](c30.xhtml#Page_749)
    
    -   natural history  [742](c30.xhtml#Page_742)
    -   pathophysiology  _[743](c30.xhtml#Page_743)_
        -   anatomic variables  [743](c30.xhtml#Page_743)
        -   parallel circulation  [742](c30.xhtml#Page_742)
        -   prenatal diagnosis  [744](c30.xhtml#Page_744)
        -   Single Ventricle Reconstruction Trial (SVRT)  [743](c30.xhtml#Page_743)
    
    -   postoperative considerations
        -   cardiac arrest  [752](c30.xhtml#Page_752)
        -   excessive hypoxemia  [750](c30.xhtml#Page_750)
        -   metabolic disturbances  [751](c30.xhtml#Page_751)
        -   pathophysiology  _[750](c30.xhtml#Page_750)_
        -   systemic hypoxemia  [751](c30.xhtml#Page_751)
    
    -   preoperative considerations  [747](c30.xhtml#Page_747)
    -   surgical and transcatheter approaches  [744](c30.xhtml#Page_744)–747
        -   biventricular repair  [746](c30.xhtml#Page_746)–747
        -   hybrid procedure  [746](c30.xhtml#Page_746)
        -   Norwood Stage I palliation  [744](c30.xhtml#Page_744), _[744](c30.xhtml#Page_744), [745](c30.xhtml#Page_745)_
        -   RV‐to‐pulmonary artery shunt  [744](c30.xhtml#Page_744)–745
        -   systemic‐to‐pulmonary artery shunt  [744](c30.xhtml#Page_744)–745

-   Iloprost (Ventavis®)  [881](c33.xhtml#Page_881)
-   immediate perioperative complications  [861](c32.xhtml#Page_861)–862
    
    -   bleeding  [861](c32.xhtml#Page_861)
    -   medical complications
        -   anesthesia after lung transplant surgery  [867](c32.xhtml#Page_867)
        -   antibiotic prophylaxis  [863](c32.xhtml#Page_863)
        -   chronic lung allograft dysfunction  [863](c32.xhtml#Page_863)–864
        -   COVID‐19 pandemic and lung transplantation  [867](c32.xhtml#Page_867)
        -   drug interactions  [863](c32.xhtml#Page_863)
        -   graft rejection  [863](c32.xhtml#Page_863)
        -   immune therapy  [863](c32.xhtml#Page_863)
        -   long‐term survival  [864](c32.xhtml#Page_864)–867, _[865](c32.xhtml#Page_865), [866](c32.xhtml#Page_866)_
        -   opportunistic infections  [863](c32.xhtml#Page_863)
        -   post‐transplant lymphoproliferative disorder  [863](c32.xhtml#Page_863)
        -   surveillance  [864](c32.xhtml#Page_864)
    
    -   physiological changes  [861](c32.xhtml#Page_861)–862
    -   primary graft failure  [861](c32.xhtml#Page_861), **[861](c32.xhtml#Page_861)**
    -   surgical complications
        -   airway complications  [862](c32.xhtml#Page_862)
        -   arrhythmias  [862](c32.xhtml#Page_862)
        -   nerve injuries  [862](c32.xhtml#Page_862)
        -   vascular anastomotic complications  [862](c32.xhtml#Page_862)
-   Improving Pediatric and Adult Congenital Treatment (IMPACT)  [32](c03.xhtml#Page_32), [918](c34.xhtml#Page_918)
-   inotropic agents
    
    -   amrinone  [504](c21.xhtml#Page_504)
    -   arginine vasopressin (AVP)  [506](c21.xhtml#Page_506)
    -   β‐adrenergic receptor agonists  [500](c21.xhtml#Page_500)–501
    -   calcium sensitizers  [505](c21.xhtml#Page_505)–506
    -   catecholamines  [503](c21.xhtml#Page_503)–504
    -   circulatory function  [510](c21.xhtml#Page_510)–511
    -   current practices  [511](c21.xhtml#Page_511)–512, **[512](c21.xhtml#Page_512)**
    -   dobutamine  [503](c21.xhtml#Page_503)
    -   dopamine  [502](c21.xhtml#Page_502)–503
    -   epinephrine  [501](c21.xhtml#Page_501)–502, **[502](c21.xhtml#Page_502)**
    -   hemodynamic effects  **[501](c21.xhtml#Page_501)**
    -   inhibitors of phosphodiesterase type [3](c01.xhtml#Page_3)  [504](c21.xhtml#Page_504)
    -   milrinone  [504](c21.xhtml#Page_504)–505
    -   norepinephrine  [503](c21.xhtml#Page_503), [506](c21.xhtml#Page_506)
    -   phenylephrine  [506](c21.xhtml#Page_506)
    -   postoperative hemodynamic management  [513](c21.xhtml#Page_513)–515, **[514](c21.xhtml#Page_514)**
    -   pulmonary vasodilators  [507](c21.xhtml#Page_507)–509, _[508](c21.xhtml#Page_508)_
    -   schematic representation  _[501](c21.xhtml#Page_501)_
    -   systemic vasodilators  [506](c21.xhtml#Page_506)–507
    -   vasoactive scores  [512](c21.xhtml#Page_512)–513
    
-   International Paediatric and Congenital Cardiac Code (IPCCC)  [32](c03.xhtml#Page_32), [117](c07.xhtml#Page_117)
-   Internet, educational resources  [22](c02.xhtml#Page_22)
-   interventional catheterization  [895](c34.xhtml#Page_895)–914
    
    -   balloon angioplasty/stent placement  [902](c34.xhtml#Page_902)–907
        -   coarctation of aorta (CoA)  _[905](c34.xhtml#Page_905),_ [905](c34.xhtml#Page_905)–906
        -   patent ductus arteriosus stenting  _[906](c34.xhtml#Page_906),_ [906](c34.xhtml#Page_906)–907
        -   pulmonary arteries  [902](c34.xhtml#Page_902), _[902](c34.xhtml#Page_902)_
        -   pulmonary vein stenosis (PVS)  [902](c34.xhtml#Page_902)–904, _[903](c34.xhtml#Page_903), [904](c34.xhtml#Page_904)_
        -   right ventricular outflow tract (RVOT)  _[904](c34.xhtml#Page_904),_ [904](c34.xhtml#Page_904)–905
    
    -   balloon dilation of cardiac valves
        -   aortic valvuloplasty  [901](c34.xhtml#Page_901)–902
        -   pulmonary valvuloplasty  [899](c34.xhtml#Page_899)–901, _[900](c34.xhtml#Page_900), [901](c34.xhtml#Page_901)_
    
    -   creation of cardiovascular communications  [907](c34.xhtml#Page_907)–908
        -   balloon atrial septostomy (BAS)  [907](c34.xhtml#Page_907)
        -   fontan fenestration creation  [908](c34.xhtml#Page_908)
        -   pulmonary hypertension palliation  [907](c34.xhtml#Page_907)–908
    
    -   device closure of cardiovascular communications
        -   atrial septal defects  [896](c34.xhtml#Page_896)
        -   coronary artery fistulas (CAFs)  [898](c34.xhtml#Page_898)–899, _[899](c34.xhtml#Page_899)_
        -   preterm patent ductus arteriosus  [896](c34.xhtml#Page_896)–898, **[897](c34.xhtml#Page_897),** _[897](c34.xhtml#Page_897)_
        -   shared considerations  [895](c34.xhtml#Page_895)–896, _[896](c34.xhtml#Page_896)_
        -   ventricular septal defects  [898](c34.xhtml#Page_898), _[898](c34.xhtml#Page_898)_
    
    -   hybrid procedures  [911](c34.xhtml#Page_911), _[911](c34.xhtml#Page_911)_
    -   percutaneous mechanical circulatory support  _[913](c34.xhtml#Page_913),_ [913](c34.xhtml#Page_913)–914, **[914](c34.xhtml#Page_914)**
    -   pericardiocentesis  _[912](c34.xhtml#Page_912),_ [912](c34.xhtml#Page_912)–913
    -   transcatheter valve replacement
        -   transcatheter aortic valves  [909](c34.xhtml#Page_909)–911, _[910](c34.xhtml#Page_910)_
        -   transcatheter pulmonary valves  _[908](c34.xhtml#Page_908),_ [908](c34.xhtml#Page_908)–909, _[909](c34.xhtml#Page_909)_
-   intraoperative care
    -   anesthetic technique  [951](c35.xhtml#Page_951)
    -   laparoscopic surgery  [951](c35.xhtml#Page_951)–952
    -   monitoring  [950](c35.xhtml#Page_950)–951
    -   otolaryngologic procedures  [952](c35.xhtml#Page_952)–953
    -   spinal instrumentation  [953](c35.xhtml#Page_953)
    -   surgery  [951](c35.xhtml#Page_951)
-   intravascular pressure waveforms
    -   arterial pressure waveform  [295](c13.xhtml#Page_295)
    -   central venous and left atrial waveforms  [295](c13.xhtml#Page_295)–296
    -   ringing and damping  [295](c13.xhtml#Page_295)

-   Joint CCAS‐STS Congenital Cardiac Anesthesia Database **[34](c03.xhtml#Page_34)**–**[36](c03.xhtml#Page_36),** [40](c03.xhtml#Page_40)–41

-   ketamine  [886](c33.xhtml#Page_886)

-   laboratory evaluation  [432](c18.xhtml#Page_432)–433
-   learner assessment methods  [2](c01.xhtml#Page_2)
-   left–sided obstructive lesions
    
    -   aortic coarctation  [660](c27.xhtml#Page_660)–664
        -   anatomy  [660](c27.xhtml#Page_660)–661
        -   anesthetic considerations  [663](c27.xhtml#Page_663)–664
        -   incidence of  [660](c27.xhtml#Page_660)–661
        -   natural history  [660](c27.xhtml#Page_660)–661
        -   pathophysiology  [661](c27.xhtml#Page_661)
        -   repair of  _[662](c27.xhtml#Page_662)_
        -   surgical and transcatheter approaches  [661](c27.xhtml#Page_661)–663
    
    -   aortic valve stenosis  [650](c27.xhtml#Page_650)–653
        -   anatomy  [650](c27.xhtml#Page_650)–651
        -   anesthetic considerations  [652](c27.xhtml#Page_652)
        -   biventricular repair of  **[651](c27.xhtml#Page_651)**
        -   concurrent congenital anomalies  **[654](c27.xhtml#Page_654)**
        -   grading of  **[651](c27.xhtml#Page_651)**
        -   incidence of  [650](c27.xhtml#Page_650)–651
        -   natural history  [650](c27.xhtml#Page_650)–651
        -   outcomes in children  **[654](c27.xhtml#Page_654)**
        -   Ozaki procedure  _[654](c27.xhtml#Page_654)_
        -   pathophysiology  [651](c27.xhtml#Page_651)
        -   Ross–Konno procedure  [652](c27.xhtml#Page_652), _[653](c27.xhtml#Page_653)_
        -   surgical and transcatheter approaches  [651](c27.xhtml#Page_651)–653, _[653](c27.xhtml#Page_653)_
        -   surgical repair  _[655](c27.xhtml#Page_655)_
    
    -   Cor triatriatum  _[669](c27.xhtml#Page_669),_ [672](c27.xhtml#Page_672)
    -   hypertrophic cardiomyopathy  [658](c27.xhtml#Page_658)–660
        -   anatomy  [658](c27.xhtml#Page_658)–659
        -   anesthetic considerations  [660](c27.xhtml#Page_660)
        -   incidence of  [658](c27.xhtml#Page_658)–659
        -   left ventricular outflow tract (LVOY) obstruction  _[659](c27.xhtml#Page_659)_
        -   natural history  [658](c27.xhtml#Page_658)–659
        -   non‐sarcomeric causes  **[658](c27.xhtml#Page_658)**
        -   pathophysiology  [659](c27.xhtml#Page_659)
        -   surgical and transcatheter approaches  [659](c27.xhtml#Page_659)–660
    
    -   interrupted/hypoplastic aortic arch  [664](c27.xhtml#Page_664)–668
        -   anesthetic considerations  [666](c27.xhtml#Page_666)–668
        -   demographic and anatomic features **[665](c27.xhtml#Page_665)**
        -   incidence, anatomy, and natural history  [664](c27.xhtml#Page_664)
        -   pathophysiology  [664](c27.xhtml#Page_664), [666](c27.xhtml#Page_666)
        -   surgical and transcatheter approaches  [666](c27.xhtml#Page_666)
        -   Yasui operation  [666](c27.xhtml#Page_666), _[667](c27.xhtml#Page_667)_
    
    -   mitral stenosis  [670](c27.xhtml#Page_670)–672
        -   anatomy  [670](c27.xhtml#Page_670)–671
        -   anesthetic considerations  [672](c27.xhtml#Page_672)
        -   incidence of  [670](c27.xhtml#Page_670)–671
        -   natural history  [670](c27.xhtml#Page_670)–671
        -   pathophysiology  [671](c27.xhtml#Page_671)–672
        -   surgical and transcatheter approaches  [672](c27.xhtml#Page_672)
    
    -   Shone’s anomaly  [668](c27.xhtml#Page_668)–670
        -   anatomy  [668](c27.xhtml#Page_668)
        -   anesthetic considerations  [670](c27.xhtml#Page_670)
        -   incidence of  [668](c27.xhtml#Page_668)
        -   modified Konno operation  [669](c27.xhtml#Page_669), _[670](c27.xhtml#Page_670)_
        -   natural history  [668](c27.xhtml#Page_668)
        -   pathophysiology  [668](c27.xhtml#Page_668)–669
        -   surgical and transcatheter approaches  [669](c27.xhtml#Page_669)–670
    
    -   subvalvular AS  [653](c27.xhtml#Page_653)–655
        -   anatomy  [653](c27.xhtml#Page_653)
        -   anesthetic considerations  [655](c27.xhtml#Page_655)
        -   incidence of  [653](c27.xhtml#Page_653)
        -   natural history  [653](c27.xhtml#Page_653)
        -   pathophysiology  [654](c27.xhtml#Page_654)
        -   surgical and transcatheter approaches  [654](c27.xhtml#Page_654)–655
    
    -   supravalvular AS  [655](c27.xhtml#Page_655)–658
        -   anatomy  [655](c27.xhtml#Page_655)–656
        -   anesthetic considerations  [657](c27.xhtml#Page_657)–658
        -   incidence of  [655](c27.xhtml#Page_655)–656
        -   natural history  [655](c27.xhtml#Page_655)–656
        -   pathophysiology  [656](c27.xhtml#Page_656)
        -   patient with Williams syndrome  _[656](c27.xhtml#Page_656)_
        -   repair of  _[657](c27.xhtml#Page_657)_
        -   surgical and transcatheter approaches  [656](c27.xhtml#Page_656)
-   left‐to‐right shunt lesions
    
    -   aortopulmonary window (APW)  [628](c26.xhtml#Page_628)–630
        -   anatomy  [628](c26.xhtml#Page_628)–629
        -   anesthetic considerations  [630](c26.xhtml#Page_630)
        -   classification of  _[629](c26.xhtml#Page_629)_
        -   incidence  [628](c26.xhtml#Page_628)–629
        -   natural history  [628](c26.xhtml#Page_628)–629
        -   patch closure of type II  _[630](c26.xhtml#Page_630)_
        -   pathophysiology  [630](c26.xhtml#Page_630)
        -   surgical and transcatheter approaches  [630](c26.xhtml#Page_630)
    
    -   atrial septal defects (ASDs)  [630](c26.xhtml#Page_630)–633
        -   anesthetic considerations  [633](c26.xhtml#Page_633)
        -   coronary sinus ASD  [632](c26.xhtml#Page_632)
        -   embryologic development  _[631](c26.xhtml#Page_631)_
        -   incidence  [630](c26.xhtml#Page_630)–631
        -   natural history  [632](c26.xhtml#Page_632)
        -   patent foramen ovale  [632](c26.xhtml#Page_632)
        -   primum ASD  [631](c26.xhtml#Page_631)–632
        -   secundum ASD  [631](c26.xhtml#Page_631)
        -   Sinus venosus ASD  [632](c26.xhtml#Page_632)
        -   surgical and transcatheter approaches  [632](c26.xhtml#Page_632)–633
        -   surgical repair of  _[633](c26.xhtml#Page_633)_
        -   types of  _[632](c26.xhtml#Page_632)_
    
    -   atrioventricular canal (AVC)  [636](c26.xhtml#Page_636)–639
        -   anesthetic considerations  [639](c26.xhtml#Page_639)
        -   complete  [636](c26.xhtml#Page_636)–637, _[637](c26.xhtml#Page_637), [638](c26.xhtml#Page_638)_
        -   incidence  [636](c26.xhtml#Page_636)
        -   natural history  [637](c26.xhtml#Page_637)
        -   partial  [636](c26.xhtml#Page_636)
        -   pathophysiology  [637](c26.xhtml#Page_637)
        -   surgical approaches  [637](c26.xhtml#Page_637)–639
        -   transitional  [636](c26.xhtml#Page_636)
    
    -   double outlet right ventricle (DORV)  [639](c26.xhtml#Page_639)–642
        -   anatomic sub‐types  _[640](c26.xhtml#Page_640)_
        -   anesthetic considerations  [641](c26.xhtml#Page_641)–642
        -   doubly committed VSD  [639](c26.xhtml#Page_639)
        -   incidence  [639](c26.xhtml#Page_639)
        -   natural history  [640](c26.xhtml#Page_640)–641
        -   noncommitted VSD  [639](c26.xhtml#Page_639)–640
        -   pathophysiology  [640](c26.xhtml#Page_640)–641
        -   subaortic VSD  [639](c26.xhtml#Page_639)
        -   subpulmonary VSD  [639](c26.xhtml#Page_639)
        -   surgical approaches  [641](c26.xhtml#Page_641)
        -   surgical repair  _[641](c26.xhtml#Page_641)_
    
    -   heart chamber dilation patterns  _[647](c26.xhtml#Page_647)_
    -   partial anomalous pulmonary venous return (PAPVR)  [644](c26.xhtml#Page_644)–648
        -   anatomy  [645](c26.xhtml#Page_645)
        -   anesthetic considerations  [646](c26.xhtml#Page_646)–648
        -   incidence  [644](c26.xhtml#Page_644)–645
        -   natural history  [646](c26.xhtml#Page_646)
        -   pathophysiology  [646](c26.xhtml#Page_646)
        -   surgical approaches  [646](c26.xhtml#Page_646)–647
    
    -   patent ductus arteriosus (PDA)  [626](c26.xhtml#Page_626)–628
        -   anesthetic considerations  [628](c26.xhtml#Page_628)
        -   incidence, anatomy, and natural history  [626](c26.xhtml#Page_626)–627, _[627](c26.xhtml#Page_627)_
        -   pathophysiology  [627](c26.xhtml#Page_627)
        -   surgical and transcatheter approaches  _[627](c26.xhtml#Page_627),_ [627](c26.xhtml#Page_627)–628
    
    -   pathophysiology of  _[626](c26.xhtml#Page_626)_
    -   total anomalous pulmonary venous return (TAPVR)  [644](c26.xhtml#Page_644)–648
        -   anesthetic considerations  [647](c26.xhtml#Page_647)–648
        -   cardiac  _[645](c26.xhtml#Page_645),_ [646](c26.xhtml#Page_646)
        -   incidence  [644](c26.xhtml#Page_644)–645
        -   infracardiac  _[645](c26.xhtml#Page_645),_ [646](c26.xhtml#Page_646)
        -   mixed  _[645](c26.xhtml#Page_645),_ [646](c26.xhtml#Page_646)
        -   natural history  [646](c26.xhtml#Page_646)
        -   pathophysiology  [646](c26.xhtml#Page_646)
        -   subtypes of  _[645](c26.xhtml#Page_645)_
        -   supracardiac  [645](c26.xhtml#Page_645), _[645](c26.xhtml#Page_645)_
        -   surgical approaches  [646](c26.xhtml#Page_646)–647
        -   surgical repair  _[647](c26.xhtml#Page_647)_
    
    -   truncus arteriosus  [642](c26.xhtml#Page_642)–644
        -   anesthetic considerations  [644](c26.xhtml#Page_644)
        -   classification of  _[642](c26.xhtml#Page_642)_
        -   incidence  [642](c26.xhtml#Page_642)
        -   natural history  [643](c26.xhtml#Page_643)
        -   pathophysiology  [643](c26.xhtml#Page_643)
        -   surgical and transcatheter approaches  [643](c26.xhtml#Page_643)–644
        -   surgical repair  _[643](c26.xhtml#Page_643)_
        -   type I  [642](c26.xhtml#Page_642)
        -   type II  [642](c26.xhtml#Page_642)
        -   type III  [642](c26.xhtml#Page_642)–643
        -   type IV  [643](c26.xhtml#Page_643)
    
    -   ventricular septal defects (VSD)  [633](c26.xhtml#Page_633)–636
        -   anesthetic considerations  [636](c26.xhtml#Page_636)
        -   incidence  [633](c26.xhtml#Page_633)
        -   inlet  [634](c26.xhtml#Page_634)
        -   muscular  [634](c26.xhtml#Page_634)
        -   natural history  [634](c26.xhtml#Page_634)–635
        -   pathophysiology  [635](c26.xhtml#Page_635)
        -   perimembranous  [634](c26.xhtml#Page_634)
        -   subarterial  [634](c26.xhtml#Page_634)
        -   surgical and transcatheter approaches  [635](c26.xhtml#Page_635)–636
        -   surgical repair  _[635](c26.xhtml#Page_635)_
        -   types of  _[634](c26.xhtml#Page_634)_
-   left ventricular end‐diastolic pressure (LVEDP)  [891](c34.xhtml#Page_891)
-   Loeys‐Dietz syndrome (LDS) **[144](c08.xhtml#Page_144),** [156](c08.xhtml#Page_156)
-   low birthweight (LBW) neonates  [448](c19.xhtml#Page_448), [449](c19.xhtml#Page_449)
-   low cardiac output state (LCOS)  [997](c37.xhtml#Page_997)
-   lung POCUS  [420](c17.xhtml#Page_420)–422
    -   A‐line reflections  [420](c17.xhtml#Page_420), _[421](c17.xhtml#Page_421), [422](c17.xhtml#Page_422)_
    -   artifact visualization  [420](c17.xhtml#Page_420)–421
    -   barcode sign  [421](c17.xhtml#Page_421), _[422](c17.xhtml#Page_422)_
    -   B‐lines  [420](c17.xhtml#Page_420), _[421](c17.xhtml#Page_421), [422](c17.xhtml#Page_422)_
    -   hemodynamic instability _[419](c17.xhtml#Page_419)_
    -   pleural line and A‐lines  _[422](c17.xhtml#Page_422)_
    -   probe positioning  _[421](c17.xhtml#Page_421)_
    -   scan planes  _[420](c17.xhtml#Page_420)_
    -   seashore sign  [421](c17.xhtml#Page_421), _[422](c17.xhtml#Page_422)_
    -   shadowing  _[421](c17.xhtml#Page_421)_
    -   spine sign  [421](c17.xhtml#Page_421)
-   LV outflow obstruction
    -   subvalvular aortic stenosis  [358](c15.xhtml#Page_358)
    -   supravalvular aortic stenosis  [358](c15.xhtml#Page_358)
    -   TEE examination  [358](c15.xhtml#Page_358), [360](c15.xhtml#Page_360)
    -   valvular aortic stenosis  [358](c15.xhtml#Page_358)

-   machine learning  **[78](c05.xhtml#Page_78)**
    -   deep learning algorithms  [76](c05.xhtml#Page_76)
    -   pattern recognition task  [76](c05.xhtml#Page_76)
    -   supervised learning algorithms  [76](c05.xhtml#Page_76)
    -   types of _[77](c05.xhtml#Page_77)_
-   magnetic resonance imaging (MRI)
    -   black‐blood sequences  [435](c18.xhtml#Page_435)
    -   bright‐blood sequences  [435](c18.xhtml#Page_435)
    -   and CT  [953](c35.xhtml#Page_953)–955, _[954](c35.xhtml#Page_954)_
    -   flow velocity mapping  [436](c18.xhtml#Page_436)
    -   hypoplastic left heart syndrome  _[437](c18.xhtml#Page_437)_
    -   magnetic resonance angiography  [436](c18.xhtml#Page_436)
    -   preexisting and new postoperative neurologic injuries  [306](c14.xhtml#Page_306), _[306](c14.xhtml#Page_306)_
    -   preoperative sagittal T1‐weighted  [306](c14.xhtml#Page_306), _[307](c14.xhtml#Page_307)_
    -   use of  [437](c18.xhtml#Page_437)
    -   white matter injury  [306](c14.xhtml#Page_306), _[306](c14.xhtml#Page_306)_
-   management of bleeding
    
    -   cell salvage  [393](c16.xhtml#Page_393)–394
    -   global hemostasis cartridge  [394](c16.xhtml#Page_394), _[394](c16.xhtml#Page_394)_
    -   platelet‐poor plasma (PPP)  [394](c16.xhtml#Page_394)
    -   QuantraR QPlus System
        -   QPlus cartridge, and parameters _[396](c16.xhtml#Page_396)_
        -   QuantraR Hemostasis Analyzer  [395](c16.xhtml#Page_395)
    
    -   ROTEM®
        -   assays and clinical indications  **[395](c16.xhtml#Page_395)**
        -   charge‐coupled device  [395](c16.xhtml#Page_395)
        -   clot initiation  [397](c16.xhtml#Page_397), _[397](c16.xhtml#Page_397)_
        -   clot lysis  [397](c16.xhtml#Page_397), _[397](c16.xhtml#Page_397)_
        -   clot strength  [397](c16.xhtml#Page_397), _[397](c16.xhtml#Page_397)_
        -   sigma and cartridges  _[395](c16.xhtml#Page_395)_
        -   trace _[396](c16.xhtml#Page_396)_
    
    -   standard coagulation assays  [394](c16.xhtml#Page_394)
    -   TEG®
        -   clot initiation  [397](c16.xhtml#Page_397), _[397](c16.xhtml#Page_397)_
        -   clot lysis  [397](c16.xhtml#Page_397), _[397](c16.xhtml#Page_397)_
        -   clot strength  [397](c16.xhtml#Page_397), _[397](c16.xhtml#Page_397)_
        -   device and cartridge  _[394](c16.xhtml#Page_394)_
        -   PlateletMapping cartridge  [394](c16.xhtml#Page_394)
        -   resonance‐frequency viscoelasticity  [394](c16.xhtml#Page_394)
        -   trace _[396](c16.xhtml#Page_396)_
    
    -   transfusion algorithms  [394](c16.xhtml#Page_394)–397
    -   viscoelastic hemostatic tests  [395](c16.xhtml#Page_395)
-   Management of Bradycardia in Adults With Adult Congenital Heart Disease  [553](c22.xhtml#Page_553)
-   Manitoba Pediatric Cardiac Surgery  [30](c03.xhtml#Page_30)
-   Marfan syndrome **[144](c08.xhtml#Page_144)**–**[145](c08.xhtml#Page_145),** [154](c08.xhtml#Page_154), [156](c08.xhtml#Page_156), **[156](c08.xhtml#Page_156)**
-   Mayo Clinic, Rochester, anesthesia data collection  [38](c03.xhtml#Page_38)
-   mechanical circulatory support
    
    -   anesthesia, analgesia, and sedation
        -   drug disposition changes  [1016](c37.xhtml#Page_1016)–1017
        -   intraoperative management  [1017](c37.xhtml#Page_1017)–1018
        -   postoperative management  [1018](c37.xhtml#Page_1018)
        -   preoperative management  [1017](c37.xhtml#Page_1017)
    
    -   anticoagulation  [1018](c37.xhtml#Page_1018)–1019
    -   antifibrinolytics  [1018](c37.xhtml#Page_1018)–1019
    -   anti‐infective therapy  [1019](c37.xhtml#Page_1019)
    -   contraindications  [1001](c37.xhtml#Page_1001)–1002
    -   extracorporeal membrane oxygenation (ECMO)  [1002](c37.xhtml#Page_1002)–1004
        -   cardiac support  [1019](c37.xhtml#Page_1019)–1020
        -   draining deoxygenated blood  _[1004](c37.xhtml#Page_1004)_
        -   future of  [1024](c37.xhtml#Page_1024)
        -   Jostra Rotaflow®  [1002](c37.xhtml#Page_1002), _[1002](c37.xhtml#Page_1002)_
        -   mechanical complications  **[1020](c37.xhtml#Page_1020)**
        -   neurological outcome  [1022](c37.xhtml#Page_1022)–1023
        -   outcomes and complications  [1019](c37.xhtml#Page_1019)–1024
        -   overall long‐term survival  [1022](c37.xhtml#Page_1022)
        -   oxygenator  _[1002](c37.xhtml#Page_1002),_ [1003](c37.xhtml#Page_1003)
        -   parental outcomes  [1024](c37.xhtml#Page_1024)
        -   patient‐related complications  **[1020](c37.xhtml#Page_1020)**
        -   pump  _[1002](c37.xhtml#Page_1002),_ [1002](c37.xhtml#Page_1002)–1003
        -   quality of life  [1023](c37.xhtml#Page_1023)
        -   renal function  [1021](c37.xhtml#Page_1021)–1022
        -   renal injury  **[1021](c37.xhtml#Page_1021)**
        -   respiratory support  [1020](c37.xhtml#Page_1020)–1021
        -   sepsis  [1021](c37.xhtml#Page_1021)
        -   thromboresistant surfaces  [1003](c37.xhtml#Page_1003)–1004
        -   Transthoracic echocardiography (TTE)  [1009](c37.xhtml#Page_1009)
        -   _vs._ VAD  [1023](c37.xhtml#Page_1023)
        -   volume of cases  [1023](c37.xhtml#Page_1023)–1024
        -   weaning  [1013](c37.xhtml#Page_1013)–1015
    
    -   history of  [996](c37.xhtml#Page_996)
    -   indications for
        -   arrhythmias  [1000](c37.xhtml#Page_1000)
        -   cardiac catheterization instability  [1000](c37.xhtml#Page_1000)
        -   cardiac transplantation  [999](c37.xhtml#Page_999)–1000
        -   cardiomyopathy  [999](c37.xhtml#Page_999)–1000
        -   failure to wean after cardiac surgery  [997](c37.xhtml#Page_997)–998
        -   intoxicants  [1000](c37.xhtml#Page_1000)
        -   lung transplantation  [998](c37.xhtml#Page_998)–999
        -   myocarditis  [999](c37.xhtml#Page_999)–1000
        -   organ donation  [1000](c37.xhtml#Page_1000)
        -   preoperative stabilization and support  [997](c37.xhtml#Page_997)
        -   pulmonary hypertension  [1000](c37.xhtml#Page_1000)
        -   respiratory failure  [998](c37.xhtml#Page_998)–999
        -   resuscitation  [998](c37.xhtml#Page_998)
        -   sepsis  [999](c37.xhtml#Page_999)
    
    -   platelet antiaggregation  [1018](c37.xhtml#Page_1018)–1019
    -   role of echocardiography  [1009](c37.xhtml#Page_1009)–1013
    -   ventricular assist devices (VAD)  [1004](c37.xhtml#Page_1004)–1009, **[1005](c37.xhtml#Page_1005),** _[1005](c37.xhtml#Page_1005)_
        -   advantages of  [1004](c37.xhtml#Page_1004)
        -   Berlin Heart VAD (EXCOR)  [1006](c37.xhtml#Page_1006), _[1007](c37.xhtml#Page_1007)_
        -   dilated cardiomyopathy with biventricular failure _[1014](c37.xhtml#Page_1014)_
        -   draining oxygenated blood  _[1004](c37.xhtml#Page_1004)_
        -   future of  [1024](c37.xhtml#Page_1024)
        -   HeartMate III Centrifugal‐Flow Pump  [1008](c37.xhtml#Page_1008), _[1008](c37.xhtml#Page_1008), [1009](c37.xhtml#Page_1009)_
        -   HeartMate III implantation _[1014](c37.xhtml#Page_1014)_
        -   HeartWare inflow cannula  _[1013](c37.xhtml#Page_1013)_
        -   HeartWare Ventricular Assist System  [1007](c37.xhtml#Page_1007), _[1007](c37.xhtml#Page_1007)_
        -   Impella  [1004](c37.xhtml#Page_1004), _[1006](c37.xhtml#Page_1006), [1015](c37.xhtml#Page_1015)_
        -   role of echocardiography  [1011](c37.xhtml#Page_1011)–1013
        -   septal defects  [1012](c37.xhtml#Page_1012), _[1012](c37.xhtml#Page_1012)_
        -   SynCardia Total Artificial Heart  [1009](c37.xhtml#Page_1009), _[1010](c37.xhtml#Page_1010)_
        -   transesophageal echocardiography  **[1011](c37.xhtml#Page_1011)**
        -   troubleshooting  **[1016](c37.xhtml#Page_1016)**
        -   weaning from CPB  [1015](c37.xhtml#Page_1015)–1016
        -   weaning to recovery  [1016](c37.xhtml#Page_1016)
-   medical informatics
    
    -   data  [72](c05.xhtml#Page_72)
    -   databases  [74](c05.xhtml#Page_74)–75
    -   data organization  [74](c05.xhtml#Page_74)–75
    -   data processing pipelines
        -   analytical processing and algorithms  [75](c05.xhtml#Page_75)
        -   cleaning  [75](c05.xhtml#Page_75)
        -   data collection  [75](c05.xhtml#Page_75)
        -   data selection  [75](c05.xhtml#Page_75)
        -   feature extraction  [75](c05.xhtml#Page_75)
        -   presentation and knowledge  [75](c05.xhtml#Page_75)
    
    -   data size  [72](c05.xhtml#Page_72), **[72](c05.xhtml#Page_72)**
    -   data type
        -   character arrays  [73](c05.xhtml#Page_73)
        -   floating‐point numbers  [73](c05.xhtml#Page_73)
        -   within a hospital  [73](c05.xhtml#Page_73)
        -   integers  [72](c05.xhtml#Page_72)
        -   strings  [73](c05.xhtml#Page_73)
        -   text  [73](c05.xhtml#Page_73)
    
    -   definitions and terminologies  **[73](c05.xhtml#Page_73)–74**
    -   history of  [70](c05.xhtml#Page_70)–71
    -   information  [72](c05.xhtml#Page_72)
    -   knowledge  [72](c05.xhtml#Page_72)
    -   limitations and challenges  [80](c05.xhtml#Page_80)–81
    -   querying data  [74](c05.xhtml#Page_74)–75
    -   wisdom  [72](c05.xhtml#Page_72)
    -   working with big data  [72](c05.xhtml#Page_72), _[72](c05.xhtml#Page_72)_
-   Midazolam  [886](c33.xhtml#Page_886)
-   milestones for anesthesiology training  [25](c02.xhtml#Page_25)
-   miscellaneous cardiac lesions
    -   aortic aneurysm and aortopathy [820](c31.xhtml#Page_820)–826
    -   cardiac tumors in childhood [816](c31.xhtml#Page_816)–820
    -   coronary arteries anomalies [794](c31.xhtml#Page_794)–802
    -   mediastinal masses [826](c31.xhtml#Page_826)–830
    -   mitral regurgitation [808](c31.xhtml#Page_808)–816
    -   pericardial effusion and tamponade [802](c31.xhtml#Page_802)–808
    -   vascular rings [782](c31.xhtml#Page_782)–783
-   mitochondrial permeability transition pore (MPTP)  [186](c09.xhtml#Page_186)
-   mitral regurgitation
    -   anatomy [808](c31.xhtml#Page_808), _[809](c31.xhtml#Page_809)_
    -   anesthetic considerations [813](c31.xhtml#Page_813)–816
    -   Carpentier classification [810](c31.xhtml#Page_810), _[810](c31.xhtml#Page_810)_
    -   classification of [809](c31.xhtml#Page_809)–810
    -   drainage and retransfusion system _[808](c31.xhtml#Page_808)_
    -   incidence [808](c31.xhtml#Page_808)
    -   mechanisms of [810](c31.xhtml#Page_810)–811
    -   mitral clip insertion _[814](c31.xhtml#Page_814)_
    -   modified Melody valve implantation _[815](c31.xhtml#Page_815)_
    -   natural history [808](c31.xhtml#Page_808)
    -   normal mitral valve [808](c31.xhtml#Page_808)–809, _[809](c31.xhtml#Page_809)_
    -   pathophysiology [811](c31.xhtml#Page_811), _[814](c31.xhtml#Page_814)_
    -   spontaneous regression _[798](c31.xhtml#Page_798)_
    -   surgical approaches and outcomes [811](c31.xhtml#Page_811)–813
-   mitral valve stenosis  [97](c06.xhtml#Page_97)
-   multidisciplinary approach, TCH
    
    -   AAOCA  [49](c04.xhtml#Page_49)
    -   anesthesiologist involvement  [53](c04.xhtml#Page_53)
    -   communication and team functioning (_see_ [communication and team functioning](#ind1860))
    -   coronary anomalies program algorithm _[50](c04.xhtml#Page_50)_
    -   data, validation, and consistency  [47](c04.xhtml#Page_47)–49
    -   handbook  [66](c04.xhtml#Page_66)–67, _[67](c04.xhtml#Page_67)_
    -   Heart Center Executive Committee (HCEC)  [45](c04.xhtml#Page_45)
    -   leadership structure  **[45](c04.xhtml#Page_45)**
    -   morning report  [47](c04.xhtml#Page_47), _[48](c04.xhtml#Page_48)_
    -   multidisciplinary surgical patient ICU rounds  [49](c04.xhtml#Page_49)
    -   parent and family involvement  [67](c04.xhtml#Page_67)
    -   patient case conferences  [47](c04.xhtml#Page_47)
    -   presurgical planning conferences  [45](c04.xhtml#Page_45)–46, _[46](c04.xhtml#Page_46), [47](c04.xhtml#Page_47)_
    -   quality and outcomes improvement conferences
        -   multidisciplinary meetings  [52](c04.xhtml#Page_52), _[52](c04.xhtml#Page_52)_
        -   performance rounds  [49](c04.xhtml#Page_49), _[51](c04.xhtml#Page_51)_
        -   quality conference  [52](c04.xhtml#Page_52)
    
    -   surgical patient ICU rounds  [49](c04.xhtml#Page_49)
    -   validation  [49](c04.xhtml#Page_49)
    -   wide communication activities
        -   Heart Center annual retreat  [52](c04.xhtml#Page_52)–53, _[53](c04.xhtml#Page_53)_
        -   Heart Center Town Hall  [52](c04.xhtml#Page_52), _[53](c04.xhtml#Page_53)_
-   myocardial dysfunction
    -   decreased contractility  [972](c36.xhtml#Page_972)–973
    -   delayed sternal closure  [973](c36.xhtml#Page_973)–974
    -   dysrhythmias  [972](c36.xhtml#Page_972)
    -   ischemia  [971](c36.xhtml#Page_971)
    -   surgical factors  [970](c36.xhtml#Page_970)–971
    -   systemic inflammatory response  [971](c36.xhtml#Page_971)–972
-   myocardial preconditioning
    -   biological effects  _[186](c09.xhtml#Page_186)_
    -   cGMP‐dependent mechanism  [186](c09.xhtml#Page_186)
    -   mitochondrial permeability transition pore (MPTP)  [186](c09.xhtml#Page_186)
    -   remote ischemic preconditioning (RIPC)  [186](c09.xhtml#Page_186), [187](c09.xhtml#Page_187)
    -   ST‐elevation myocardial infarction (STEMI) [187](c09.xhtml#Page_187)
-   myocardial sequelae, CHD  [173](c09.xhtml#Page_173)–175

-   near‐misses  [30](c03.xhtml#Page_30)
-   neonates
    -   banding of the pulmonary artery  [450](c19.xhtml#Page_450)
    -   early complete repair  [450](c19.xhtml#Page_450)–451
    -   early palliation  [449](c19.xhtml#Page_449)
    -   limited physiologic reserve  [451](c19.xhtml#Page_451)–452
    -   management of  [451](c19.xhtml#Page_451)
    -   neurologic injury  [455](c19.xhtml#Page_455)–456
    -   optimal timing of delivery of  [451](c19.xhtml#Page_451)
    -   stress response  [452](c19.xhtml#Page_452)–454
    -   symptoms and signs  [451](c19.xhtml#Page_451)
    -   systemic inflammatory response  [454](c19.xhtml#Page_454)–455
    -   systemic response to injury  [453](c19.xhtml#Page_453)
    -   systemic‐to‐pulmonary artery shunt  [449](c19.xhtml#Page_449)
    -   transcatheter ductus arteriosus stent  [450](c19.xhtml#Page_450)
-   neonate to older infant and child development
    -   cell‐to‐cell connectivity  [170](c09.xhtml#Page_170)–171, _[172](c09.xhtml#Page_172)_
    -   extracellular matrix (ECM)  [170](c09.xhtml#Page_170), _[170](c09.xhtml#Page_170), [171](c09.xhtml#Page_171)_
    -   Frank‐Starling curve  [168](c09.xhtml#Page_168)
    -   gene expression in cardiac development  [169](c09.xhtml#Page_169)–170
    -   innervation of the heart  [171](c09.xhtml#Page_171)–172
    -   resting tension  [168](c09.xhtml#Page_168), _[168](c09.xhtml#Page_168)_
-   neurological monitoring
    
    -   advantages and disadvantages  **[329](c14.xhtml#Page_329)**
    -   anesthesiologists  [313](c14.xhtml#Page_313)
    -   electroencephalographic technologies  [313](c14.xhtml#Page_313)–315
    -   modifiable and monmodifiable factors  **[329](c14.xhtml#Page_329)**
    -   monitors of cerebral autoregulation  [319](c14.xhtml#Page_319)–321, _[320](c14.xhtml#Page_320), [321](c14.xhtml#Page_321)_
    -   monitors of cerebral oxygenation
        -   absorption spectra  _[317](c14.xhtml#Page_317)_
        -   bilateral regional  [317](c14.xhtml#Page_317), _[317](c14.xhtml#Page_317)_
        -   CBF and CMRO2  [319](c14.xhtml#Page_319), _[320](c14.xhtml#Page_320)_
        -   frequency‐domain NIRS, DCS  [319](c14.xhtml#Page_319), _[319](c14.xhtml#Page_319)_
        -   jugular venous bulb oximetry  [315](c14.xhtml#Page_315)
        -   near‐infrared spectroscopy  [315](c14.xhtml#Page_315)–318
    
    -   TCD ultrasonography  [315](c14.xhtml#Page_315), _[316](c14.xhtml#Page_316)_
-   New York Heart Association (NYHA) classification  [876](c33.xhtml#Page_876)
-   noncardiac sequelae, CHD
    -   hematological sequelae  [468](c20.xhtml#Page_468)–469
    -   hepatic sequelae  [469](c20.xhtml#Page_469)–470
    -   neurological sequelae  [469](c20.xhtml#Page_469)
    -   pulmonary sequelae  [467](c20.xhtml#Page_467)–468, _[468](c20.xhtml#Page_468)_
    -   renal sequelae  [469](c20.xhtml#Page_469)
-   noncardiac surgery
    
    -   ACHD management issues  **[950](c35.xhtml#Page_950)**
    -   high‐risk patient groups
        -   adult CHD  **[949](c35.xhtml#Page_949),** [949](c35.xhtml#Page_949)–950
        -   ductal dependent unpalliated neonates  [943](c35.xhtml#Page_943)
        -   Eisenmenger syndrome  **[948](c35.xhtml#Page_948),** [948](c35.xhtml#Page_948)–949
        -   hypertrophic cardiomyopathy (HCM)  [946](c35.xhtml#Page_946), [948](c35.xhtml#Page_948), **[948](c35.xhtml#Page_948)**
        -   pulmonary hypertension  _[944](c35.xhtml#Page_944),_ [944](c35.xhtml#Page_944)–945
        -   severe aortic stenosis  [945](c35.xhtml#Page_945)
        -   shunt‐dependent single‐ventricle  [943](c35.xhtml#Page_943)–944
        -   single‐ventricle with AV valve regurgitation  [944](c35.xhtml#Page_944)
        -   transplant coronary artery disease (TCAD)  [948](c35.xhtml#Page_948)
        -   Williams syndrome  [945](c35.xhtml#Page_945)–946, **[946](c35.xhtml#Page_946), [947](c35.xhtml#Page_947)**
    
    -   intraoperative care
        -   anesthetic technique  [951](c35.xhtml#Page_951)
        -   laparoscopic surgery  [951](c35.xhtml#Page_951)–952
        -   monitoring  [950](c35.xhtml#Page_950)–951
        -   otolaryngologic procedures  [952](c35.xhtml#Page_952)–953
        -   spinal instrumentation  [953](c35.xhtml#Page_953)
        -   surgery  [951](c35.xhtml#Page_951)
    
    -   patients with pacemakers and defibrillators  [938](c35.xhtml#Page_938)–939
    -   patients with ventricular assist device support  **[939](c35.xhtml#Page_939),** [939](c35.xhtml#Page_939)–942, _[940](c35.xhtml#Page_940), [941](c35.xhtml#Page_941)_
    -   postoperative considerations
        -   home discharge criteria  [956](c35.xhtml#Page_956)
        -   intensive care _vs._ general unit  [956](c35.xhtml#Page_956)
    
    -   preoperative preparation
        -   continuation of medications  [937](c35.xhtml#Page_937)
        -   endocarditis prophylaxis  [937](c35.xhtml#Page_937)–938, **[938](c35.xhtml#Page_938)**
        -   hemodynamics studies  [936](c35.xhtml#Page_936)–937
        -   imaging studies  [936](c35.xhtml#Page_936)–937
        -   multidisciplinary planning  [936](c35.xhtml#Page_936)
        -   Nil per os  [936](c35.xhtml#Page_936)–937, _[937](c35.xhtml#Page_937)_
        -   preoperative cardiology visit  [936](c35.xhtml#Page_936)
    
    -   radiologic procedures
        -   lymphatic mapping and intervention  [955](c35.xhtml#Page_955)–956
        -   MRI and CT  [953](c35.xhtml#Page_953)–955, _[954](c35.xhtml#Page_954)_
    
    -   single‐ventricle palliation  **[942](c35.xhtml#Page_942),** [942](c35.xhtml#Page_942)–943
-   non‐invasive oscillometric method (NIBP)  [173](c09.xhtml#Page_173)
-   normal heart rates and systolic blood pressure  [172](c09.xhtml#Page_172)–173, **[173](c09.xhtml#Page_173),** _[173](c09.xhtml#Page_173)_
-   Novalung®  [1000](c37.xhtml#Page_1000)

-   online educational resources  [22](c02.xhtml#Page_22)
-   operator‐directed sedation (ODS)  [918](c34.xhtml#Page_918)
-   Opioids  [886](c33.xhtml#Page_886)
-   orotracheal _vs._ nasotracheal intubation  [559](c23.xhtml#Page_559)–560
-   outcome transparency  [30](c03.xhtml#Page_30)

-   pacemaker therapy  [552](c22.xhtml#Page_552)–557
    
    -   cardiac pacing
        -   external  [556](c22.xhtml#Page_556)
        -   hardware selection  [554](c22.xhtml#Page_554)
        -   implantation  [553](c22.xhtml#Page_553)–554
        -   perioperative considerations  [554](c22.xhtml#Page_554)–555
        -   programming of devices  [554](c22.xhtml#Page_554)
        -   temporary  [555](c22.xhtml#Page_555)–556
    
    -   implantable cardioverter‐defibrillators  [556](c22.xhtml#Page_556)–557
    -   nomenclature  [552](c22.xhtml#Page_552), **[552](c22.xhtml#Page_552)**
    -   transesophageal overdrive pacing  [556](c22.xhtml#Page_556)
-   palliative surgery, complications  **[449](c19.xhtml#Page_449)**
-   partial anomalous pulmonary venous connection (PAPVC)  [108](c06.xhtml#Page_108)
-   partial anomalous pulmonary venous return (PAPVR)  [644](c26.xhtml#Page_644)–648
    -   anatomy  [645](c26.xhtml#Page_645)
    -   anesthetic considerations  [646](c26.xhtml#Page_646)–648
    -   incidence  [644](c26.xhtml#Page_644)–645
    -   natural history  [646](c26.xhtml#Page_646)
    -   pathophysiology  [646](c26.xhtml#Page_646)
    -   surgical approaches  [646](c26.xhtml#Page_646)–647
-   patent ductus arteriosus (PDA)  [16](c02.xhtml#Page_16), [44](c04.xhtml#Page_44), [99](c06.xhtml#Page_99), [626](c26.xhtml#Page_626)–628
    -   anesthetic considerations  [628](c26.xhtml#Page_628)
    -   incidence, anatomy, and natural history  [626](c26.xhtml#Page_626)–627, _[627](c26.xhtml#Page_627)_
    -   occlusion  [460](c19.xhtml#Page_460), _[461](c19.xhtml#Page_461)_
    -   pathophysiology  [627](c26.xhtml#Page_627)
    -   surgical and transcatheter approaches  _[627](c26.xhtml#Page_627),_ [627](c26.xhtml#Page_627)–628
-   patent foramen ovale (PFO)  [674](c28.xhtml#Page_674)
-   patient with a single ventricle
    -   double inlet ventricle  [758](c30.xhtml#Page_758)–759, **[759](c30.xhtml#Page_759),** _[759](c30.xhtml#Page_759)_
    -   Fontan completion  [767](c30.xhtml#Page_767)–777
    -   heart transplantation  [778](c30.xhtml#Page_778)
    -   heterotaxy syndrome  **[759](c30.xhtml#Page_759),** [760](c30.xhtml#Page_760)–761, _[761](c30.xhtml#Page_761),_ **[762](c30.xhtml#Page_762)**
    -   hypoplastic left heart syndrome (HLHS)  _[742](c30.xhtml#Page_742),_ [742](c30.xhtml#Page_742)–752
    -   mitral atresia with VSD  [759](c30.xhtml#Page_759), **[759](c30.xhtml#Page_759)**
    -   non‐cardiac surgery and anesthesia  [779](c30.xhtml#Page_779)
    -   post‐Fontan heart‐liver transplantation  [778](c30.xhtml#Page_778)–779
    -   superior cavopulmonary connection  [761](c30.xhtml#Page_761)–767
    -   tricuspid atresia  [752](c30.xhtml#Page_752)–758
    -   unbalanced complete atrioventricular septal defects (uCAVSDs)  **[759](c30.xhtml#Page_759),** [759](c30.xhtml#Page_759)–760
-   PA/VSD with major aortopulmonary collateral arteries (MAPCAs)
    
    -   anesthetic considerations
        -   intraoperative  [708](c28.xhtml#Page_708)
        -   postoperative  [708](c28.xhtml#Page_708)
        -   preoperative  [707](c28.xhtml#Page_707)–708
    
    -   management of newborns  _[706](c28.xhtml#Page_706)_
    -   surgical plan  **[705](c28.xhtml#Page_705)**
    -   unifocalization of collateral arteries  _[707](c28.xhtml#Page_707)_
    -   unilateral lung perfusion  [705](c28.xhtml#Page_705)
-   PA with intact ventricular septum (IVS)
    
    -   anesthetic considerations
        -   cardiac catheterization laboratory  [703](c28.xhtml#Page_703)
        -   neonatal palliation  [703](c28.xhtml#Page_703)
        -   RVDCC  [703](c28.xhtml#Page_703)
        -   single ventricle palliation  [703](c28.xhtml#Page_703)
    
    -   in 1day old infant  _[700](c28.xhtml#Page_700)_
    -   incidence, anatomy, and natural history  [700](c28.xhtml#Page_700)
    -   management of  _[701](c28.xhtml#Page_701)_
    -   pathophysiology  [700](c28.xhtml#Page_700)–701
    -   perioperative management  **[702](c28.xhtml#Page_702)**
    -   surgical and transcatheter approaches  [701](c28.xhtml#Page_701)–702
    -   surgical options  [702](c28.xhtml#Page_702)
-   pediatric cardiac surgery and anesthesiology
    -   databases  [31](c03.xhtml#Page_31)–42
    -   morbidity and mortality  [37](c03.xhtml#Page_37)–39
    -   prospective risk assessment  [33](c03.xhtml#Page_33)
-   pediatric CPB, management
    -   anticoagulation  _[219](c11.xhtml#Page_219),_ [219](c11.xhtml#Page_219)–220
    -   antifibrinolytic therapy  [227](c11.xhtml#Page_227)–229
    -   aortic cross‐clamping  [221](c11.xhtml#Page_221)–222
    -   cardioplegic cardiac arrest  [222](c11.xhtml#Page_222)–223
    -   conventional ultrafiltration (CUF)  [224](c11.xhtml#Page_224)–226
    -   cooling and temperature management  [221](c11.xhtml#Page_221)
    -   failure to separate  [226](c11.xhtml#Page_226)–227, _[228](c11.xhtml#Page_228)_
    -   hemostatic management  _[219](c11.xhtml#Page_219),_ [219](c11.xhtml#Page_219)–220
    -   heparin reversal  [227](c11.xhtml#Page_227)
    -   initiation of CPB  [220](c11.xhtml#Page_220)–221, _[221](c11.xhtml#Page_221)_
    -   modified ultrafiltration (MUF)  [224](c11.xhtml#Page_224)–226, **[226](c11.xhtml#Page_226)**
    -   myocardial ischemia  [221](c11.xhtml#Page_221)–222
    -   post‐bypass phase  [224](c11.xhtml#Page_224), _[225](c11.xhtml#Page_225)_
    -   pre‐bypass period  [218](c11.xhtml#Page_218)–219
    -   reperfusion  [223](c11.xhtml#Page_223)–224
    -   separation from CPB  [224](c11.xhtml#Page_224), _[225](c11.xhtml#Page_225)_
    -   stages  [218](c11.xhtml#Page_218)
    -   transfusion management  [227](c11.xhtml#Page_227)
-   Pediatric Heart Network  [42](c03.xhtml#Page_42)
-   pediatric intravascular monitoring
    -   cardiac output monitoring  [296](c13.xhtml#Page_296)–297
    -   central venous oxygen saturation monitoring  [297](c13.xhtml#Page_297)
    -   ECG demonstrating normal sinus rhythm  _[296](c13.xhtml#Page_296)_
    -   PiCCO system _[298](c13.xhtml#Page_298)_
-   pediatric lung transplantation
    -   anesthetic management  [857](c32.xhtml#Page_857)–860
    -   bridge to transplantation  [856](c32.xhtml#Page_856)
    -   bronchial anastomosis  _[859](c32.xhtml#Page_859)_
    -   bronchial artery revascularization technique  _[860](c32.xhtml#Page_860)_
    -   causes of death  **[864](c32.xhtml#Page_864)**
    -   contraindications  [851](c32.xhtml#Page_851), **[856](c32.xhtml#Page_856)**
    -   cystic fibrosis  [852](c32.xhtml#Page_852)–854, _[853](c32.xhtml#Page_853)_
    -   donor management  [855](c32.xhtml#Page_855)–856
    -   indications  [851](c32.xhtml#Page_851), **[852](c32.xhtml#Page_852), [853](c32.xhtml#Page_853)**
    -   intraoperative considerations  [858](c32.xhtml#Page_858)
    -   listing criteria  [851](c32.xhtml#Page_851), [854](c32.xhtml#Page_854)–855
    -   lung preservation  [855](c32.xhtml#Page_855)–856
    -   Maquet Quadrox‐iD membrane oxygenator  _[857](c32.xhtml#Page_857)_
    -   neonatal and infant lung transplant  [854](c32.xhtml#Page_854)
    -   pulmonary artery anastomosis  _[859](c32.xhtml#Page_859)_
    -   pulmonary hypertension  [854](c32.xhtml#Page_854)
    -   pulmonary vein anastomosis  _[859](c32.xhtml#Page_859)_
    -   surgical approach  [857](c32.xhtml#Page_857)–860
    -   timing of referral  **[855](c32.xhtml#Page_855)**
-   Pediatric Perioperative Cardiac Arrest (POCA) registry  [37](c03.xhtml#Page_37), [443](c18.xhtml#Page_443), [599](c25.xhtml#Page_599), [934](c35.xhtml#Page_934)
-   percutaneous PA catheterization  [291](c13.xhtml#Page_291)–293, **[294](c13.xhtml#Page_294)**
-   pericardial effusion
    -   anesthesia [807](c31.xhtml#Page_807)–808
    -   causes of **[803](c31.xhtml#Page_803)**
    -   classification **[802](c31.xhtml#Page_802)**
    -   incidence, anatomy, and natural history [802](c31.xhtml#Page_802)–804
    -   surgery for [807](c31.xhtml#Page_807)
-   perioperative cardiac arrest  [37](c03.xhtml#Page_37)–39
-   peritoneal dialysis
    -   postoperative fluid overload  [263](c12.xhtml#Page_263)
    -   systemic inflammatory response  [264](c12.xhtml#Page_264)
-   pharmacologic therapy
    
    -   antifibrinolytics
        -   aprotinin  [403](c16.xhtml#Page_403)–404
        -   dose regimens  **[406](c16.xhtml#Page_406)**
        -   lysine analogs  [403](c16.xhtml#Page_403)–404
        -   thrombin‐activatable fibrinolysis inhibitor (TAFI)  [403](c16.xhtml#Page_403)
        -   tissue‐type plasminogen activator(t‐PA)  [403](c16.xhtml#Page_403)
        -   tranexamic acid (TXA)  [403](c16.xhtml#Page_403)–404, _[405](c16.xhtml#Page_405)_
        -   urokinase plasminogen activator (u‐PA)  [403](c16.xhtml#Page_403)
    
    -   arrhythmias
        -   adenosine  [551](c22.xhtml#Page_551)
        -   amiodarone  [549](c22.xhtml#Page_549)–550
        -   anti‐arrhythmic agents  **[548](c22.xhtml#Page_548)**
        -   class IA agents  [547](c22.xhtml#Page_547)–552
        -   class IB agents  [549](c22.xhtml#Page_549)
        -   class III agents  [549](c22.xhtml#Page_549)–550
        -   class IV agents  [550](c22.xhtml#Page_550)
        -   dexmedetomidine  [551](c22.xhtml#Page_551)
        -   digoxin  [550](c22.xhtml#Page_550)–551
        -   ibutilide  [550](c22.xhtml#Page_550)
        -   ivabradine  [551](c22.xhtml#Page_551)
        -   lidocaine  [549](c22.xhtml#Page_549)
        -   magnesium sulfate  [551](c22.xhtml#Page_551)
        -   procainamide  [548](c22.xhtml#Page_548)–549
        -   sotalol  [550](c22.xhtml#Page_550)
        -   verapamil  [550](c22.xhtml#Page_550)
    
    -   desmopressin (DDAVP)  [406](c16.xhtml#Page_406)
-   pharyngeal arch arteries (PAAs)  [104](c06.xhtml#Page_104)
-   phosphodiesterase‐5 inhibitors (PDE‐5i)  [881](c33.xhtml#Page_881)–882
-   phospholipase C (PLC) system  _[183](c09.xhtml#Page_183)_
-   physiologically uncorrected TGA
    
    -   anatomy  _[711](c29.xhtml#Page_711),_ [711](c29.xhtml#Page_711)–712
    -   anesthetic goals  [727](c29.xhtml#Page_727)
    -   anesthetic intraoperative management  [727](c29.xhtml#Page_727)
    -   antibiotics  [728](c29.xhtml#Page_728)
    -   anticoagulation  [729](c29.xhtml#Page_729)
    -   arterial switch operation (ASO)  _[720](c29.xhtml#Page_720),_ [720](c29.xhtml#Page_720)–721, _[722](c29.xhtml#Page_722), [723](c29.xhtml#Page_723)_
    -   balloon atrial septostomy (BAS)  _[718](c29.xhtml#Page_718),_ [718](c29.xhtml#Page_718)–719
    -   bypass  [728](c29.xhtml#Page_728)
    -   clinical features  [717](c29.xhtml#Page_717)
    -   coronary artery anatomy  [712](c29.xhtml#Page_712), _[713](c29.xhtml#Page_713), [714](c29.xhtml#Page_714)_
    -   diagnostic features  [717](c29.xhtml#Page_717)
    -   ECG and Chest Radiograph (CXR) findings  **[717](c29.xhtml#Page_717)**
    -   effective pulmonary blood flow  [713](c29.xhtml#Page_713)
    -   effective systemic blood flow  [713](c29.xhtml#Page_713)
    -   feeding and nutrition  [733](c29.xhtml#Page_733)
    -   fluids and electrolytes  [732](c29.xhtml#Page_732)
    -   gadolinium‐enhanced magnetic resonance angiogram  _[723](c29.xhtml#Page_723)_
    -   incidence  [710](c29.xhtml#Page_710)
    -   indication and timing  [719](c29.xhtml#Page_719)–720
    -   intact ventricular septum  [716](c29.xhtml#Page_716)
    -   intensive care unit  **[731](c29.xhtml#Page_731)**
    -   intercirculatory mixing  [714](c29.xhtml#Page_714)–715, **[715](c29.xhtml#Page_715)**
    -   intracardiac shunting  _[715](c29.xhtml#Page_715)_
    -   LVOTO  [716](c29.xhtml#Page_716), _[721](c29.xhtml#Page_721)_
    -   natural history  [712](c29.xhtml#Page_712)–713
    -   near infrared spectroscopy  [728](c29.xhtml#Page_728)–729
    -   neonatal brain injury  **[728](c29.xhtml#Page_728)**
    -   neuromonitoring  [728](c29.xhtml#Page_728)–729
    -   Nikaidoh procedures  [722](c29.xhtml#Page_722)–723, _[725](c29.xhtml#Page_725)_
    -   outcomes  [723](c29.xhtml#Page_723)–726
    -   pathophysiology  [712](c29.xhtml#Page_712)–713
    -   post‐op complications  [731](c29.xhtml#Page_731)–732
        -   arrythmias  [731](c29.xhtml#Page_731)
        -   bleeding  [731](c29.xhtml#Page_731)
        -   low cardiac output syndrome  [731](c29.xhtml#Page_731)
        -   pulmonary hypertension  [731](c29.xhtml#Page_731)–732
    
    -   postoperative management, ASO  [730](c29.xhtml#Page_730)
    -   postoperative sequelae  **[726](c29.xhtml#Page_726)**
    -   pre‐bypass management  [727](c29.xhtml#Page_727)–728
    -   preoperative assessment  [726](c29.xhtml#Page_726)–727
    -   preoperative management  [717](c29.xhtml#Page_717)–718
    -   pulmonary blood flow  [715](c29.xhtml#Page_715)
    -   pulmonary vascular occlusive disease  [716](c29.xhtml#Page_716)
    -   Rastelli procedure  [721](c29.xhtml#Page_721), _[724](c29.xhtml#Page_724)_
    -   renal support  [732](c29.xhtml#Page_732)
    -   Réparation à l’Etage Ventriculaire (REV)  [722](c29.xhtml#Page_722), _[725](c29.xhtml#Page_725)_
    -   respiratory support and drains  [732](c29.xhtml#Page_732)
-   point‐of‐care ultrasound (POCUS)
    
    -   basics of  [410](c17.xhtml#Page_410)–411, _[411](c17.xhtml#Page_411)_
    -   cardiac
        -   apical four‐chamber view  [411](c17.xhtml#Page_411), _[414](c17.xhtml#Page_414)_
        -   atria and valves assesment  [417](c17.xhtml#Page_417)–418
        -   cardiac arrest assistance  [418](c17.xhtml#Page_418)
        -   central line placement assistance  [418](c17.xhtml#Page_418)
        -   early tamponade physiology  [416](c17.xhtml#Page_416)–417
        -   hemodynamic instability _[419](c17.xhtml#Page_419)_
        -   hypotension or shock  [418](c17.xhtml#Page_418)
        -   Impella® device  [420](c17.xhtml#Page_420)
        -   inferior vena cava views  [411](c17.xhtml#Page_411)–412, _[416](c17.xhtml#Page_416)_
        -   left ventricle assessment  [412](c17.xhtml#Page_412)–414
        -   parasternal long‐axis (PLAX) view  [411](c17.xhtml#Page_411), _[412](c17.xhtml#Page_412)_
        -   parasternal short‐axis (PSAX) view  [411](c17.xhtml#Page_411), _[413](c17.xhtml#Page_413)_
        -   pediatric  [410](c17.xhtml#Page_410)
        -   pericardial space assessment  _[416](c17.xhtml#Page_416),_ [416](c17.xhtml#Page_416)–417
        -   position of cannulae/device [419](c17.xhtml#Page_419)
        -   right ventricle assessment  [414](c17.xhtml#Page_414)–416
        -   shock assesment  [418](c17.xhtml#Page_418)–419
        -   structure assessment  [412](c17.xhtml#Page_412)–420
        -   subcostal four‐chamber view  [411](c17.xhtml#Page_411)–412, _[415](c17.xhtml#Page_415), [417](c17.xhtml#Page_417), [418](c17.xhtml#Page_418)_
    
    -   description  [409](c17.xhtml#Page_409)–410
    -   lung  [420](c17.xhtml#Page_420)–422
        -   A‐line reflections  [420](c17.xhtml#Page_420), _[421](c17.xhtml#Page_421), [422](c17.xhtml#Page_422)_
        -   artifact visualization  [420](c17.xhtml#Page_420)–421
        -   barcode sign  [421](c17.xhtml#Page_421), _[422](c17.xhtml#Page_422)_
        -   B‐lines  [420](c17.xhtml#Page_420), _[421](c17.xhtml#Page_421), [422](c17.xhtml#Page_422)_
        -   hemodynamic instability _[419](c17.xhtml#Page_419)_
        -   pleural line and A‐lines  _[422](c17.xhtml#Page_422)_
        -   probe positioning  _[421](c17.xhtml#Page_421)_
        -   scan planes  _[420](c17.xhtml#Page_420)_
        -   seashore sign  [421](c17.xhtml#Page_421), _[422](c17.xhtml#Page_422)_
        -   shadowing  _[421](c17.xhtml#Page_421)_
        -   spine sign  [421](c17.xhtml#Page_421)
    
    -   training and credentialing  [422](c17.xhtml#Page_422)–423
-   postoperative considerations
    -   home discharge criteria  [956](c35.xhtml#Page_956)
    -   intensive care _vs._ general unit  [956](c35.xhtml#Page_956)
-   predictive outcomes analysis  [37](c03.xhtml#Page_37)
-   pregnancy, ACHD
    -   anticoagulation  [473](c20.xhtml#Page_473)–474
    -   cardiac procedures  [474](c20.xhtml#Page_474)
    -   cardiac risk assessment  [471](c20.xhtml#Page_471)–473
    -   CARPREG II risk stratification index  **[472](c20.xhtml#Page_472), [473](c20.xhtml#Page_473)**
    -   delivery planning  [474](c20.xhtml#Page_474)–475
    -   general _vs._ neuraxial anesthesia for cesarean section  _[475](c20.xhtml#Page_475)_
    -   hemodynamic changes  _[471](c20.xhtml#Page_471)_
    -   maternal obstetric and fetal risks  [473](c20.xhtml#Page_473)
    -   neuraxial anesthetic dose for cesarean delivery **[476](c20.xhtml#Page_476)**
    -   physiologic changes  [471](c20.xhtml#Page_471)
    -   uterotonic medications **[476](c20.xhtml#Page_476)**
    -   WHO classification of maternal cardiovascular risk  **[472](c20.xhtml#Page_472)**
-   premature and LBW neonates
    -   cardiac function  [458](c19.xhtml#Page_458)
    -   intraventricular hemorrhage (IVH)  [459](c19.xhtml#Page_459)
    -   necrotizing enterocolitis (NEC)  [458](c19.xhtml#Page_458)
    -   outcome after congenital heart surgery  [459](c19.xhtml#Page_459)–460
    -   PDA occlusion  [460](c19.xhtml#Page_460), _[461](c19.xhtml#Page_461)_
    -   physiologic challenges  **[457](c19.xhtml#Page_457)**
    -   pulmonary function  [456](c19.xhtml#Page_456)–458
-   preoperative considerations
    -   anemia  [385](c16.xhtml#Page_385)–386, _[386](c16.xhtml#Page_386)_
    -   autologous donation  [386](c16.xhtml#Page_386)–387, _[387](c16.xhtml#Page_387)_
    -   bleeding post‐CPB  _[384](c16.xhtml#Page_384),_ [384](c16.xhtml#Page_384)–385
    -   laboratory testing  [385](c16.xhtml#Page_385)
-   preoperative evaluation
    -   congestive heart failure  [428](c18.xhtml#Page_428)–430, **[430](c18.xhtml#Page_430)**
    -   defibrillators  [431](c18.xhtml#Page_431)–432
    -   electrocardiographic evaluation  [431](c18.xhtml#Page_431)–432
    -   history and physical examination  [427](c18.xhtml#Page_427)–428
    -   medications  [431](c18.xhtml#Page_431)
    -   neonates and premature infants  [430](c18.xhtml#Page_430)–431
    -   pacemakers  [431](c18.xhtml#Page_431)–432
    -   pulmonary arterial hypertension  [430](c18.xhtml#Page_430)
-   preoperative imaging studies
    
    -   cardiac catheterization  [435](c18.xhtml#Page_435), _[436](c18.xhtml#Page_436)_
    -   chest radiography  [433](c18.xhtml#Page_433), _[434](c18.xhtml#Page_434)_
    -   computed tomography  [437](c18.xhtml#Page_437)–438, _[438](c18.xhtml#Page_438), [439](c18.xhtml#Page_439)_
    -   echocardiography  [434](c18.xhtml#Page_434)–435
    -   magnetic resonance imaging (MRI)
        -   black‐blood sequences  [435](c18.xhtml#Page_435)
        -   bright‐blood sequences  [435](c18.xhtml#Page_435)
        -   flow velocity mapping  [436](c18.xhtml#Page_436)
        -   hypoplastic left heart syndrome  _[437](c18.xhtml#Page_437)_
        -   magnetic resonance angiography  [436](c18.xhtml#Page_436)
        -   use of  [437](c18.xhtml#Page_437)
    
    -   non‐invasive assessment of CHD  [439](c18.xhtml#Page_439)–440, _[440](c18.xhtml#Page_440),_ **[441](c18.xhtml#Page_441)**
-   preoperative preparation
    -   continuation of medications  [937](c35.xhtml#Page_937)
    -   endocarditis prophylaxis  [937](c35.xhtml#Page_937)–938, **[938](c35.xhtml#Page_938)**
    -   fasting  [441](c18.xhtml#Page_441)–442
    -   hemodynamics studies  [936](c35.xhtml#Page_936)–937
    -   imaging studies  [936](c35.xhtml#Page_936)–937
    -   infective endocarditis (IE)  [442](c18.xhtml#Page_442)–443
    -   multidisciplinary planning  [936](c35.xhtml#Page_936)
    -   Nil per os  [936](c35.xhtml#Page_936)–937, _[937](c35.xhtml#Page_937)_
    -   preoperative cardiology visit  [936](c35.xhtml#Page_936)
    -   psychological preparation and premedication  [442](c18.xhtml#Page_442)
    -   sickle cell disease  [443](c18.xhtml#Page_443)
-   primary myocardium  _[103](c06.xhtml#Page_103)_
-   PRISM (Pediatric Risk of Mortality)  [79](c05.xhtml#Page_79)
-   Propofol  [886](c33.xhtml#Page_886)
-   PS with intact ventricular septum
    -   anesthetic considerations  [698](c28.xhtml#Page_698)–699
    -   genetic syndromes associated with  **[698](c28.xhtml#Page_698)**
    -   incidence, anatomy, and natural history  [697](c28.xhtml#Page_697)
    -   pathophysiology  [697](c28.xhtml#Page_697)–698
    -   perioperative anesthesia  [700](c28.xhtml#Page_700)
    -   periprocedural anesthesia  [699](c28.xhtml#Page_699)–700
    -   surgical and transcatheter approaches  [698](c28.xhtml#Page_698)
-   pulmonary hypertension (PH)
    
    -   acute and long‐term response  **[872](c33.xhtml#Page_872)**
    -   anesthetic management (_see_ [anesthetic management, PH](#ind158))
    -   assessment of  [876](c33.xhtml#Page_876)–879, _[878](c33.xhtml#Page_878)_
        -   clinical presentation  [876](c33.xhtml#Page_876)
        -   tricuspid regurgitant jet  [876](c33.xhtml#Page_876), [877](c33.xhtml#Page_877)
    
    -   classification  [870](c33.xhtml#Page_870), **[871](c33.xhtml#Page_871)**
    -   definition  [869](c33.xhtml#Page_869)–870, **[870](c33.xhtml#Page_870)**
    -   diagnostic algorithm  _[873](c33.xhtml#Page_873)_
    -   drugs and toxins associated with  **[872](c33.xhtml#Page_872)**
    -   epidemiology
        -   heritable PAH (HPAH)  [870](c33.xhtml#Page_870)
        -   idiopathic PAH (IPAH)  [870](c33.xhtml#Page_870)
        -   PAH associated with CHD (PAH‐CHD)  [870](c33.xhtml#Page_870)
        -   Tracking Outcomes and Practice in Pediatric (TOPP) PH registry  [872](c33.xhtml#Page_872)
    
    -   infiltrating adaptive _[875](c33.xhtml#Page_875)_
    -   innate immune cells _[875](c33.xhtml#Page_875)_
    -   medical management
        -   atrial septostomy  [882](c33.xhtml#Page_882)
        -   calcium channel blockers (CCBs)  [880](c33.xhtml#Page_880)–881
        -   endothelin receptor antagonists (ERA)  [881](c33.xhtml#Page_881)
        -   Epoprostenol (Flolan®)  [881](c33.xhtml#Page_881)
        -   Iloprost (Ventavis®)  [881](c33.xhtml#Page_881)
        -   Phosphodiesterase‐5 inhibitors (PDE‐5i)  [881](c33.xhtml#Page_881)–882
        -   Prostanoids  [881](c33.xhtml#Page_881)
        -   Sildenafil (Revatio®)  [881](c33.xhtml#Page_881)–882
        -   Tadalafil (Adcirca®)  [882](c33.xhtml#Page_882)
        -   Treprostinil (Remodulin®, Tyvaso®)  [881](c33.xhtml#Page_881)
        -   vasodilators  [879](c33.xhtml#Page_879)
    
    -   Panama classification  **[872](c33.xhtml#Page_872)**
    -   pathophysiology
        -   Eisenmenger syndrome  [874](c33.xhtml#Page_874)
        -   morphometric approach  [874](c33.xhtml#Page_874)
        -   patient genetic and environmental factors  [874](c33.xhtml#Page_874)
    
    -   perioperative risk considerations  [883](c33.xhtml#Page_883)–885, **[884](c33.xhtml#Page_884)**
        -   estimated incidence of  **[883](c33.xhtml#Page_883)**
    
    -   pulmonary hypertensive crisis  [883](c33.xhtml#Page_883)–884
        -   noxious tracheal stimulation  [883](c33.xhtml#Page_883)
        -   pulmonary artery pressure (MPAP)  _[885](c33.xhtml#Page_885)_
        -   self‐perpetuating cycle  _[884](c33.xhtml#Page_884)_
        -   treatment  [884](c33.xhtml#Page_884), **[885](c33.xhtml#Page_885)**
    
    -   pulmonary vascular changes _[875](c33.xhtml#Page_875)_
    -   pulmonary vascular resistance (PVR)  _[884](c33.xhtml#Page_884)_
    -   therapeutic drug targets  _[880](c33.xhtml#Page_880)_
    -   treatment algorithm  _[881](c33.xhtml#Page_881)_
-   pulmonary hypertension (PHTN)  [996](c37.xhtml#Page_996)
-   pulmonary vascular resistance (PVR)  [166](c09.xhtml#Page_166), _[167](c09.xhtml#Page_167),_ [624](c26.xhtml#Page_624)
-   pulmonary vasodilators
    -   inhaled nitric oxide  [508](c21.xhtml#Page_508)–509
    -   prostaglandins  [509](c21.xhtml#Page_509)
    -   schematic representation  _[508](c21.xhtml#Page_508)_
    -   sildenafil  [509](c21.xhtml#Page_509)

-   RACHS‐1 scoring system  [33](c03.xhtml#Page_33)
-   receptor signaling
    -   acute myocardial dysfunction  [184](c09.xhtml#Page_184)–185
    -   in CHD  [185](c09.xhtml#Page_185)
    -   congestive heart failure and cardiomyopathy  [185](c09.xhtml#Page_185)
-   regulation of vascular tone
    -   endothelium‐dependent control  [181](c09.xhtml#Page_181)
    -   pulmonary circulations  [181](c09.xhtml#Page_181)–182
    -   schematic representation  _[181](c09.xhtml#Page_181)_
    -   systemic circulation  [182](c09.xhtml#Page_182)–183
-   remote ischemic preconditioning (RIPC)  [186](c09.xhtml#Page_186), [187](c09.xhtml#Page_187)
-   RIFLE classification system  [469](c20.xhtml#Page_469)
-   right heart catheterization (RHC)  [892](c34.xhtml#Page_892)
-   right‐sided obstructive lesions
    
    -   atresia/ventriculoseptal defect
        -   anatomy  [704](c28.xhtml#Page_704)
        -   anesthetic considerations  [707](c28.xhtml#Page_707)–708
        -   incidence  [704](c28.xhtml#Page_704)
        -   natural history  [704](c28.xhtml#Page_704)
        -   pathophysiology  [704](c28.xhtml#Page_704)–705
        -   surgical and transcatheter approaches  [705](c28.xhtml#Page_705)–707
    
    -   Ebstein anomaly (EA)
        -   anesthetic considerations  [681](c28.xhtml#Page_681)–684
        -   Carpentier classifications  _[676](c28.xhtml#Page_676)_
        -   characteristics  **[675](c28.xhtml#Page_675)**
        -   cone repair  [679](c28.xhtml#Page_679), _[679](c28.xhtml#Page_679), [680](c28.xhtml#Page_680)_
        -   electrophysiologic abnormalities  **[677](c28.xhtml#Page_677)**
        -   incidence, anatomy, and natural history  [675](c28.xhtml#Page_675)–676
        -   normal heart and  _[677](c28.xhtml#Page_677)_
        -   normal tricuspid valve attachments  _[676](c28.xhtml#Page_676)_
        -   outcomes  [680](c28.xhtml#Page_680)–681
        -   pathophysiology  [676](c28.xhtml#Page_676)–677
        -   surgical and transcatheter approaches  [677](c28.xhtml#Page_677)–681
        -   surgical intervention _[678](c28.xhtml#Page_678)_
        -   timing of intervention  [677](c28.xhtml#Page_677)
        -   treatment _[678](c28.xhtml#Page_678),_ **[679](c28.xhtml#Page_679)**
        -   tricuspid valve (TV) leaflet augmentations  _[680](c28.xhtml#Page_680)_
    
    -   PA/VSD with MAPCAs
        -   anatomy  [704](c28.xhtml#Page_704)
        -   anesthetic considerations  [707](c28.xhtml#Page_707)–708
        -   incidence  [704](c28.xhtml#Page_704)
        -   natural history  [704](c28.xhtml#Page_704)
        -   pathophysiology  [704](c28.xhtml#Page_704)–705, _[705](c28.xhtml#Page_705)_
        -   surgical and transcatheter approaches  [705](c28.xhtml#Page_705)–707
    
    -   PA with intact ventricular septum (IVS)
        -   anesthetic considerations  [702](c28.xhtml#Page_702)–703
        -   in 1day old infant  _[700](c28.xhtml#Page_700)_
        -   incidence, anatomy, and natural history  [700](c28.xhtml#Page_700)
        -   management of  _[701](c28.xhtml#Page_701)_
        -   pathophysiology  [700](c28.xhtml#Page_700)–701
        -   surgical and transcatheter approaches  [701](c28.xhtml#Page_701)–702
        -   surgical options  [702](c28.xhtml#Page_702)
    
    -   physiology of  [675](c28.xhtml#Page_675)
    -   PS with intact ventricular septum
        -   anesthetic considerations  [698](c28.xhtml#Page_698)–699
        -   genetic syndromes associated with  **[698](c28.xhtml#Page_698)**
        -   incidence, anatomy, and natural history  [697](c28.xhtml#Page_697)
        -   pathophysiology  [697](c28.xhtml#Page_697)–698
        -   perioperative anesthesia  [700](c28.xhtml#Page_700)
        -   periprocedural anesthesia  [699](c28.xhtml#Page_699)–700
        -   surgical and transcatheter approaches  [698](c28.xhtml#Page_698)
    
    -   tetralogy of fallot
        -   anesthetic considerations  [693](c28.xhtml#Page_693)–697
        -   cardiac anomalies  **[687](c28.xhtml#Page_687)**
        -   computed tomographic images _[686](c28.xhtml#Page_686)_
        -   incidence, anatomy, and natural history  [685](c28.xhtml#Page_685)–689
        -   pathophysiology  [689](c28.xhtml#Page_689)
        -   schematic representation  _[689](c28.xhtml#Page_689)_
        -   surgical and transcatheter approaches  [689](c28.xhtml#Page_689)–693
        -   syndromes **[688](c28.xhtml#Page_688)**
        -   TTE images _[686](c28.xhtml#Page_686)_
-   Riley–Day syndrome  [112](c06.xhtml#Page_112)
-   Risk Adjustment for Congenital Heart Surgery (RACHS)  [305](c14.xhtml#Page_305)
-   Risk Adjustment for Congenital Heart Surgery (RACHS‐1)  [33](c03.xhtml#Page_33), [444](c18.xhtml#Page_444), **[444](c18.xhtml#Page_444)**
-   rotational thromboelastometry (ROTEM®)
    -   assays and clinical indications  **[395](c16.xhtml#Page_395)**
    -   charge‐coupled device  [395](c16.xhtml#Page_395)
    -   clot initiation  [397](c16.xhtml#Page_397), _[397](c16.xhtml#Page_397)_
    -   clot lysis  [397](c16.xhtml#Page_397), _[397](c16.xhtml#Page_397)_
    -   clot strength  [397](c16.xhtml#Page_397), _[397](c16.xhtml#Page_397)_
    -   guided goal‐directed therapy algorithm _[63](c04.xhtml#Page_63)_
    -   normal values  [1018](c37.xhtml#Page_1018), **[1018](c37.xhtml#Page_1018)**
    -   sigma and cartridges  _[395](c16.xhtml#Page_395)_
    -   trace _[396](c16.xhtml#Page_396)_
-   Royal Children’s Hospital, Melbourne, Australia, anesthesia related mortality data  [39](c03.xhtml#Page_39)

-   ß adrenoreceptor (ß‐AR), desensitization and downregulation  _[184](c09.xhtml#Page_184)_
-   sarcoplasmic reticulum (SR)  [190](c10.xhtml#Page_190)
-   secondary myocardium  _[103](c06.xhtml#Page_103)_
-   sedative agents, hemodynamic and cardiac conduction **[204](c10.xhtml#Page_204)**
-   segmental approach, CHD  [117](c07.xhtml#Page_117)
    -   aortic arch  [129](c07.xhtml#Page_129)
    -   atrial situs  [120](c07.xhtml#Page_120)–122, _[121](c07.xhtml#Page_121), [122](c07.xhtml#Page_122)_
    -   atrioventricular connections  [125](c07.xhtml#Page_125), _[126](c07.xhtml#Page_126)_
    -   atrioventricular valves  [125](c07.xhtml#Page_125)
    -   branch pulmonary arteries  [128](c07.xhtml#Page_128)–129
    -   cardiac position and apex orientation  [119](c07.xhtml#Page_119), _[120](c07.xhtml#Page_120)_
    -   conal/infundibular anatomy  [126](c07.xhtml#Page_126), _[127](c07.xhtml#Page_127)_
    -   coronary arteries  [129](c07.xhtml#Page_129)
    -   ductus arteriosus  [128](c07.xhtml#Page_128)–129
    -   great arterial situs  [127](c07.xhtml#Page_127)
    -   great veins and atria  [123](c07.xhtml#Page_123)
    -   malformations  [129](c07.xhtml#Page_129)
    -   semilunar valves  [126](c07.xhtml#Page_126)
    -   ventricles and ventricular septum  [123](c07.xhtml#Page_123)–124, _[125](c07.xhtml#Page_125)_
    -   ventriculoarterial connections  [127](c07.xhtml#Page_127), _[128](c07.xhtml#Page_128)_
    -   ventriculoarterial junction  [126](c07.xhtml#Page_126)
    -   visceral situs  [120](c07.xhtml#Page_120)
-   selected congenital heart defects (CHD)
    -   aortic stenosis **[352](c15.xhtml#Page_352),** [358](c15.xhtml#Page_358)
    -   atrial septal defects **[352](c15.xhtml#Page_352),** [354](c15.xhtml#Page_354)–356, _[355](c15.xhtml#Page_355), [356](c15.xhtml#Page_356)_
    -   atrioventricular septal defects **[352](c15.xhtml#Page_352),** [357](c15.xhtml#Page_357)–358, _[359](c15.xhtml#Page_359)_
    -   congenitally corrected transposition of the great arteries **[352](c15.xhtml#Page_352),** [366](c15.xhtml#Page_366), _[368](c15.xhtml#Page_368)_
    -   double‐outlet right ventricle **[352](c15.xhtml#Page_352),** [362](c15.xhtml#Page_362)–364, _[364](c15.xhtml#Page_364)_
    -   LV outflow obstruction  [358](c15.xhtml#Page_358)–360, _[361](c15.xhtml#Page_361)_
    -   RV outflow obstruction  [360](c15.xhtml#Page_360), _[362](c15.xhtml#Page_362)_
    -   single ventricle **[353](c15.xhtml#Page_353),** [366](c15.xhtml#Page_366), [369](c15.xhtml#Page_369)–371, _[370](c15.xhtml#Page_370), [372](c15.xhtml#Page_372)_
    -   tetralogy of Fallot **[353](c15.xhtml#Page_353),** [360](c15.xhtml#Page_360)–362, _[363](c15.xhtml#Page_363)_
    -   transposition of great arteries **[353](c15.xhtml#Page_353),** [364](c15.xhtml#Page_364)–366, _[365](c15.xhtml#Page_365), [367](c15.xhtml#Page_367)_
    -   truncus arteriosus **[353](c15.xhtml#Page_353),** [366](c15.xhtml#Page_366), _[369](c15.xhtml#Page_369)_
    -   ventricular septal defects **[353](c15.xhtml#Page_353),** [356](c15.xhtml#Page_356)–357, _[357](c15.xhtml#Page_357)_
-   selective cerebral perfusion
    -   arterial blood pressure (ABP)  [311](c14.xhtml#Page_311), _[312](c14.xhtml#Page_312)_
    -   circulatory arrest  [311](c14.xhtml#Page_311)
    -   neurocognitive testing  [310](c14.xhtml#Page_310)
    -   piglet models of  [311](c14.xhtml#Page_311), **[312](c14.xhtml#Page_312),** _[312](c14.xhtml#Page_312)_
    -   pump flow rates  [311](c14.xhtml#Page_311), _[312](c14.xhtml#Page_312)_
    -   translation of  [312](c14.xhtml#Page_312)
-   sickle cell disease (SCD)  [406](c16.xhtml#Page_406)–407
-   Sildenafil (Revatio®)  [881](c33.xhtml#Page_881)–882
-   simulation in medical education  [22](c02.xhtml#Page_22)
-   sinoatrial node (SAN)  [102](c06.xhtml#Page_102)
-   six “Cs,” [31](c03.xhtml#Page_31)
-   Society of Cardiovascular Anesthesiologists (SCA) Adult Cardiothoracic Anesthesia Database  [32](c03.xhtml#Page_32)
-   Society of Pediatric Anesthesia (SPA)  [27](c02.xhtml#Page_27)
-   Society of Thoracic Surgeons (STS)  [30](c03.xhtml#Page_30)
    -   Congenital Heart Surgery Database(STS‐CHSD)  [32](c03.xhtml#Page_32), **[34](c03.xhtml#Page_34)–36,** [42](c03.xhtml#Page_42)
    -   STAT mortality score  [33](c03.xhtml#Page_33), **[34](c03.xhtml#Page_34)**–**[36](c03.xhtml#Page_36),** [42](c03.xhtml#Page_42)
-   Society of Thoracic Surgeons (STAT) Score  [444](c18.xhtml#Page_444), **[445](c18.xhtml#Page_445)**
-   Stanford Children’s Hospital pediatric cardiac transplant flight plan _[841](c32.xhtml#Page_841)_
-   ST‐elevation myocardial infarction (STEMI) [187](c09.xhtml#Page_187)
-   stem cell and cell‐based therapy  [188](c09.xhtml#Page_188)
-   structural examination, training need  [16](c02.xhtml#Page_16), [17](c02.xhtml#Page_17), [20](c02.xhtml#Page_20)
-   subvalvular aortic stenosis  [100](c06.xhtml#Page_100)
-   sudden infant death syndrome  [112](c06.xhtml#Page_112)
-   summative assessment  [25](c02.xhtml#Page_25)
-   superior cavopulmonary connection
    
    -   anesthetic considerations  [763](c30.xhtml#Page_763)–767
        -   cavopulmonary–cerebral circulation  [766](c30.xhtml#Page_766), _[766](c30.xhtml#Page_766)_
        -   intraoperative  [764](c30.xhtml#Page_764)–765
        -   postoperative  [765](c30.xhtml#Page_765)–767
        -   preoperative  [763](c30.xhtml#Page_763)–764
        -   pre‐superior cavopulmonary connection  **[764](c30.xhtml#Page_764)**
    
    -   bidirectional Glenn (BDG)  [761](c30.xhtml#Page_761), _[762](c30.xhtml#Page_762)_
    -   differential diagnosis  **[767](c30.xhtml#Page_767)**
    -   early cyanosis postbidirectional Glenn/Hemi‐Fontan  **[765](c30.xhtml#Page_765)**
    -   Hemi‐Fontan procedure  [761](c30.xhtml#Page_761), _[763](c30.xhtml#Page_763)_
    -   hemodynamic status  **[767](c30.xhtml#Page_767)**
    -   outcomes  [767](c30.xhtml#Page_767)
    -   surgical procedure  [761](c30.xhtml#Page_761)–763
-   supravalvular aortic stenosis (SVAS)  [100](c06.xhtml#Page_100)
-   supraventricular arrhythmias
    -   premature atrial contractions (PACs)  [531](c22.xhtml#Page_531), _[532](c22.xhtml#Page_532),_**[535](c22.xhtml#Page_535)**
    -   supraventricular tachycardia (SVT)  [531](c22.xhtml#Page_531)–542
        -   adenosine treatment  _[542](c22.xhtml#Page_542)_
        -   atrial electrogram  [532](c22.xhtml#Page_532)–533, _[534](c22.xhtml#Page_534)_
        -   atrial fibrillation **[535](c22.xhtml#Page_535),** [539](c22.xhtml#Page_539)–540
        -   atrial flutter **[535](c22.xhtml#Page_535),** [538](c22.xhtml#Page_538)–539, _[539](c22.xhtml#Page_539)_
        -   atrial tachycardias **[535](c22.xhtml#Page_535),** [536](c22.xhtml#Page_536), _[536](c22.xhtml#Page_536)_
        -   atrioventricular nodal reentrant tachycardia (AVNRT) **[535](c22.xhtml#Page_535),** [540](c22.xhtml#Page_540)–541, _[541](c22.xhtml#Page_541)_
        -   atrioventricular reentrant tachycardia (AVRT) **[535](c22.xhtml#Page_535),** [540](c22.xhtml#Page_540)–541, _[541](c22.xhtml#Page_541)_
        -   automatic  [532](c22.xhtml#Page_532)
        -   characteristics of  **[533](c22.xhtml#Page_533)**
        -   electrocardiographic features  **[533](c22.xhtml#Page_533)**
        -   focal atrial tachycardia (AT)  [536](c22.xhtml#Page_536)
        -   junctional tachycardias **[535](c22.xhtml#Page_535),** [537](c22.xhtml#Page_537), _[538](c22.xhtml#Page_538)_
        -   management principles of  [533](c22.xhtml#Page_533), [536](c22.xhtml#Page_536)
        -   mechanisms  **[533](c22.xhtml#Page_533)**
        -   multifocal atrial tachycardia (MAT) **[535](c22.xhtml#Page_535),** [537](c22.xhtml#Page_537)
        -   postoperative EAT  [536](c22.xhtml#Page_536)–537
        -   postoperative JET  [537](c22.xhtml#Page_537)–538
        -   reentrant  [532](c22.xhtml#Page_532), [538](c22.xhtml#Page_538)
        -   Wolff–Parkinson–White syndrome  [540](c22.xhtml#Page_540), _[540](c22.xhtml#Page_540)_
-   Swiss cheese model  [29](c03.xhtml#Page_29), [30](c03.xhtml#Page_30), _[31](c03.xhtml#Page_31)_
-   systemic air embolism  [61](c04.xhtml#Page_61)
-   systemic circulation, regulation of vascular tone
    
    -   angiotensin II  [182](c09.xhtml#Page_182)
    -   atrial natriuretic factor (ANF)  [182](c09.xhtml#Page_182)
    -   hormonal control  [182](c09.xhtml#Page_182)
    -   phospholipase C (PLC) system  [182](c09.xhtml#Page_182), _[183](c09.xhtml#Page_183)_
    -   receptor‐mediated intracellular signaling  [182](c09.xhtml#Page_182)
    -   vasodilatation  [183](c09.xhtml#Page_183)
    
-   systemic vascular resistance (SVR)  [624](c26.xhtml#Page_624)
-   systemic vasodilators
    -   hydralazine  [507](c21.xhtml#Page_507)
    -   nesiritide  [507](c21.xhtml#Page_507)
    -   nitric oxide donors  [507](c21.xhtml#Page_507)
    -   phenoxybenzamine  [507](c21.xhtml#Page_507)
    -   phentolamine  [507](c21.xhtml#Page_507)

-   Tadalafil (Adcirca®)  [882](c33.xhtml#Page_882)
-   tamponade
    -   anatomy [803](c31.xhtml#Page_803)
    -   anesthesia [807](c31.xhtml#Page_807)–808
    -   diagnosis [804](c31.xhtml#Page_804)–806
    -   echocardigraphic features **[806](c31.xhtml#Page_806)**
    -   incidence [803](c31.xhtml#Page_803)
    -   natural history [803](c31.xhtml#Page_803)
    -   pathophysiology [804](c31.xhtml#Page_804)–806, _[804](c31.xhtml#Page_804), [805](c31.xhtml#Page_805)_
    -   surgery for [807](c31.xhtml#Page_807)
-   teamwork  [31](c03.xhtml#Page_31)
-   TEE examination, CHD  [337](c15.xhtml#Page_337)–349
    
    -   functional assessment
        -   diastolic function evaluation  [348](c15.xhtml#Page_348)
        -   LV systolic function  [345](c15.xhtml#Page_345)–347
        -   regional wall motion  [347](c15.xhtml#Page_347)
        -   RV systolic function  [347](c15.xhtml#Page_347)–348
    
    -   hemodynamic evaluation  [348](c15.xhtml#Page_348)–349, **[349](c15.xhtml#Page_349)**
    -   structural examination
        -   aortic views  [344](c15.xhtml#Page_344)
        -   DTG views  [343](c15.xhtml#Page_343)–344
        -   imaging windows  [341](c15.xhtml#Page_341), _[341](c15.xhtml#Page_341)_
        -   ME views  [343](c15.xhtml#Page_343)
        -   multiplane imaging views  [341](c15.xhtml#Page_341)–344, **[342](c15.xhtml#Page_342)**– **[343](c15.xhtml#Page_343)**
        -   sequential segmental approach  [339](c15.xhtml#Page_339)–340, _[340](c15.xhtml#Page_340)_
        -   structure‐based approach  [338](c15.xhtml#Page_338)–339
        -   TG views  [343](c15.xhtml#Page_343)
        -   view‐based approach  [337](c15.xhtml#Page_337)–338, _[338](c15.xhtml#Page_338), [339](c15.xhtml#Page_339)_
    
    -   three‐dimensional TEE  **[344](c15.xhtml#Page_344),** [344](c15.xhtml#Page_344)–345
        -   clinical use of  **[345](c15.xhtml#Page_345)**
        -   real‐time imaging  _[344](c15.xhtml#Page_344)_
        -   virtual dissection  [344](c15.xhtml#Page_344)
-   TEE hardware  [333](c15.xhtml#Page_333)–337
    -   echocardiographic system  [333](c15.xhtml#Page_333)–334
    -   imaging probes  **[334](c15.xhtml#Page_334),** [334](c15.xhtml#Page_334)–337
        -   adult multiplane TEE probe  _[337](c15.xhtml#Page_337)_
        -   device selection  [334](c15.xhtml#Page_334)–335, **[335](c15.xhtml#Page_335)**
        -   instrument manipulation and probe controls  _[336](c15.xhtml#Page_336),_ [336](c15.xhtml#Page_336)–337
        -   micro‐multiplane probe  [334](c15.xhtml#Page_334), _[335](c15.xhtml#Page_335)_
        -   pediatric multiplane probe  [334](c15.xhtml#Page_334), _[337](c15.xhtml#Page_337)_
        -   probe insertion  [335](c15.xhtml#Page_335)–336
-   TEG®
    -   clot initiation  [397](c16.xhtml#Page_397), _[397](c16.xhtml#Page_397)_
    -   clot lysis  [397](c16.xhtml#Page_397), _[397](c16.xhtml#Page_397)_
    -   clot strength  [397](c16.xhtml#Page_397), _[397](c16.xhtml#Page_397)_
    -   device and cartridge  _[394](c16.xhtml#Page_394)_
    -   PlateletMapping cartridge  [394](c16.xhtml#Page_394)
    -   resonance‐frequency viscoelasticity  [394](c16.xhtml#Page_394)
    -   trace _[396](c16.xhtml#Page_396)_
-   tetralogy of fallot (TOF)  [99](c06.xhtml#Page_99)
    
    -   anatomy  [685](c28.xhtml#Page_685)–689
    -   anesthetic considerations
        -   hypercyanotic episodes management  [694](c28.xhtml#Page_694)–695
        -   initial assessment and planning  [693](c28.xhtml#Page_693)–694
    
    -   Blalock–Taussig shunt  [690](c28.xhtml#Page_690), _[690](c28.xhtml#Page_690)_
    -   cardiac anomalies  **[687](c28.xhtml#Page_687)**
    -   computed tomographic images _[686](c28.xhtml#Page_686)_
    -   incidence  [685](c28.xhtml#Page_685)–689
    -   initial stabilization and planning  [689](c28.xhtml#Page_689)–690
    -   long‐term surgical complications  [691](c28.xhtml#Page_691)–692
    -   natural history  [685](c28.xhtml#Page_685)–689
    -   overview of  **[694](c28.xhtml#Page_694)**
    -   pathophysiology  [689](c28.xhtml#Page_689)
    -   schematic representation  _[689](c28.xhtml#Page_689)_
    -   surgical palliation  [690](c28.xhtml#Page_690)
        -   perioperative anesthetic management  [695](c28.xhtml#Page_695)
        -   postoperative care  [695](c28.xhtml#Page_695)–696
    
    -   surgical repair  [690](c28.xhtml#Page_690)–692, _[691](c28.xhtml#Page_691)_
        -   perioperative anesthetic management  [695](c28.xhtml#Page_695)–696
        -   postoperative care  [696](c28.xhtml#Page_696)
    
    -   syndromes associated with **[688](c28.xhtml#Page_688)**
    -   tet spell/hypercyanotic episode  **[695](c28.xhtml#Page_695)**
    -   transcatheter palliation  [690](c28.xhtml#Page_690)
    -   transcatheter pulmonary valveimplantation  [692](c28.xhtml#Page_692)–693, _[693](c28.xhtml#Page_693)_
    -   treatment  _[690](c28.xhtml#Page_690)_
    -   TTE images _[686](c28.xhtml#Page_686)_
-   Texas Children’s Hospital (TCH)  [44](c04.xhtml#Page_44)
    
    -   AAOCA  [49](c04.xhtml#Page_49)
    -   anesthesiologist involvement  [53](c04.xhtml#Page_53)
    -   communication activities (_see_ [communication and team functioning](#ind1860))
    -   coronary anomalies program algorithm _[50](c04.xhtml#Page_50)_
    -   cortical desaturation  **[318](c14.xhtml#Page_318)**
    -   data, validation, and consistency  [47](c04.xhtml#Page_47)–49
    -   handbook  [66](c04.xhtml#Page_66)–67, _[67](c04.xhtml#Page_67)_
    -   Heart Center Executive Committee (HCEC)  [45](c04.xhtml#Page_45)
    -   leadership structure  **[45](c04.xhtml#Page_45)**
    -   morning report  [47](c04.xhtml#Page_47), _[48](c04.xhtml#Page_48)_
    -   multidisciplinary surgical patient ICU rounds  [49](c04.xhtml#Page_49)
    -   operating room extubation  **[61](c04.xhtml#Page_61), [62](c04.xhtml#Page_62)**
    -   parent and family involvement  [67](c04.xhtml#Page_67)
    -   patient case conferences  [47](c04.xhtml#Page_47)
    -   presurgical planning conferences  [45](c04.xhtml#Page_45)–46, _[46](c04.xhtml#Page_46), [47](c04.xhtml#Page_47)_
    -   quality and outcomes improvement conferences
        -   multidisciplinary meetings  [52](c04.xhtml#Page_52), _[52](c04.xhtml#Page_52)_
        -   performance rounds  [49](c04.xhtml#Page_49), _[51](c04.xhtml#Page_51)_
        -   quality conference  [52](c04.xhtml#Page_52)
    
    -   surgical patient ICU rounds  [49](c04.xhtml#Page_49)
    -   systemic air embolism  _[61](c04.xhtml#Page_61)_
    -   validation  [49](c04.xhtml#Page_49)
    -   wide communication activities
        -   Heart Center annual retreat  [52](c04.xhtml#Page_52)–53, _[53](c04.xhtml#Page_53)_
        -   Heart Center Town Hall  [52](c04.xhtml#Page_52), _[53](c04.xhtml#Page_53)_
-   thoracic surgery
    -   airway management (_see_ [airway management, thoracic surgery](#ind64))
    -   ventilatory management  [567](c23.xhtml#Page_567), [569](c23.xhtml#Page_569)
-   time‐out system  [31](c03.xhtml#Page_31)
-   tissue plasminogen activator (tPA)  [379](c16.xhtml#Page_379)
-   total anomalous pulmonary venous connection (TAPVC)  [108](c06.xhtml#Page_108)
-   total anomalous pulmonary venous return (TAPVR)  [644](c26.xhtml#Page_644)–648
    -   anesthetic considerations  [647](c26.xhtml#Page_647)–648
    -   cardiac  _[645](c26.xhtml#Page_645),_ [646](c26.xhtml#Page_646)
    -   incidence  [644](c26.xhtml#Page_644)–645
    -   infracardiac  _[645](c26.xhtml#Page_645),_ [646](c26.xhtml#Page_646)
    -   mixed  _[645](c26.xhtml#Page_645),_ [646](c26.xhtml#Page_646)
    -   natural history  [646](c26.xhtml#Page_646)
    -   pathophysiology  [646](c26.xhtml#Page_646)
    -   subtypes of  _[645](c26.xhtml#Page_645)_
    -   supracardiac  [645](c26.xhtml#Page_645), _[645](c26.xhtml#Page_645)_
    -   surgical approaches  [646](c26.xhtml#Page_646)–647
    -   surgical repair  _[647](c26.xhtml#Page_647)_
-   tranexamic acid (TA)  [228](c11.xhtml#Page_228)–229
-   transesophageal echocardiography (TEE)
    
    -   applications  [350](c15.xhtml#Page_350)
        -   cardiac catheterization laboratory  [350](c15.xhtml#Page_350)
        -   intensive care unit  [350](c15.xhtml#Page_350)
        -   intraoperative setting  [350](c15.xhtml#Page_350)
        -   mechanical support  [371](c15.xhtml#Page_371)
    
    -   contraindications  [333](c15.xhtml#Page_333), **[333](c15.xhtml#Page_333)**
    -   examination, CHD  [337](c15.xhtml#Page_337)–349
        -   functional assessment  [345](c15.xhtml#Page_345)–348
        -   hemodynamic evaluation  [348](c15.xhtml#Page_348)–349
        -   structural examination  [337](c15.xhtml#Page_337)–344
        -   three‐dimensional TEE  [344](c15.xhtml#Page_344)–345
    
    -   hardware  [333](c15.xhtml#Page_333)–337
        -   echocardiographic system  [333](c15.xhtml#Page_333)–334
        -   imaging probes  [334](c15.xhtml#Page_334)–337
    
    -   indications for  [331](c15.xhtml#Page_331)–333, **[332](c15.xhtml#Page_332)**
    -   intraoperative evaluation  [332](c15.xhtml#Page_332)
    -   limitations  [333](c15.xhtml#Page_333)
    -   safety and complications  [351](c15.xhtml#Page_351)
    -   selected congenital heart defects  [351](c15.xhtml#Page_351)–371
        -   aortic stenosis **[352](c15.xhtml#Page_352),** [358](c15.xhtml#Page_358)
        -   atrial septal defects **[352](c15.xhtml#Page_352),** [354](c15.xhtml#Page_354)–356, _[355](c15.xhtml#Page_355), [356](c15.xhtml#Page_356)_
        -   atrioventricular septal defects **[352](c15.xhtml#Page_352),** [357](c15.xhtml#Page_357)–358, _[359](c15.xhtml#Page_359)_
        -   congenitally corrected transposition of the great arteries **[352](c15.xhtml#Page_352),** [366](c15.xhtml#Page_366), _[368](c15.xhtml#Page_368)_
        -   double‐outlet right ventricle **[352](c15.xhtml#Page_352),** [362](c15.xhtml#Page_362)–364, _[364](c15.xhtml#Page_364)_
        -   LV outflow obstruction  [358](c15.xhtml#Page_358)–360, _[361](c15.xhtml#Page_361)_
        -   RV outflow obstruction  [360](c15.xhtml#Page_360), _[362](c15.xhtml#Page_362)_
        -   single ventricle **[353](c15.xhtml#Page_353),** [366](c15.xhtml#Page_366), [369](c15.xhtml#Page_369)–371, _[370](c15.xhtml#Page_370), [372](c15.xhtml#Page_372)_
        -   tetralogy of Fallot **[353](c15.xhtml#Page_353),** [360](c15.xhtml#Page_360)–362, _[363](c15.xhtml#Page_363)_
        -   transposition of great arteries **[353](c15.xhtml#Page_353),** [364](c15.xhtml#Page_364)–366, _[365](c15.xhtml#Page_365), [367](c15.xhtml#Page_367)_
        -   truncus arteriosus **[353](c15.xhtml#Page_353),** [366](c15.xhtml#Page_366), _[369](c15.xhtml#Page_369)_
        -   ventricular septal defects **[353](c15.xhtml#Page_353),** [356](c15.xhtml#Page_356)–357, _[357](c15.xhtml#Page_357)_
    
    -   ventricular assist device surgery **[373](c15.xhtml#Page_373)**
-   transposition of great arteries (TGA)
    
    -   congenitally corrected
        -   anatomical factors  _[736](c29.xhtml#Page_736)_
        -   anatomy  [733](c29.xhtml#Page_733)–734
        -   diagnostic testing  [735](c29.xhtml#Page_735)
        -   double switch (DS) procedure  [737](c29.xhtml#Page_737), _[738](c29.xhtml#Page_738)_
        -   Fontan procedure  [738](c29.xhtml#Page_738)
        -   incidence  [733](c29.xhtml#Page_733)
        -   long‐term outcomes  **[738](c29.xhtml#Page_738)**
        -   natural history  [734](c29.xhtml#Page_734)–735
        -   normal anatomy  _[733](c29.xhtml#Page_733)_
        -   outcomes  [738](c29.xhtml#Page_738)
        -   pathophysiology  [735](c29.xhtml#Page_735)
        -   postoperative complications  [739](c29.xhtml#Page_739)
        -   preoperative assessment  [739](c29.xhtml#Page_739)
        -   section of heart with  _[734](c29.xhtml#Page_734)_
        -   Senning and Rastelli  [737](c29.xhtml#Page_737)–738
        -   surgical options  [736](c29.xhtml#Page_736)–737
    
    -   dextro‐transposition of the great arteries (D‐TGA)  [364](c15.xhtml#Page_364), _[365](c15.xhtml#Page_365), [367](c15.xhtml#Page_367), [711](c29.xhtml#Page_711)_
    -   normal circulation _vs.  [715](c29.xhtml#Page_715)_
    -   physiologically uncorrected
        -   anatomy  _[711](c29.xhtml#Page_711),_ [711](c29.xhtml#Page_711)–712
        -   anesthetic goals  [727](c29.xhtml#Page_727)
        -   anesthetic intraoperative management  [727](c29.xhtml#Page_727)
        -   antibiotics  [728](c29.xhtml#Page_728)
        -   anticoagulation  [729](c29.xhtml#Page_729)
        -   arterial switch operation (ASO)  _[720](c29.xhtml#Page_720),_ [720](c29.xhtml#Page_720)–721, _[722](c29.xhtml#Page_722), [723](c29.xhtml#Page_723)_
        -   balloon atrial septostomy (BAS)  _[718](c29.xhtml#Page_718),_ [718](c29.xhtml#Page_718)–719
        -   bypass  [728](c29.xhtml#Page_728)
        -   chest radiograph (CXR) findings  **[717](c29.xhtml#Page_717)**
        -   clinical features  [717](c29.xhtml#Page_717)
        -   coronary artery anatomy  [712](c29.xhtml#Page_712), _[713](c29.xhtml#Page_713), [714](c29.xhtml#Page_714)_
        -   diagnostic features  [717](c29.xhtml#Page_717)
        -   ECG  **[717](c29.xhtml#Page_717)**
        -   effective pulmonary blood flow  [713](c29.xhtml#Page_713)
        -   effective systemic blood flow  [713](c29.xhtml#Page_713)
        -   feeding and nutrition  [733](c29.xhtml#Page_733)
        -   fluids and electrolytes  [732](c29.xhtml#Page_732)
        -   gadolinium‐enhanced magnetic resonance angiogram  _[723](c29.xhtml#Page_723)_
        -   incidence  [710](c29.xhtml#Page_710)
        -   indication and timing  [719](c29.xhtml#Page_719)–720
        -   intact ventricular septum  [716](c29.xhtml#Page_716)
        -   intensive care unit  **[731](c29.xhtml#Page_731)**
        -   intercirculatory mixing  [714](c29.xhtml#Page_714)–715, **[715](c29.xhtml#Page_715)**
        -   intracardiac shunting  _[715](c29.xhtml#Page_715)_
        -   LVOTO  [716](c29.xhtml#Page_716), _[721](c29.xhtml#Page_721)_
        -   natural history and pathophysiology  [712](c29.xhtml#Page_712)–713
        -   near infrared spectroscopy  [728](c29.xhtml#Page_728)–729
        -   neonatal brain injury  **[728](c29.xhtml#Page_728)**
        -   neuromonitoring  [728](c29.xhtml#Page_728)–729
        -   Nikaidoh procedures  [722](c29.xhtml#Page_722)–723, _[725](c29.xhtml#Page_725)_
        -   outcomes  [723](c29.xhtml#Page_723)–726
        -   post‐op complications  [731](c29.xhtml#Page_731)–732
        -   postoperative management, ASO  [730](c29.xhtml#Page_730)
        -   postoperative sequelae  **[726](c29.xhtml#Page_726)**
        -   pre‐bypass management  [727](c29.xhtml#Page_727)–728
        -   preoperative assessment  [726](c29.xhtml#Page_726)–727
        -   preoperative management  [717](c29.xhtml#Page_717)–718
        -   pulmonary blood flow  [715](c29.xhtml#Page_715)
        -   pulmonary vascular occlusive disease  [716](c29.xhtml#Page_716)
        -   Rastelli procedure  [721](c29.xhtml#Page_721), _[724](c29.xhtml#Page_724)_
        -   renal support  [732](c29.xhtml#Page_732)
        -   Réparation à l’Etage Ventriculaire (REV)  [722](c29.xhtml#Page_722), _[725](c29.xhtml#Page_725)_
        -   respiratory support and drains  [732](c29.xhtml#Page_732)
        -   RVOTO  [716](c29.xhtml#Page_716)
        -   sedation and analgesia  [732](c29.xhtml#Page_732)
        -   Senning and mustard procedures  [721](c29.xhtml#Page_721)–722, _[724](c29.xhtml#Page_724)_
        -   separation from bypass  [730](c29.xhtml#Page_730)
        -   sepsis  [733](c29.xhtml#Page_733)
        -   shunting  [713](c29.xhtml#Page_713)
        -   surgical options  [719](c29.xhtml#Page_719)
        -   systemic inflammatory response syndrome  [728](c29.xhtml#Page_728)
        -   thromboelastography/thromboelastometry  [729](c29.xhtml#Page_729)
        -   transcatheter approaches  [718](c29.xhtml#Page_718)
        -   ventricular septal defect  [716](c29.xhtml#Page_716)
    
    -   TEE examination
        -   arterial switch operation (ASO)  [365](c15.xhtml#Page_365)
        -   evaluation  [365](c15.xhtml#Page_365)
        -   Rastelli‐type operations  [366](c15.xhtml#Page_366)
-   transthoracic echocardiography (TTE)  [651](c27.xhtml#Page_651)
-   Treprostinil (Remodulin®, Tyvaso®)  [881](c33.xhtml#Page_881)
-   tricuspid atresia  [97](c06.xhtml#Page_97)
    
    -   anatomic classification  **[756](c30.xhtml#Page_756)**
    -   anesthetic considerations
        -   Damus‐Kaye‐Stansel operation  [758](c30.xhtml#Page_758)
        -   ductal stenting  [757](c30.xhtml#Page_757)–758
        -   palliative ASO  [758](c30.xhtml#Page_758)
        -   pulmonary artery banding  [755](c30.xhtml#Page_755)–757
        -   systemic‐PA shunt  [757](c30.xhtml#Page_757)–758
    
    -   blood flow  _[753](c30.xhtml#Page_753)_
    -   classification of  _[755](c30.xhtml#Page_755)_
    -   hemodynamics of  _[754](c30.xhtml#Page_754)_
    -   incidence, anatomy, and natural history  [752](c30.xhtml#Page_752)–753
    -   pathophysiology
        -   type I‐A  [753](c30.xhtml#Page_753)
        -   type I‐B  [753](c30.xhtml#Page_753)
        -   type I‐C  [753](c30.xhtml#Page_753)
        -   type II‐A  [753](c30.xhtml#Page_753)
        -   type II‐B  [753](c30.xhtml#Page_753)
        -   type II‐C  [753](c30.xhtml#Page_753)
        -   type III‐A  [754](c30.xhtml#Page_754)
        -   type III‐B  [754](c30.xhtml#Page_754)
    
    -   physiologic classification  **[756](c30.xhtml#Page_756)**
    -   surgical methods  _[757](c30.xhtml#Page_757)_
-   truncus arteriosus  [642](c26.xhtml#Page_642)–644
    -   anesthetic considerations  [644](c26.xhtml#Page_644)
    -   classification of  _[642](c26.xhtml#Page_642)_
    -   incidence  [642](c26.xhtml#Page_642)
    -   natural history  [643](c26.xhtml#Page_643)
    -   pathophysiology  [643](c26.xhtml#Page_643)
    -   surgical and transcatheter approaches  [643](c26.xhtml#Page_643)–644
    -   surgical repair  _[643](c26.xhtml#Page_643)_
    -   type I  [642](c26.xhtml#Page_642)
    -   type II  [642](c26.xhtml#Page_642)
    -   type III  [642](c26.xhtml#Page_642)–643
    -   type IV  [643](c26.xhtml#Page_643)

-   ultrasound‐guided arterial catheterization  [289](c13.xhtml#Page_289)–291
-   ultrasound‐guided IJV puncture
    -   anatomic relations  _[285](c13.xhtml#Page_285)_
    -   Doppler color‐flow imaging  [285](c13.xhtml#Page_285), _[286](c13.xhtml#Page_286)_
    -   in‐plane ultrasound images  _[289](c13.xhtml#Page_289)_
    -   needle advancement  [286](c13.xhtml#Page_286)
    -   out‐of‐plane images  [285](c13.xhtml#Page_285), _[286](c13.xhtml#Page_286)_
    -   real‐time ultrasound guidance _[287](c13.xhtml#Page_287)_
    -   ultrasound beam and needle angles  _[288](c13.xhtml#Page_288)_
-   ultrasound‐guided vascular access
    -   brachiocephalic vein puncture  [289](c13.xhtml#Page_289)
    -   central vascular access  [284](c13.xhtml#Page_284)–285
    -   FV puncture  [289](c13.xhtml#Page_289)
    -   IJV puncture  [285](c13.xhtml#Page_285)–288
    -   peripheral vein access  [283](c13.xhtml#Page_283)–284
    -   sonoanatomy  [283](c13.xhtml#Page_283)
-   umbilical cord blood (UCB‐MNC)  [188](c09.xhtml#Page_188)
-   unrestricted shunts  [470](c20.xhtml#Page_470)

-   Van Praagh
    -   nomenclature systems  [117](c07.xhtml#Page_117)–118
    -   notation  [118](c07.xhtml#Page_118)–119
-   vascular access  [272](c13.xhtml#Page_272)
    -   adult congenital heart disease (ACHD)  [470](c20.xhtml#Page_470)
    -   arrhythmias  [302](c13.xhtml#Page_302)–303
    -   cardiac tamponade  [302](c13.xhtml#Page_302)
    -   complications  [303](c13.xhtml#Page_303)
    -   CRBSIs  [300](c13.xhtml#Page_300)
    -   foreign bodies  [303](c13.xhtml#Page_303)
    -   inadvertent arterial puncture  [302](c13.xhtml#Page_302)
    -   incidence and risk factors  [297](c13.xhtml#Page_297), [299](c13.xhtml#Page_299)
    -   infection  [300](c13.xhtml#Page_300)–301
    -   insertion bundle  [301](c13.xhtml#Page_301)
    -   intracardiac catheters  [303](c13.xhtml#Page_303)
    -   loss of palpable pedal pulse (LOP)  _[300](c13.xhtml#Page_300)_
    -   maintenance bundle  [301](c13.xhtml#Page_301)
    -   malposition/perforation  [301](c13.xhtml#Page_301)–302
    -   pneumothorax/hemothorax  [302](c13.xhtml#Page_302)
    -   systemic venous air embolus  [303](c13.xhtml#Page_303)
    -   thrombosis  [299](c13.xhtml#Page_299)–300
-   vascular rings
    
    -   anatomy [781](c31.xhtml#Page_781)–782
    -   classification [781](c31.xhtml#Page_781)–782
    -   diagnosis of [782](c31.xhtml#Page_782), _[783](c31.xhtml#Page_783)_
    -   double and right aortic arches [782](c31.xhtml#Page_782)–785, _[784](c31.xhtml#Page_784), [786](c31.xhtml#Page_786)_
        -   anesthesia [784](c31.xhtml#Page_784)–785
        -   pathophysiology of [783](c31.xhtml#Page_783)
        -   surgery for [783](c31.xhtml#Page_783)–784, _[787](c31.xhtml#Page_787), [788](c31.xhtml#Page_788)_
    
    -   embryonic aortic arches _[784](c31.xhtml#Page_784)_
    -   incidence [781](c31.xhtml#Page_781)–782
    -   innominate artery compression syndrome _[789](c31.xhtml#Page_789)_
        -   anesthesia for repair [787](c31.xhtml#Page_787)
        -   pathophysiology of [786](c31.xhtml#Page_786)
        -   surgery for [786](c31.xhtml#Page_786)–787, _[789](c31.xhtml#Page_789)_
    
    -   Lurie Children’s Hospital patient’s experience **[782](c31.xhtml#Page_782)**
    -   pulmonary artery sling with tracheal stenosis
        -   anesthesia for repair [792](c31.xhtml#Page_792)–794
        -   operative technique _[791](c31.xhtml#Page_791)_
        -   pathophysiology [789](c31.xhtml#Page_789), _[789](c31.xhtml#Page_789), [790](c31.xhtml#Page_790)_
        -   surgery for [789](c31.xhtml#Page_789)–792_, [793](c31.xhtml#Page_793)_
    
    -   symptoms **[785](c31.xhtml#Page_785)**
-   venous access
    
    -   CVC proper placement
        -   echocardiography  [278](c13.xhtml#Page_278)
        -   electrocardiographically guided placement  [278](c13.xhtml#Page_278)
        -   height‐and weight‐based formulae  [278](c13.xhtml#Page_278)–279
        -   radiograph  [278](c13.xhtml#Page_278)
        -   recommended lengths  **[279](c13.xhtml#Page_279)**
    
    -   direct transthoracic intracardiac vascular access  [277](c13.xhtml#Page_277)
    -   percutaneous central venous access
        -   catheter sizes and lengths  **[274](c13.xhtml#Page_274)**
        -   common carotid artery (CCA)  [275](c13.xhtml#Page_275), **[276](c13.xhtml#Page_276)**
        -   external jugular vein (EJV)  [276](c13.xhtml#Page_276)–277
        -   femoral vein  [277](c13.xhtml#Page_277)
        -   internal jugular vein (IJV)  [275](c13.xhtml#Page_275)–276
        -   subclavian vein  [276](c13.xhtml#Page_276)
        -   superior vena cava (SVC)  _[276](c13.xhtml#Page_276)_
        -   total anomalous pulmonary venous return (TAPVR)  [275](c13.xhtml#Page_275)
        -   transesophageal echocardiography (TEE)  [275](c13.xhtml#Page_275)
        -   umbilical vein  [277](c13.xhtml#Page_277)
        -   vertebral artery puncture  [274](c13.xhtml#Page_274), **[275](c13.xhtml#Page_275)**
    
    -   peripherally inserted central catheter (PICC)  [279](c13.xhtml#Page_279)
    -   peripheral venous access  [273](c13.xhtml#Page_273), _[274](c13.xhtml#Page_274)_
    -   tunneled percutaneous/intracardiac lines  [278](c13.xhtml#Page_278)
-   ventilatory management, thoracic surgery  [567](c23.xhtml#Page_567), [569](c23.xhtml#Page_569)
-   ventricular arrhythmias  [543](c22.xhtml#Page_543)–547
    
    -   premature ventricular contractions  [543](c22.xhtml#Page_543)
    -   ventricular tachycardia (VT)
        -   Brugada syndrome (BrS)  _[546](c22.xhtml#Page_546),_ [546](c22.xhtml#Page_546)–547
        -   catecholaminergic polymorphic ventricular tachycardia (CPVT)  [547](c22.xhtml#Page_547)
        -   long QT syndrome (LQTS)  [543](c22.xhtml#Page_543)–545, _[545](c22.xhtml#Page_545)_
        -   management principles  [545](c22.xhtml#Page_545)–546
        -   monomorphic  [543](c22.xhtml#Page_543), _[544](c22.xhtml#Page_544)_
        -   polymorphic  [543](c22.xhtml#Page_543)
        -   Torsades de pointes  [543](c22.xhtml#Page_543), _[544](c22.xhtml#Page_544)_
    
-   ventricular assist devices (VAD)  [1004](c37.xhtml#Page_1004)–1009, **[1005](c37.xhtml#Page_1005),** _[1005](c37.xhtml#Page_1005)_
    -   advantages of  [1004](c37.xhtml#Page_1004)
    -   Berlin Heart VAD (EXCOR)  [1006](c37.xhtml#Page_1006), _[1007](c37.xhtml#Page_1007)_
    -   dilated cardiomyopathy with biventricular failure _[1014](c37.xhtml#Page_1014)_
    -   draining oxygenated blood  _[1004](c37.xhtml#Page_1004)_
    -   future of  [1024](c37.xhtml#Page_1024)
    -   HeartMate III Centrifugal‐Flow Pump  [1008](c37.xhtml#Page_1008), _[1008](c37.xhtml#Page_1008), [1009](c37.xhtml#Page_1009)_
    -   HeartMate III implantation _[1014](c37.xhtml#Page_1014)_
    -   HeartWare inflow cannula  _[1013](c37.xhtml#Page_1013)_
    -   HeartWare Ventricular Assist System  [1007](c37.xhtml#Page_1007), _[1007](c37.xhtml#Page_1007)_
    -   Impella  [1004](c37.xhtml#Page_1004), _[1006](c37.xhtml#Page_1006), [1015](c37.xhtml#Page_1015)_
    -   role of echocardiography  [1011](c37.xhtml#Page_1011)–1013
    -   septal defects  [1012](c37.xhtml#Page_1012), _[1012](c37.xhtml#Page_1012)_
    -   SynCardia Total Artificial Heart  [1009](c37.xhtml#Page_1009), _[1010](c37.xhtml#Page_1010)_
    -   transesophageal echocardiography  **[1011](c37.xhtml#Page_1011)**
    -   troubleshooting  **[1016](c37.xhtml#Page_1016)**
    -   weaning from CPB  [1015](c37.xhtml#Page_1015)–1016
    -   weaning to recovery  [1016](c37.xhtml#Page_1016)
-   ventricular chambers characteristics  [124](c07.xhtml#Page_124)
-   ventricular septal defects (VSD)  [633](c26.xhtml#Page_633)–636
    
    -   anesthetic considerations  [636](c26.xhtml#Page_636)
    -   device occlusion  _[358](c15.xhtml#Page_358)_
    -   incidence  [633](c26.xhtml#Page_633)
    -   inlet  [634](c26.xhtml#Page_634)
    -   inlet defect  [356](c15.xhtml#Page_356)
    -   muscular  [634](c26.xhtml#Page_634)
    -   muscular defect  [356](c15.xhtml#Page_356)
    -   natural history  [634](c26.xhtml#Page_634)–635
    -   pathophysiology  [635](c26.xhtml#Page_635)
    -   perimembranous  [634](c26.xhtml#Page_634)
    -   perimembranous defect  [356](c15.xhtml#Page_356)
    -   subarterial  [634](c26.xhtml#Page_634)
    -   surgical and transcatheter approaches  [635](c26.xhtml#Page_635)–636
    -   surgical repair  _[635](c26.xhtml#Page_635)_
    -   TEE examination
        -   post‐CPB  [356](c15.xhtml#Page_356)
        -   preoperative  [356](c15.xhtml#Page_356)
    
    -   types of  _[634](c26.xhtml#Page_634)_
-   ventricular septation
    -   conoventricular/subaortic defect  [95](c06.xhtml#Page_95)
    -   defects in  [95](c06.xhtml#Page_95)
    -   formation of cardiac chambers  _[94](c06.xhtml#Page_94)_
    -   membranous septum  [95](c06.xhtml#Page_95)
    -   muscular portion  [95](c06.xhtml#Page_95)
-   VO2/DO2 balance, CHD surgery
    -   low cardiac output syndrome (LCOS  [496](c21.xhtml#Page_496)–498, _[497](c21.xhtml#Page_497)_
    -   mechanisms underlying in DO2  [496](c21.xhtml#Page_496)–499
    -   mechanisms underlying in VO2  [496](c21.xhtml#Page_496)
    -   oxygen extraction rate (OER)  [495](c21.xhtml#Page_495)
    -   pathologic imbalance  [495](c21.xhtml#Page_495)
    -   pathophysiological changes  _[495](c21.xhtml#Page_495)_
    -   systemic and pulmonary circulations  [495](c21.xhtml#Page_495)
-   volatile anesthetics  [886](c33.xhtml#Page_886)

-   Wake Up Safe (WUS) Database  [38](c03.xhtml#Page_38)